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PREFACE - VOORWOORD 
Dit proefschrift is tot stand gekomen op een voor Nederland 
ongebruikelijke wijze: bet wetenschappelijke werk dat ervoor door 
ons is gedaan is uitgevoerd in Amerika, in bet Laboratory of Viral 
Carcinogenesis van de National Institutes of Health te Frederick, 
M.D. Dat wij in de gelegenheid zijn gesteld om daar een aantal jaren 
onderzoek te doen is, als we teruggaan naar onze studententijd, 
indirect te danken aan Prof. Dr. M. Gruber: hij was ten zeerste 
bereid om mij, John (die niet eens een doctoraal onderzoek in zijn 
afdeling had gedaan) te helpen met mijn wens om 11 te leren 
kloneren". Het resultaat was, dat ik een periode in Landen kon 
doorbrengen in de Laboratory of Gene Structure and Expression te 
Mill Hill, waar ik een enorme hoeveelheid kennis en ervaring heb 
opgedaan. Een interesse in het kankeronderzoek, de mogelijkheid om 
de opgedane kloneringservaring toe te passen en bet feit, dat wij 
onderzoeksplaatsen niet al te ver van elkaar zochten leidde ertoe 
dat wij uiteindelijk in de NIH zijn terechtgekomen. Hierbij zijn wij 
veel dank verschuldigd aan Dr. W.J.M. van de Ven, Elly van de Ven en 
Dr. H.P.J. Bloemers. 
Het contact met de mensen in Mill Hill is nag steeds aanwezig; 
hoewel vele van de oude groep naar elders zijn verhuisd geldt het 
gezegde "uit het oog, uit bet hart" bepaald niet. Dick Flavell en 
Frank Grosveld willen we in de eerste plaats bedanken voor alles wat 
ze in het verleden en heden voor ons hebben gedaan. Zander hun 
bereidheid, om een student uit Nederland een kans te geven was dit 
alles niet mogelijk geweest.Ook een aantal andere mensen van de Mill 
Hill groep, ondanks bet feit dat zij niet direct betrakken zijn 
geweest bij dit praefschrift, hebben tach in zekere zin een invloed 
gehad. Er moet dan speciaal worden gedacht aan Cora, Dimitris, 
Tarben, Titia, Chris, Andy, Elizabeth, Stephanie, Rene, Henrik, Lex 
en Ernie. Oak Gerard Grosveld en Annelies de Klein hebben een grate 
ral gehad in bet tot stand komen van dit proefschrift; wie had aoit 
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gedacht dat bet oversturen van een "proobje" zulke spectaculaire 
resultaten zou opleveren! Wij willen jullie bedanken voor jullie 
enthousiasme en voor de hele plezierige samenwerking. Oak de andere 
mensen van de vakgroep Celbiologie en Genetica in Rotterdam zijn 
wij zeer erkentelijk. 
Tot onze promotor, Prof. Dr. Dick Bootsma willen we een 
speciaal woord van dank richten: bet is al een opgave, om promotor 
te zijn voor promovendi binnen je vakgroep, laat staan als de 
promovendi niet tot je vakgroep behoren en hun onderzoek verrichten 
op een heel ander continent. Ondanks deze belemmering hebben we bet 
contact als bijzonder prettig en probleemloos ervaren; wij willen je 
nogmaals be dan ken voor alles, wat j e voor ons hebt gedaan en bet 
feit, dat je bereid bent geweest als promotor op te treden. 
We also wish to thank all our colleagues from the Laboratory of 
Viral Carcinogenesis; first of all, Dr. John Stephenson, who 
initially did not believe in the great virtues of molecular cloning. 
However, we presume he has changed his mind since then, if we 
interpret his threat that "one day he will run a DNA sequencing gel" 
correctly. We would like to thank Dr. Fred Reynolds, Dr. Fulvia 
Veronese and their technicians Chris, Dick and Bob, the latter who 
did some of the photography work for our manuscripts. A special 
word of thanks goes to Siobahn, who did all the tissue culture work 
and kept John's weird cell lines alive. 
Last but not least we want to thank Gail Blennerhasset and 
Pamela Hansen, our technicians. Although DNA work is certainly not 
among the easiest, you have both done your very best and thanks to 
you we have been able to set up a well-running DNA laboratory. Dear 
Pam and Gail, we have very much appreciated your technical 
assistance, your patience and you involvement in the work. 
Finally, in America, we thank all the secretaries who have typed and 
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retyped different parts of the manuscript even though they were 
busy: Mrs. Barbara Eader and Mrs. Beverly Bales in Frederick, Mrs. 
Ann Newson, Mrs. Peggy Brandeburg and Ms. Marianne Lewis in Mineola. 
Tot slot willen wij nog een speciaal woord van dank aan onze ouders 
richten, hoewel zij zich misschien hieronder een beetje 
ongemakkelijk voelen. Dankzij de opvoeding die ik, Nora, heb 
gekregen heb ik ten volle gebruik kunnen maken van het beste wat het 
Nederlandse onderwijssysteem te bieden heeft; mijn ouders hebben de 
term "emancipatie" in mijn opvoeding in de practijk toegepast lang 
voordat de term mode werd. Ook ik, John, ben ervan overtuigd dat 
mijn ouders heel belangrijk zijn geweest voor mijn geestelijke 
vorming en moet daarbij speciaal denken aan de vele weekeinden die 
in de "natuur" werden doorgebracht. 
Mineola, maart 1984 
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Nora Heisterkamp 
John Groffen 
I. INTRODUCTION 
1.1 General Introduction 
The first demonstrations that cancer could have an infectious 
nature was by Ellerman and Bang (1) ~ who showed that leukemia in 
chickens was transmissible with cell-free extracts and by Rous (2), 
who found in a similar fashion that naturally occurring chicken 
sarcomas were transmissible. Although they were able to show that 
these cell-free extracts contained a transmissible agent~ the idea 
that this induced cancer was received by the scientific world at that 
time with great skepticism. The interest in oncogenic viruses was 
strongly enhanced in the early 60's by the isolation of mammalian 
tumor viruses and the general acceptance that at least some of these 
viruses were tumorigenic. The discovery of the reverse transcriptase 
enzyme in RNA tumor viruses (3,4), gave a logical explanation for how 
these viruses became integrated in the chromosomes of eukaryotic 
cells. 
Taxonomically, oncogenic viruses are members of diverse 
families. DNA viruses (herpes-, adeno- and papovaviruses) as well as 
many members of the retrovirus family (containing RNA such as the 
type C RNA viruses) are capable of inducing tumors. For the 
retroviruses two different routes to become transforming (oncogenic) 
have become clear. The majority of these viruses (the acute type C 
RNA transforming viruses) 11 acquire11 certain genetic sequences 
(oncogenes) from their host, which are necessary to initiate and 
maintain the malignant transformation of the cell by the virus. 
Other retroviruses integrate their genome nearby oncogenic sequences 
in the chromosome of their host. Independent of the exact mechanism, 
these viruses share the capability of inducing tumorigenesis by 
triggering the transcription of certain sequences, and it is the 
proteins encoded by these sequences which are necessary to maintain 
the neoplastic phenotype of the infected cell. 
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The accumulating number of independent isolates of tumorigenic 
retroviruses induced in the mid-70's a worldwide search for these 
viruses in humans. Only very recently the isolation of a human tumor 
T-cell leukemia retrovirus (HTLV) was reported (5,6). 
Another approach was initiated in the beginning of the 80's, 
with the finding that the acquired sequences of retroviruses are 
strongly conserved among species. In general, the cellular homologs 
of these sequences were easily detectable and could be studied in 
more detail by molecular cloning, using the oncogenic acquired 
sequences of retroviruses as probes. This approach seems to be very 
fruitful and will be discussed in more detail below. 
Although the oncogenic potential of the acquired sequences in a 
number of these viruses in vertebrates is well estabished, the 
involvement of their human cellular homologs in human tumorigenesis 
has been and will be a rich source for discussion. However, at the 
moment they provide us the best available model for the induction of 
human cancer at the molecular level. 
1.2 Scope of the Thesis 
The detailed structure of type C RNA viruses became clear once 
they had been molecularly cloned: as discussed before, most acute 
type C RNA transforming viruses had acquired DNA sequences from their 
host (e.g. chicken, cat, mouse, rat) which were responsible for the 
tumorigenic properties of the virus. A new approach, in the research 
of human cancer as a molecular biological discipline, became evident; 
by using the acquired cellular sequences of, for example, a cat acute 
type C RNA transforming virus, as a molecular probe, one could 
investigate the possible existence of homologous sequences in man. 
If the evolutionary divergence between these feline sequences and the 
homologous sequences in human were sufficiently low, the human 
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cellular homologs could be molecularly cloned and their possible 
involvement in human cancer could be studied in a detailed way. We 
have chosen that approach in the research described in this thesis: 
initially, three distinct acute type C RNA transforming viruses (see 
Introduction 1. 3 for a more detailed description of these viruses) 
were chosen as a source for molecular probes. Two of these, the 
Snyder-Theilen Feline Sarcoma virus (ST-FeSV) and the Sarma-McDonough 
Feline Sarcoma virus (SM-FeSV) were molecularly cloned from 
transformed cell lines containing a complete integrated provirus. 
The third, Abelson Murine Leukemia virus (Ab-MuLV) was obtained as a 
gift from P. Reddy. Each of these viruses contains different 
acquired cellular sequences, v-fes in ST-FeSV, v-fms in SM-FeSV and 
v-abl in Ab-MuLV. Molecular probes specific for the acquired 
cellular sequences of each hybridized strongly to sequences in human 
DNA, indicating that these sequences were strongly conserved during 
evolution. The human cellular homologs of v-fes, v-fms and v-abl 
were subsequently molecularly cloned (!Japer I, III and VII) and 
research on the potential involvement of these human oncogenes in 
cancer was initiated. As a preliminary characterization we made 
detailed restriction maps of these human oncogenes and the position 
of sequences homologous to the viral acquired cellular sequences were 
determined; extensive homology between the v-abl tyrosine 
phosphorylation acceptor region and a corresponding region in human 
c-abl was established more precisely by nucleic acid sequencing 
(paper VIII). Additionally, human c-fes was examined for homology 
with the acquired cellular sequences (v-fps) of Fujinami Sarcoma 
virus (FSV); earlier reports (7) had indicated, that v-fes (from cat) 
and v-fps (from chicken) were related. Our results indicated that 
one locus exists in man having homology both to v-fes and v-~ 
(paper IV). 
One straightforward method of examining the transforming poten-
tial of the human cellular homologs is, to introduce these sequences 
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into rodent cells in culture and to investigate, if they can trans-
form the cells to a malignant phenotype (see Introduction 1.4) 
However, the c-fes, c-fms or c-abl human oncogenes were incapable of 
transforming cells in culture. This is in concordance with the 
results of others obtained with other human oncogenes: generally, 
human oncogenes do not have transforming ability unless they are 
manipulated extensively in vitro before introduction into cells, We 
have chosen not to pursue the effort to attempt to modify the cloned 
oncogenes in vitro in such a way that they might become transforming: 
one major obstacle in such an effort would have been the large size 
of the genes encoding human c-abl and c-fms. Rather, we have ex-
amined the possible involvement of human c-fes, c-fms and c-abl in 
existing human malignancies. As a first step, the chromosomal 
localization of each of these human oncogenes was determined. Such 
information might be of value in view of the accumulating evidence, 
that specific chromosomal aberrations are associated with specific 
types of neoplasia (See Introduction 1.5). The localization of human 
c-fms to chromosome 5 (paper II) and human c-fes to chromosome 15 
(paper V) has to date been of moderate value. Aberrations on chromo-
some 5 have not been intimately associated with one type of 
neoplasia. Although c-fes is translocated from chromosome 15 to 
chromosome 17 in patients with acute promyelocytic leukemia (APL) in 
which a t (15; 17) is characteristic (paper VI), we have not found a 
chromosomal breakpoint in the proximity of c-fes. 
Human c-abl, on chromosome 9 (paper V) has provided us with an 
excellent tool to study leukemogenesis at the molecular level: in the 
t(9;22) characteristic of chronic myelogenous leukemia (GML) human 
c-abl is translocated to chromosome 22, the Philadelphia (Ph') 
chromosome (paper IX). As another human oncogene, c-sis, is located 
on chromosome 22, we examined if c-sis was also involved in the 
Philadelphia translocation. Although we could demonstrate the 
translocation of c-sis to chromosome 9 (paper X) human c-sis was 
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subsequently localized far from the Philadelphia translocation 
breakpoint (8). Therefore~ our attention concentrated on the human 
c-abl oncogene; in one CML patient~ we found~ after an elaborate 
search, a chromosomal breakpoint 5' to the human c-abl locus (paper 
XI) . Furthermore, we were able to clone a region from chromosome 22 
in which the breakpoints occur in all Ph'-positive CML DNAs examined 
to date (paper XII). 
The three acute type C transforming viruses utilized in our 
research represent only part of the many type C RNA viruses isolated 
to date (see table I). We have not concentrated our research on the 
viral oncogenes but rather, have used them as a tool in characteriz-
ing human oncogenes. However, the molecular organization, protein 
products, relatedness and transforming mechanism of the viral 
oncogenes has been studied extensively by others. Although this does 
not directly bear on the question if human oncogenes are involved in 
human tumorigenesis, studies on viral oncogenes may ultimately 
explain how cellular sequences can become transforming. Therefore, 
we have included research regarding type C RNA viruses (Introduction 
!. 3). Cellular oncogenes in animal models have also yielded much 
information (Introduction 1.4). 
Many human oncogenes have been molecularly cloned and charac-
terized as we have done (Introduction 1.5). We have attempted to 
provide a limited amount of structural information for each. Of the 
human oncogenes, c-abl, c-myc and the ~ gene family have been most 
strongly implicated in neoplastic diseases. The putative transform-
ing mechanism of c-abl and c-myc seem to be similar. We have done 
most of the research on c-abl; the research on c-myc is very elabo-
rate and we have attempted to summarize this information. 
·In the above described research projects, Drs. N. Heisterkamp 
has concentrated on the human c-fms oncogene (papers I and II) and 
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human c-abl (papers V, VII, IX and XI). Drs. J. Groffen has had a 
major contribution in research concerning human c-fes (papers III, IV 
and VI), sequencing of human c-abl (paper VIII) and sequences on 
chromosome 22 (papers X and XII). However, all projects were per-
formed in close collaboration between both authors. 
1.3 Type C RNA Viruses 
Type C RNA viruses can be divided into two classes on the basis 
of tumorigenicity. The first class (the chronic type C RNA viruses) 
cannot transform cells in culture. in vivo, however, these viruses, 
such as Feline leukemia virus (FeLV) and Moloney murine leukemia 
virus (MoMuLV), can induce leukemias in infected animals after a 
relatively long period of latency ranging from 6 to 12 months. The 
viral genome consists of several genes, which together are necessary 
for the life cycle of the virus. After infection of the cell, the 
RNA genome is converted to a double stranded DNA copy by the vi-
ral-encoded enzyme reverse transcriptase. 
The DNA copy of the viral genome is integrated into the genome 
of the infected cell; this provirus carries two identical LTR's (long 
terminal repeats), one at either end of the viral genome. The LTR 
contains promoter sequences, signals for transcription termination 
and polyadenylation signals (9) . Transcription is initiated from the 
5' LTR; RNA is transported to the cytoplasm and translated into the 
proteins utilized for the formation of a new virus particle. The 
order of the genes on the linear double stranded DNA copy of the 
viral RNA is: 
5' LTR ---- gag pol env ---- LTR 3' 
The ~ gene encodes the structural proteins of the viral core. 
These proteins are synthesized as part of a polyprotein, which is 
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processed into the mature viral proteins. Pol encodes the viral 
reverse transcriptase and~ the viral envelope glycoproteins. 
The second class of type C RNA viruses (the acute type C RNA 
viruses) is called transforming because of their ability to transform 
cells in culture. In general, they cause sarcomas and acute 
leukemias in vivo after a relatively short latency period (a few days 
or weeks). What has been described for the "chronic" viruses also 
applies to these viruses; the latter, however, are generally replica-
tion deficient and require the presence of a helper virus for the 
production of infectious viral particles. Acute type C transforming 
RNA viruses are thought to have originated from chronic type C 
viruses through a recombination event between the latter viruses and 
host cellular sequences. As a consequence, part of the structural 
information of the viral genome has been deleted and replaced by 
"non-structural11 or "acquired" sequences of host cellular origin. 
These acquired sequences have imparted a new ability on the virus, 
enabling it to transform fibroblasts in vitro and to have an acute 
oncogenic potential in vivo (10, 11). 
At least 15 different type C transforming viruses have been 
isolated, from species as diverse as chicken and baboon. Each 
isolate contains acquired cellular sequences. To distinguish the 
cellular homologs from their viral counterparts a standard nomencla-
ture (12) is accepted: viral oncogenes are denoted by "v" as in 
v-~, the cellular progenitors by "c" as in c-src. 
The chicken has been a particularly rich source for the iso-
lation of type C transforming viruses (Table I). Rous sarcoma virus 
(RSV), in contrast with the other virus isolates, is not replication 
deficient: chicken cellular sequences have been inserted 3' to the 
structural genes of avian leukosis virus, resulting in the formation 
of a replication competent transforming virus. The acquired cellular 
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TABLE I 
Gene Virus Animal Origin Protein Protein 
Kinase 
src RSV chicken p60 PK 
B77 chicken p60 PK 
rASV chicken/quail p60 PK 
fEs/fes FSV chicken Pl40 PK 
PRCll chicken Pl05 PK 
URl chicken P250 PK 
16L chicken Pl42 PK 
ST-FeSV cat P85 PK 
GA-FeSV cat Pll5 PK 
~ Y73 chicken P90 PK 
ESV chicken P80 PK 
ros UR2 chicken P68 PK 
myb liliV chicken 
E26 chicken 
erb AEV chicken P75+40 
myc MC29 chicken PllO 
CMll chicken P90 
MH2 chicken PlOO 
OKlO chicken P200 
rel AEV turkey 
mos Mo-MuSV mouse 
GZ-MuSV mouse 
ras-Ki Ki-MuSV rat p21 
ras-Ha/bas Ha-MuSV rat p21 
Ra-RaSV rat p29 
Balb-MuSV mouse p21 
abl Ab-MuLV mouse Pl20 PK 
fms SM-FeSV cat Pl70 
sis SiSV monkey 
ra£ 3611-MuSV mouse P90 
fos FBJ-MuSV mouse pSS 
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sequences of RSV are called ~· Two different strains of avian 
sarcoma virus, Y73 (13) and Esh (14) have independently recombined 
with the same cellular sequence, e-yes (15). Fujinami, PRCII and 
URl avian sarcoma viruses all contain a strongly related oncogene. 
v-~ (7, 16). A new avian sarcoma virus isolate, UR2 (17), 
contains a unique oncogene, v-ros ( 18). Avia~ erythroblastosis 
virus contains two 11 domains" of acquired cellular sequences, erbA 
and B. Each encodes a protein: erbA encodes a ~ fusion protein 
(see later) of MW 75,000 (19). ErbB, which consists entirely of 
acquired cellular sequences, encodes a 40,000 MW protein (20) which 
is thought to be responsible for the transforming activity of the 
virus (21). The acquired cellular sequences of avian myeloblastosis 
virus (AMV) have been called both amv and myb (22, 12). Finally, 
MC29 (myelocytomatosis virus) is one of a series of avian type C 
transforming viruses that have transduced a cellular oncogene called 
myc from chicken. One species of transforming type C virus has been 
isolated from turkey; the reticuloendotheliosis virus strain (REV-T) 
contains the rel oncogene (23). 
In mammals, the isolation of type C transforming viruses has 
been reported from mouse, rat, cat and baboon., In mouse, murine 
leukemia virus has recombined with different cellular oncogenes, 
giving rise to Abelson murine leukemia virus (v-abl) (24,25), 
:Holoney murine sarcoma virus (v-mos) (26), 3611-:HuSV (v-raf) (27), 
and Finkel-Biskis-Jinkins murine osteosarcoma virus (v-fos) (28). 
Through passage of a murine leukemia virus on rat cells Harvey and 
Kirsten murine sarcoma virus were obtained (29, 30). Both contain 
an oncogene (v-Ha-ras (31) and v-Ki-~) flanked at either end by 
rat "30S" DNA sequences, which are retrovirus-like but without 
transforming capacity. v-Ha-ras and v-Ki-ras are related but not 
identical: they contain homologous and unique sequences (32). From 
cat, two strains of feline sarcoma virus have been independently 
isolated which both contain portions of the same cellular oncogene 
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c-fes: Snyder-Theilen FeSV and Gardner FeSV (33, 34, paper IV). 
Another cat isolate yielded McDonough FeSV which carries a unique 
oncogene, v-fms (35, paper I). One type C transforming RNA virus 
has been isolated from primates, the simian sarcoma virus (v-sis 
oncogene) (36, 37). 
From this summary it is clear that a large variety of type C 
transforming viruses has been isolated. In this context it should 
be mentioned that in most cases the viruses have been molecularly 
cloned, allowing a detailed comparison at the nucleic acid level 
with respect to the relatedness of various isolates; most references 
in this thesis refer to the molecular cloning of the virus and not 
the original isolation. From a comparison of the fes oncogene in 
ST-FeSV and GA-FeSV with the fps oncogene, in Fujinami sarcoma 
virus, it became clear that fps and fes represent the same oncogene 
from chicken and from cat (38, 39, paper IV). New viral isolates do 
not always yield new oncogenes: a type C RNA virus isolated from 
cat contains a sis-like oncogene (40). The acquired cellular 
sequences from Balb murine sarcoma virus (bas) seem to be analogous 
to ras from rats (41). Therefore, the amount of different oncogenes 
transduced by type C RNA viruses may be quite limited. This may 
reflect a situation wherein the number of oncogenes in the genome is 
low; on the other hand, it is possible that certain oncogenes cannot 
fulfill certain "requirements 11 necessary to become integrated in the 
retroviral genome. At the moment, it is not known if this type of 
requirement exists; however, with the development of retroviral 
vectors for eukaryotic cells, analogous to the E. coli cloning 
vectors, this type of information should become available. The 
isolation of new oncogenes with DNA-mediated transfection 
experiments (see Introduction 1. 5, j) lends support to the 
hypothesis that there may be still a large repertoire of sequences 
with oncogenic potential in the genome not yet isolated, 
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The protein products of the type C transforming RNA viruses are 
very diverse in size. As mentioned, the cellular sequences have 
been integrated in phase in the structural genes of the virus. 
Where this recombination has taken place differs in various viral 
isolates. Fuj inami sarcoma virus has the structure 5 '-Llgag-~-3' 
(38), indicating that part of the~ gene and the entire~ and 
~ gene have been deleted and replaced by ~ sequences. As a 
consequence, ~ is expressed as a polyprotein, with amino 
acid-terminus encoded structural components covalently linked to the 
acquired cellular sequence encoded carboxy-terminus component: Pl40 
5'-b gag-fps Both ST-FeSV and Gardner FeSV have the structure 
They express fes 
polyprotein; the difference in molecular 
Gardner FeSV, P85gag-fes for ST-FeSV) is 
as part of a gag-fes 
weight (Pll5gag-fes for 
caused by the different 
size of the ~ portion and differences in the acquired sequence 
component (39). MC29 also encodes a gag-~ fusion protein, of MW 
llO,OOO (PllOgag-myc); the genomic organization is similar to that 
of STand Gardner FeSV: 5!..,6. gag-myc-.6.~-3' (42). Simian sarcoma 
virus has a variant structure~ in which the sis sequences are 
situated in the env gene (36). As mentioned before, avian 
erythroblastosis virus encodes two proteins, a gag-erbA fusion 
protein and a protein completely encoded by the acquired sequence 
component (20,21). A number of other type C transforming viruses 
have oncogenes, which are not expressed as part of a polyprotein; 
Rous sarcoma virus (in which structural genes have not been replaced 
by an oncogene) encodes a pp60src ( 43). Both Ha-MuSV and Ki-MuSV 
encode a p21 protein from the acquired cellular sequences (32). 
The protein products of many of these viral oncogene sequences 
have been identified; in many cases, however, the putative enzymatic 
activity or function remains obscure. Even though for some an 
enzymatic activity has been found it is difficult to unravel the 
pathway by which the viral oncogene mediates its transforming 
effect, 
19 
However, some retroviruses have acquired sequences that encode 
proteins, which all possess a tyrosine-specific protein kinase 
activity. Protein kinases are thought to have a regulatory function 
in the cell through the activation and deactivation of cellular 
enzymes by phosphorylation. That pp60src (Rous sarcoma virus) 
possessed a protein kinase activity with specificity for tyrosine 
residues (44) came somewhat as a surprise; until then it was thought 
that phosphorylation involved only serine or threonine residues. In 
normal cells only one of the 3000 phosphorylated residues is a 
tyrosine; in RSV transformed cells this amount increases five-to 
tenfold. Soon after this enzymatic activity had been discovered it 
was found for a number of other viral oncogene products (Table I): 
v-fes/fps (45,46), v-abl (47 ,48), v-~ (49) and v-E.'?.'!_ (SO). This 
enzymatic activity seems required for the maintenance of the trans-
formed state; temperature sensitive mutants of RSV (51) and FSV (52) 
are no longer able to transform cells and do not exhibit protein 
kinase activity at the non-permissive temperature. Transformation 
deficient mutants of AbMuLV lack protein kinase activity (53, 54). 
Although phosphotyrosine residues in the protein kinases themselves 
are thought to be of importance for their enzymatic activity (55), 
their exact functional significance remains to be determined. 
Nucleic acid sequencing data have shown that the different 
oncogene encoded protein kinases may be related and have evolved 
from a common ancestor: v-fps and v-~ are 40% homologous in the 
carboxy terminal 280 amino acids (38). Although v-yes and v-src did 
not exhibit significant homology in nucleic acid hybridization 
experiments (13), the amino acid sequence predicted on the base of 
nucleic acid sequencing data revealed that both oncogenes were 
strikingly similar (56). That v-abl and v-src are related stems 
from two lines of evidence. Firstly, in Drosophila melanogaster 
sequences have been cloned that exhibit nucleic acid homology to 
both v-abl and v-src (which might represent a common ancestor), and 
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ones that have exclusive homology to ~ (57, 58). Interestingly, 
the regions of v-abl and v-src that show cross homology with this 
putative progenitor sequence (called c-Dash) are those that are 
essential for the protein kinase activity in v-abl (25) and v-src 
(59). Secondly, nucleic acid sequence data have shown that v-~, 
v-fes, v-abl and human c-abl contain a common region that is highly 
conserved (paper VIII). 
Even v-~ appears to have limited homology with v-src at the 
amino acid level (60). The phosphorylation of tyrosine residues 
does not seem to be an exclusive property of viral oncogene 
products. The cell surface receptor for epidermal growth factor 
(EGF) is phosphorylated in tyrosine after binding EGF, a small 
polypeptide with growth promoting activity (61,, 62). Furthermore, 
the same reaction is found after the binding of insulin to the 
insulin receptor (63) and the binding of platelet derived growth 
factor (PDGF) to its receptor (64). Although it seems plausible 
that these receptors are themselves protein kinases specific for 
tyrosine residues, it remains to be established if this is the case 
(65) or that such protein kinases are intimately associated with 
them. Interestingly, cells transformed by either AbMuLV (v-abl) or 
ST-FeSV (v-fes) and some human tumor derived cell lines show an 
overall increase in phosphotyrosine level and a reduced binding of 
exogenously added EGF to its receptor. The cause of this reduced 
binding capability seems to be, that in cells transformed by these 
viruses, a new growth factor (TGF = transforming growth factor) is 
produced, that competes with EGF for the binding of its receptor 
( 66). That a connection exists between some oncogene encoded 
products and growth factors became clear, when protein sequencing of 
a part of human PDGF revealed complete concordance in 104 amino acid 
residues with the deduced protein sequence of v-sis (67, 68). 
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The information regarding the other viral oncogene products is 
less elaborate. None encode proteins with tyrosine specific kinase 
activity. v-myc codes for a DNA-binding nuclear protein (69, 70). 
No protein product of v-rel has been reported to date. v-fms and 
v-raf both encode identifiable products of unknown function (71, 
72). v-erbB seems to be a cell membrane glycoprotein (73). The p21 
of Harvey and Kirsten MuSV (v-Ha-~ and v-Ki-ras) has a protein 
kinase activity; it specifically binds guanine containing 
nucleotides and can phosphorylate itself by transferring a phosphate 
of GTP to a threonine residue on its own molecule (74). 
1.4 Cellular Progenitors of Viral Oncogenes 
With the isolation of new oncogenic retroviruses, the possibil-
ity emerged that these viruses, during passage in animals, 
recombined with the genome of the host and that this recombination 
resulted in the formation of an acutely transforming virus. 
Molecular hybridization and the ability to prepare radioactive cDNAs 
were the tools used to show that the Rous sarcoma virus had acquired 
specific sequences (c-src) from the chicken genome (75). 
Subsequently it was possible to show that the presence of these 
sequences was not restricted to chicken; v-src homologous sequences 
were found in fish and human with a nucleotide divergence possibly 
as low as 15%, indicating that this gene is evolutionarily conserved 
(76). Very recently (57, 77) v-~ related sequences were found in 
the insect Drosophila, which extends the conservation of this gene 
over an even longer evolutionary period. 
With the introduction of molecular cloning it became possible 
to specifically clone the acquired sequences of tumorigenic 
retroviruses and to perform these studies in a much more 
straightforward and detailed way. These types of studies 
established that the majority of the retroviral oncogenes are 
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acquired from the cellular genome and that the extent of 
evolutionary conservation varies among the different oncogenes. 
The cellular homologs of most of the known viral oncogenes 
exist as single loci within a given species. Although in some cases 
additional related sequences can be detected (78) these cellular 
sequences are only partly homologous to viral oncogenes, which makes 
it unlikely that viral oncogenes are derived from them. More likely 
these related sequences are derivatives of the original cellular 
gene and unable to encode a functional protein ("pseudo-genes"), 
"processed genes, 11 or related loci. The latter possibility is 
illustrated by v-ras, of which two distinctive forms have been 
acquired, one by the Harvey and one by the Kirsten strain of sarcoma 
virus (79,80). Although the acquired sequences of these viruses are 
related they are derived from different loci. The acquired 
sequences of the transforming viruses do not exceed a stretch of 
more than 3 kb of DNA. However their cellular progenitors are in 
most cases found to be distributed over a much larger stretch Of 
DNA, indicating the presence of intervening sequences. The finding 
that most of the cellular homologs contain one or more intervening 
sequences unambiguously demonstrates that their origin is not viral. 
That the cellular oncogenes are strongly conserved in evolution 
implies that these sequences encode mRNAs and that their 
translational products are essential for the cell (i.e.~ "housekeep-
ing" enzymes). First experimental evidence for their presence was 
obtained with the discovery of RNA homologous to v-src in uninfected 
fibroblasts of several avian species (81). Similar findings were 
subsequently made for other cellular oncogenes. Exceptions were, 
however, found; no c-fes transcript so far has been detected; more-
over, a detailed search for c-mos mRNAs in many different tissues 
has not revealed any transcripts. 
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Detection of cellular oncogene proteins has not been easy. To 
date, three proteins have been identified. The most thoroughly 
studied is pp60c-src, a 60,000 MW phosphoprotein; p21c-ras, a 21,000 
MW protein encoded by Harvey e-ras and P150c-abl• a 150,000 MW 
protein most probably encoded by c-abl. 
The translation products of v-src and c-src are remarkably 
identical; moreover. deletion mutants of v-src can be restored by 
recombination with c-~ resulting in a functional oncogene (82). 
The DNA-mediated transfection procedure, introduced by Graham 
and van der Eb in 1973 (83), permits transfer of genetic traits to 
cells in culture by exposing these cells to DNA containing the genes 
encoding the characteristics to be transferred. In this way, for 
instance, cells lacking the activity of thymidine kinase (TK) can be 
made TK+ by transfecting DNA of Herpes simplex type II virus, which 
carries a gene for thymidine kinase. In some cases, the donor DNA 
is stably integrated into the genome of the recipient. 
This procedure provides a new approach to investigate if DNA 
sequences have oncogenic activity; this DNA can be transferred to 
recipient non-transformed cells through DNA-mediated transfection 
procedures. The successful transfer of an oncogene would be 
apparent by the formation of foci of transformed recipient cells, 
which are usually NIH 3T3 cells. 
The finding that the viral oncogenes were derivatives of cellu-
lar progenitors introduced the tentative possibility that the cellu-
lar oncogenes could be induced to cause malignant transformation in 
other ways than through integration in retroviruses. Data 
concerning this question accumulated rapidly after the molecular 
cloning of the first cellular oncogenes: introduction of viral 
transcriptional regulatory sequences (LTR) 5 1 of normal mouse c-mos 
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and rat c-~ by ligation, subsequently followed by transfection to 
NIH 3T3 cells resulted in the activation of the transforming 
potential of these cellular genes (84, 85), The number of foci was 
comparable to that obtained upon transfection of the homologous 
sarcoma virus DNA's. The cellular~ and~ genes do not exihibit 
transforming activity on their own. However, removal of cellular 
sequences 5' of the mouse c-mos gene results in a very low 
transforming activity (86). The hypothesis that this low 
transforming activity is a consequence of the integration of this 
gene nearby strong cellular promoters is very plausible. Further 
evidence that cellular oncogene expression could be responsible for 
at least some forms of tumorigenesis was obtained from the study of 
avian leukosis virus (ALV). This virus has no acquired sequences 
(oncogene) yet it is capable of inducing B-cell lymphoma in 
chickens. Its tumorigenicity was explained by the finding that in 
these ALV-induced lymphomas, ALV is integrated adjacent to the c-myc 
gene and that transcription, initiated from the viral promotor of 
ALV, causes enhanced expression of c-myc, leading to neoplastic 
transformation (87), These data showed that a carcinogenic agent 
(ALV) acts by altering the expression of a cellular oncogene, c-myc. 
Recently the DNA transfection procedure was employed in a new 
way to detect DNA sequences possibly involved in tumorigenesis. 
Instead of transfection of a particular DNA segment to recipient 
contact inhibited eukaryotic cells~ the cells were exposed to total 
cellular DNA. This type of experiment resulted in the 
identification of oncogenes homologous to the acquired sequences of 
retroviruses, However, in some experiments the results were not in 
agreement with the expectations. When DNA of an ALV induced chicken 
lymphoma was transfected to NIH 3T3 cells a number of foci were 
obtained. Upon cloning, DNA sequences responsible for focus 
formation were distinct from the expected c-myc gene, Nucleotide 
sequencing identified the transforming sequence to be coding for a 
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small protein characterized by partial homology with transferrin 
(88) 0 In similar experiments, by the same group, the DNA of 
lymphoid neoplasms induced by Abelson murine leukaemia virus 
(AbMuLV) was used to transfect NIH 3T3 cells. Again it was shown 
that the transforming sequences were distinct from AbMuLV sequences 
(89). This apparent contradiction of results could be explained if 
some forms of tumorigenesis are multiple step events. 
Strong evidence for the involvement of cellular oncogenes in 
tumorigenesis was recently obtained from mouse myelomas and 
plasmacytomas. In a mouse myeloma it was found that 5' of the c-mos 
gene normal cellular sequences were substituted by an insertion 
sequence (IS)-like element. Upon cloning of this rearranged gene it 
was subsequently shown that in transfection experiments it was 
capable of transforming mouse fibroblasts (90). Many mouse 
plasmacytomas were found to have rearranged immunoglobulin heavy 
chain constant regions. A certain DNA sequence (called LyR, NIARD 
or NIRD by different investigators) was found to be translocated 
into this region; (91, 92, 93) subsequently it could be shown that 
this sequence represented c-myc sequences (94, 95, 96). As a result 
of these findings an analogous translocation was found with human 
c-myc in Burkitt lymphoma. In the next chapter, the involvement of 
c-myc in tumorigenesis will be discussed in more detail. 
1.5 Human sequences with potential transforming activity. 
a. Overview 
An increasing number of human sequences with a potential 
to transform cells in culture has been isolated. Using viral 
oncogene sequences as probes, the following human cellular homologs 
have been isolated: c-abl (paper VII), c-fes (97, 98, paper III), 
c-fms (paper I), c-fos (99), c-~ (100, 101), c-myb (102), c-myc 
(103, 104), c-Ha-ras (lOS), c-Ki-ras (105), and c-sis (106). The 
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isolation of the human cellular homologs of v-~, v-erb and v-rel 
has not yet been reported, This may reflect difficulty using avian 
probes to isolate human sequences that are evolutionary distant, 
For instance, although v-fps (chicken) and v-fes (cat) both detect 
an identical locus in human (paper IV) the strength of hybridization 
is much less when v-fps sequences are used as a probe, Sequences 
homologous to v-rel seem not to be highly conserved in non-avian 
species (23, 107), 
Other human sequences, with transforming activity, have been 
shown to exist by means of DNA-mediated transfection experiments; 
DNA from either human tumor tissue or cell lines established from 
human tumors transfected to mouse NIH 3T3 cells induces focus 
formation at a low frequency. These foci contain human sequences, 
detectable by an Alu-repeat probe, which is specific for human DNA. 
Some of these transforming sequences have been molecularly cloned. 
What could be regarded as evidence that these human oncogenes 
represent causative agents in tumorigenesis? Because the protein 
products of many human oncogenes have not yet been identified, 
expression has mostly been studied on the RNA level, using either 
viral or human probes, An increased level of RNA production of a 
particular oncogene in transformed cells is thought to be an in-
dication that the oncogene may have taken part in the neoplastic 
process, However, elevated levels of oncogene RNA may also be a 
phenomenon accompanying neoplastic transformation but not 
necessarily causing it: altered expression of many enzymes and 
proteins in tumors has been reported (for a review, see 108), 
reflecting changes in metabolism of the transformed cells. 
Hypomethylation of human growth hormone, o( -globin and ~-globin 
sequences in cancerous tissues in comparison with healthy tissue of 
the same patient has also been reported (109); the tissues studied 
normally do not express these genes, 
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Increased mRNA production can be caused by an amplification of 
oncogene sequences, for example by duplication of the chromosome on 
which the oncogene is situated. Alternatively, only limited regions 
of a chromosome may be amplified. Alterations in the signals 
responsible for the regulation of transcription can also cause an 
increase in mRNA production. These alterations can be local, by the 
insertion or deletion of sequences near the oncogene or by mutations 
in the promoter sequences of an oncogene. Or as a part of a gross 
rearrangement~ oncogene sequences can be translocated to other 
chromosomes and either activated through position effects (e.g., an 
oncogene that is normally not transcribed is translocated into a 
region of high transcriptional activity) or through replacement of 
its own promoter by a promoter at the breakpoint on the recipient 
chromosome. Novel species of mRNA could be synthesized in this 
case. 
One firmly established fact is, that human neoplasms do very 
often contain chromosomal aberrations. Double minute chromosomes 
(DM), which contain as yet unidentified portions of chromosomes have 
been found in tumor cell lines; they could represent amplification 
of one limited large stretch of DNA. Translocations between 
chromosomes in human neoplasms, especially in leukemias and 
lymphomas, have been reported in an increasing number (110). The 
first discovered and most well known example is the Philadelphia 
translocation, t(9;22), associated with chronic myelogenous leukemia 
(CML) (111). In this translocation a piece of the long arm of 
chromosome 22 (qll-qter) is translocated to chromosome 9 (112); a 
very small piece of chromosome 9 is translocated to chromosome 22 
(paper IX). The 22q- chromosome (the Philadelphia chromosome) is 
present in the leukemic cells of about 96% of all CML patients; this 
generally appears to be the only chromosomal abnormality prior to 
the blast crisis during which other abnormalities become apparent 
(110). 
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In certain forms of acute promyelocytic leukemia (APL) a 
t (15; 17) is characteristic (113, 114). Recently, a correlation has 
been found between Burkitt lymphoma and translocations involving 
chromosome 2, 14 or 22 with chromosome 8 (115). With the 
improvement of cytogenetic techniques, the number of specific 
chromosomal aberrations associated with specific neoplastic disease 
is increasing rapidly (116). For example, among the solid tumors 
small lung cell carcinoma ( 117) is correlated with a deletion in 
chromosome 3 and Wilms tumor with a deletion of chromosome 11 at 
band pl3 (ll8), However, if a chromosomal translocation is the 
direct cause of a neoplastic disease or if the disease causes 
chromosomal aberrations is a question difficult to answer but 
important to the debate if human oncogenes have oncogenic potential. 
Another mechanism, by which an oncogene might acquire 
tumorigenic properties is by a mutation, for example in the coding 
sequences; the oncogene sequences could then code for a protein with 
activity or characteristics different from the normal protein, which 
makes it turmorigenic. This will be discussed in the chapter 
concerning human c-Ki-ras and c-Ha-ras. 
Models have been proposed which catagorize all the above de-
scribed mechanisms by which an oncogene might become tumorigenic. 
One model states that the overproduction of an oncogene product may 
cause malignancy; the second model supposes that a mutation in the 
coding region of an oncogene leads to the production of a new 
oncogenic protein. A third alternative is that a normal oncogene 
product is produced in normal quantities, but at the wrong moment in 
a developmental process. 
b. Human c-abl 
Human c-abl has been molecularly cloned using a cosmid 
vector system because of the presence of an extensive region of DNA 
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homologous to v-abl (paper VII). Apart from the main human c-abl 
locus, other regions of more limited homology to v-abl were found, 
encompassed by two separate EcoRI fragments of 4.1 and 12.5 kb 
(paper VII). The 12.5 kb EcoRI fragment has been molecularly cloned 
in phage (unpublished results). Homology only to a central part of 
v-abl could be detected; in v-abl, this region contains the putative 
tyrosine phosphorylation acceptor site which is highly conserved 
between v-abl, v-src and v-fes. It is possible that sequences in 
the 12.5 kb EcoRI fragment code for a protein with tyrosine-specific 
protein kinase activity. That these sequences represent a 
"processed gene 11 is not likely: the region of homology to v-abl 
stretches out over 7.4 kb whereas v-abl itself is approximately 3.0 
kb in length. Therefore these human sequences may contain introns. 
The human v-abl homologue is located on chromosome 9q34 (paper 
V). In CML, it is translocated to chromosome 22 in the standard 
t(9;22) Philadelphia translocation (paper IX) and in complex 
translocations such as the t(l;9;22) and the t(9;11;22) (ref. 141). 
In one CML patient, a chromosomal breakpoint was found 5' to the 
human c-abl locus; a restriction enzyme fragment containing 
sequences from chromosome 9 and 22 was molecularly cloned from the 
DNA of this patient (paper XI). Using a probe isolated from the 
chromosome 22-specific sequences of this fragment, an extended 
region of chromosome 22 DNA was cloned. In the DNAs of all 
Ph' -positive CML patients examined a chromosomal breakpoint was 
found within a limited region of approximately 5 kb on chromosome 22 
(paper XII). The human CML cell line K562 appears to be 
representative of CML in that a chromosomal breakpoint is present 
within that same region on chromosome 22 (unpublished observations); 
furthermore, the five fold amplification of the immunoglobulin~ 
light chain constant region on chromosome 22 (paper XI), of the 
breakpoint region remaining on chromosome 22 (unpublished 
observations) and of the human v-abl homologue (paper XI) suggests 
that at least part of the Philadelphia chromosome has selectively 
been amplified in this cell line. 
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Human c-abl is expressed in various human cell lines; at least 
four RNA species of different molecular weights (7.2~ 6.4~ 3.8 and 
2.0 kb) were found using a v-abl probe, both in hematopoietic and in 
tumor cell lines; normal fibroblasts contained only two species of 
high molecular weight (119, 120). Others, however, have reported 
the presence of only two species of v-abl homologous RNA, of 5.4 and 
5. 2 kb molecular weight in all human cells examined (121). Two 
additional RNA species of 6.8 and 6.2 kb were found in a human cell 
line estabished from a patient with a pre B acute lymphoblastic 
leukemia (ALL). However, transfection of this DNA to NIH 3T3 cells 
yielded foci which did not contain detectable human v-abl homologous 
sequences. Production of a transforming growth factor was evident 
both in the original ALL cell line and in NIH 3T3 cells transfected 
by DNA of this cell line. It was suggested, that sequences 
responsible for the induction of foci in NIH 3T3 either coded for a 
(human) transforming growth factor or induced the production of a 
transforming growth factor in the NIH 3T3 cells (121). 
c. Human c-fes 
RNA transcripts of human c-fes have not been found in 
detectable quantities in 36 human cell lines examined (unpublished 
observations). Molecularly cloned human c-fes does not exhibit 
transforming activity, even if a viral LTR is ligated 5' to the 
putative coding region (unpublished observations). Human c-fes maps 
on chromosome 15 (paper V, 102) in the region q25-26 (122). In the 
t(15;17) characteristic of some forms of APL, c-fes was not found on 
the 15q+ chromosome in one patient (paper VI), suggesting that it 
had been translocated to chromosome 17. However no sequences up to 
30 kb 5' and 12 kb 3' of human v-fes homologous sequences were found 
to be retained on the 15q+ chromosome from the same patient 
indicating the absence of a chromosomal breakpoint near human c-fes 
(unpublished observations) . These observations are concordant with 
the localization of human c-fes to 15q25-26 (122) and the breakpoint 
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·an chromosome 15 in APL to band q22 (paper VI). 
d. Human c-fms 
Human c-fms, as human c-abl, appears to be a very large 
gene; sequences homologous to v-fms stretch out over a region of at 
least 30 kb. Human c-fms exhibits no transforming ability when it 
is transfected to Rat-2 cells, even when all v-fms homologous 
sequences are joined together in one cosmid clone. However, as with 
human c-abl, the possibility must be considered that coding 
sequences at the 5' region, which are not represented in v-abl or 
v-fms, are missing from the clones. Human c-fms has been mapped on 
chromosome 5, band q34 (paper II). A relatively high level of c-fms 
transcripts was found in human placenta (123). 
e. Human c-fos 
Human c-fos has been cloned as a 9 kb EcoRI fragment (99). 
Sequencing of the human c-fos gene has shown, that it contains 
introns and can encode a protein of 380 aminoacids. Human c-fos 
transcripts of 2.2 kb have been found in human term fetal membranes 
(123). Human c-fos does not transform NIH 3T3 cells; however, if 
the carboxy-terminus encoding region is replaced by that of v-f os 
(human c-fos and v-fos differ in that region by a 104 bp sequence 
not present in v-fos) the hybrid gene is able to induce the 
formation of foci (124). 
f, Human c-mos 
Human c-mos was cloned as part of a 9 kb BamHI restriction 
fragment ( 100); the homology to v-~ proved to be confined to a 
very limited region (an 0. 96 kb EcoRI/Bglii restriction fragment) 
with no apparent intervening sequences. Human c-mos and v-mos are 
77% homologous in nucleic acid sequence. Although the mouse c-mos 
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readily transforms cells in culture when an LTR is ligated 5' to the 
putative coding region, human c-mos has no detectable transforming 
activity in a similar transfection assay (100). RNA transcripts of 
human c-mos have not been detected in undifferentiated B-cell 
lymphomas (125); however, others have reported expression in 
Burkitt lymphoma cell lines (126). Human c-mos has been localized 
to chromosome 8 (96, 127) in band q22. 
g. Human c-myc 
Human c-myc has been isolated in two overlapping phage 
clones spanning a region of more than 20 kb (103) and as a 20 kb 
EcoRI restriction fragment from a partial EcoRI human library (104). 
Homology to v-myc was restricted to two stretches of DNA smaller 
than 1 kb, separated by an apparent intervening sequence of 
approximately 1. 4 kb (104). The sequences mentioned above 
hybridized to probes specific for both the 5' and 3' end of v-myc. 
On a genomic blot, more sequences with exclusive homology to a probe 
specific for the 5' part of v-myc are seen. Three such regions, 
representing apparent non-contiguous DNA sequences have been cloned 
(103); heteroduplex mapping showed that only 0.2-0.4 kb of these 
clones contained homology to v-myc (the central region); no 
intervening sequences were apparent. Since no transcript other than 
a 2. 7 kb RNA species, presumably encoded by the main c-myc locus 
(see below) has been found, the regions with less homology to v-myc 
could represent pseudogenes. 
Sequencing of the main human c-myc locus has revealed an open 
reading frame, which, (with omission of the putative intron) could 
code for a mRNA of 2.3 kb (104). This size is reasonably concordant 
with the size of an RNA of 2.7 kb found in human tumor cell lines, 
in normal human fibroblasts and in haematopoietic cells (119, 120), 
33 
In the acute promyelocytic leukemia cell line HL-60 (this cell 
line does not contain the t (15; 17) often found in APL (128)) the 
level of transcription of the 2.7 kb mRNA was found to be approxi-
mately tenfold enhanced (120), Moreover~ c-myc was amplified 
8-32-fold in this cell line (129, 130). These results imply that 
the increased level of c-myc expression in HL-60 is due to 
amplification of c-myc sequences. Because amplifications of the 
c-myc locus was also found in primary leukemic cells of the patient 
from which HL-60 was established before chemotherapeutic treatment, 
(129), this phenomenon does not seem to have occurred during passage 
of the cells in tissue culture. However, it is difficult to 
evaluate the possible role of c-myc in the causation of this 
leukemia because no non-leukemic cells of the same patient could be 
examined, Moreoever, no amplification of c-~ was found in cells 
from the peripheral blood of three different patients with APL. The 
correlation between c-myc and APL is therefore unclear. 
The same applies to another study, in which an elevated (20 to 
30-fold) level of c-myc expression was found in two cell lines 
established from a colon carcinoma with characteristics of a 
neuroendocrine tumor. By in situ hybridization the presence of 
v-myc homologous sequences could be demonstrated in the 
heterogenously staining region of a marker chromosome; the human 
c-myc locus was amplified in both cell lines 16 to 32-fold (131). 
Human c-mos and c-myc have both been mapped to chromosome 8; 
c-mos is located at position 8q22 (127) and c-myc at 8q24 (96, 132). 
Chromosome 8 is frequently involved in translocations associated 
with neoplastic disease; in Burkitt lymphomas for instance, 
translocations of chromosome 8 with chromosome 2, 14 and 22 have 
been described (115). In all cases the breakpoint on chromosme 8 is 
8q24; those on chromosome 2, 14 and 22 are 2p12, 14q32 and 22q11 
(133, 134, 96). 
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Chromosomes 2, 14 and 22 each contain sequences coding for 
immunoglobulins; the immunoglobulin heavy chain locus maps to 14q32 
( 135), exactly in the region that contains the breakpoint in some 
forms of Burkitt lymphoma. Using somatic cell hybrids of the human 
Burkitt lymphoma cell line Daudi with murine cells, a chromosomal 
breakpoint in the immunoglobulin heavy chain variable region was 
demonstrated (136). Subsequently, human c-myc sequences were 
detected in somatic cell hybrids carrying the 14q+ chromosome of 
Daudi and of another Burkitt lymphoma cell line, P3-HRI, indicating 
that c-myc had been translocated from chromosome 8 to 14 (132). 
Rearrangement of the c-myc locus has been found in 5 out of 15 
B-cell lymphoma cell lines tested, both of the Burkitt and 
non-Burkitt type. In three, c-myc and heavy chain immunoglobulin 
sequences were found on the same restriction enzyme fragment. The 
rearrangements had occurred 5' to c-myc, resulting in an apparent 
head-to-head joining of c-myc with immunoglobulin sequences (137). 
In another study (96), one allelic copy of c-myc was rearranged in 8 
out of 12 Burkitt lymphoma cell lines studied, including the Raj i 
cell line, 
Before the connection between c-myc and Burkitt lymphoma had 
been made, various groups had found non-immunoglobulin DNA sequences 
near the heavy chain constant region in murine plasmacytomas and in 
some B-lymphomas which contain a 15:12 translocation (chromosome 12 
contains the murine heavy chain locus). These sequences, named LyR 
(91), NIARD (92) or NIRD (93) were molecularly cloned and 
subsequently shown to be murine c-myc sequences originating from 
chromosome 15 (94-96). By testing the hybridization of probes from 
various regions of the murine c-myc to murine RNA, two additional 
coding regions were noted other than the two identified on basis of 
hybridization to v-myc: one stretch of DNA was separated by 
sequences which did not hybridize to RNA (the apparent first intron) 
from the two known exons; an additional putative coding region was 
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present 3' to the already identified exons. In murine 
plasmacytoma's, however, a probe from the 5 1 exon does not detect 
homologous RNA, indicating that the translocation has altered or 
removed the 5 1 exon and the S' regulatory sequences. A probe from 
the first intron does detect multiple RNA species. This may 
indicate, that a cryptic promotor in the first intron has been 
activated (95). In two mouse myelomas, Ml67 and M603, breaks had 
occurred in the first c-~ intron but at different positions. In 
MPC-11 the translocation had occurred in the first c-myc exon, 
without any visible rearrangements in the immunoglobulin heavy chain 
constant region. In all cases, the S' regulatory sequences and the 
first exon had been disrupted, which could possibly result in the 
activation of several putative transcription initiation sites within 
the first intron. The first (non v-myc homologous) exon contains 
stop codons in every reading frame and could represent a 
non-translated leader sequence; by removal of these sequences as a 
consequence of the translocation a shorter transcript could be 
synthesized which could have a lower probability of degradation and 
thus a prolonged half-life. The actual cause of the translocation 
remains unknown, as the recombination sites in J558, Ml67 and M603 
do not share any obvious sequence-homology; furthermore, mouse c-myc 
does not contain the repetitive sequences found in the }l switch 
region (138). 
In human c-myc, an ex on 5 1 to the v-myc homologous exons was 
detected using a probe from the murine S' exon. In contrast to the 
mouse plasmacytomas. no altered RNA product could be found or a 
significant increased level of transcription. The breakpoint seemed 
to be near immunoglobulin switch regions in two Burkitt lines (W 1, 
w2). In the c-myc locus, translocation breakpoints were all in the 
5' region, at different sites: for the Lou and w1 lines, this was 
1-2 kb 5' from the second exon; in Raji, the breakpoint seemed to be 
3-9 kb S' from the second exon. Of importance was that non-Burkitt 
cell lines of the lines w1, w2 and Lou were available and showed no 
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rearrangements in the human c-myc locus (95). The breakpoint in the 
Raji cell line was defined more accurately by the molecular cloning 
of a DNA fragment containing c-myc sequences and immunoglobulin 
constant region sequences. The presence of an exon 5' to the two 
defined on basis of hybridization to v-myc was confirmed, No 
increase in the level of c-myc mRNA could be found specifically in 
Burkitt lymphoma cell lines. Although two species of mRNA (2.4 and 
2.2 kb) were detected, both seem to be transcribed starting at the 
most 5 1 exon and neither is expressed preferentially in Burkitt 
lymphoma (139). In contrast, others (126) have claimed a 
significant increase in the levels of c-myc RNA in Burkitt lymphoma 
cell lines compared to control lymphoblastoid cell lines. 
Although no translocation of c-myc to chromosome 22 has been 
demonstrated yet in the t(8;22), immunoglobulin A light chain 
sequences are certainly involved; as mentioned, the breakpoint on 
chromosome 22 is at qll and the A light chain constant locus has 
recently been mapped to band qll using in situ hybridizing 
techniques (140). In one Burkitt lymphoma cell line, sequences 
hybridizing to the 8q+ and to the 22q chromosomes were detected 
using a \constant region probe, indicating a breakpoint in the A 
constant region. In another cell line, only the 8q + and not the 
22q chromosome retained A-homologous sequences (140). 
h. Human c-myb 
v-myb has been used as a molecular probe to investigate 
expression of human v-myb homologous RNA. None of 18 human cell 
lines established from solid tumors exhibited expression of v-myb 
homologous RNA sequences in detectable amounts. Mature T- and B-
cells also were negative in this respect. However, an RNA species 
of 4. 5 kb was detected in more immature cells and lymphoid cells. 
As with human c-myc expression in HL-60, the expression of the 4.5 
kb v-myb homologous RNA was abolished if the cell line was induced 
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to differentiate with Me 2so or retinoic acid (22). 
Using a human probe isolated from a 2. 0 kb v-myb homologous 
EcoRI restriction fragment, human c-myb has been localized on 
chromosme 6 (102) in the region q22-24 (122). 
i. Human c-sis 
Human v-sis homologous sequences have been molecularly 
cloned as a 14 kb EcoRI restriction fragment (106) from a human 
partial EcoRI library. These sequences seem to be present in one 
single locus in man, contained on large Hindiii and EcoRI 
restriction enzyme fragments. Sequences hybridizing to v-sis are 
distributed over 5 apparent exons. 
Although in this study (106) no polymorphisms were found in all 
12 human DNA samples examined, we found a polymorphism for Hindiii 
to be rather common; this polymorphism was exhibited by the presence 
of an extra Hindiii site near the second intervening sequence in 
human c-sis (unpublished observations). 
Human c-sis has been mapped on chromosme 22 (101), distal to 
band q11, since it is translocated from chromosome 22 to chromosome 
9 in CML patients carrying the Philadelphia chromosome (paper X). 
However, it is not localized in close proximity to the breakpoint on 
chromosome 22 (8) and is translocated to other chromosomes than 
chromosome 9 in complex Philadelphia translocations (141). 
Expression of human c-sis is not common; in 8 out of 23 tumor 
cell lines tested, a 4.2 kb v-sis homologous transcript was found. 
The highest level of expression was in the glioblastoma cell line A 
172 (119); expression was found in one of the haematopoietic cell 
lines tested, the T-cell lymphoma cell line HUT 102, which produces 
the human T-cell leukemia/lymphoma retrovirus HTLV (120). 
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j. Human c-Ha-~, c-Ki-~ and other 
Transforming Human Sequences Detected by 
Transfection 
Using probes specific for the acquired cellular sequences 
of Harvey and Kirsten MuSV, the human cellular homologs of v-Ha-~ 
and v-Ki-ras have been molecularly cloned from normal human DNA 
(105). Two non-overlapping stretches of DNA were isolated with 
homology to v-Ha-~, designated c-Ha-~-1 and c-Ha-~-2. Two 
distinct v-Ki-ras homologous clones, containing c-Ki-ras-1 and 
c-Ki-ras-2 were also isolated. Human c-Ha-~-1 has four apparent 
coding regions, separated by intervening sequences. In contrast·, 
c-Ha-ras-2 lacked intervening sequences and exhibited a limited 
homology to v-Ha-ras. Human c-Ki-ras-1 has 0.9 kb of sequence 
homologous to the viral probe, organized in two exons separated by 
one intron; c-Ki-ras-2 has one region of 30G bp homologous to 
v-Ki-ras without apparent introns. As both c-Ha-ras-2 and 
c-Ki-~-2 hybridize to a limited region, that is conserved between 
v-Ha-~ and v-Ki-ras, they may represent functional, related genes 
(lOS). Human c-Ha-ras-1 has been mapped on the short arm of 
chromosome 11 in the region p11-p15 (105, 142, 143); human 
c-Ki-ras-2 is localized on chromosome 12 (144), 
and c-Ki-ras-1 are on chromosome 6 and X (145). 
Human c-Ha-ras-2 
Human c-Ha-ras-1 has no transforming activity when it is 
transfected to NIH 3T3 cells without further manipulation. 
However, if a viral LTR is ligated to it, it can transform cells at 
high frequency and a p21 protein can be immunoprecipitated from 
these cells (146). Human v-~ homologous transcripts have been 
commonly found in all samples tested (120). 
Using DNA-mediated transfection experiments, a transforming 
gene had been identified in the T24 and EJ bladder carcinoma cell 
lines (147, 148). Once these genes had been cloned (147-149)-, they 
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were examined for sequence homology to other human and viral 
oncogenes; soon it was reported that the T24 and EJ bladder 
carcinoma genes were highly homologous to c-Ha-ras-1 (150) and v-bas 
(151), an oncogene of murine origin analogous to v-Ha-ras from rats 
(41). On restriction enzyme level, no obvious differences were 
observed between the T24 oncogene and a molecularly cloned human 
c-Ha-ras-1 except for a 200 bp deletion in the latter (151). 
However, the T24 oncogene transformed NIH 3T3 cells efficiently, 
whereas the human c-Ha-ras-1 did not. Two proteins (a p21 and a 
p23) could be immunoprecipitated from cells transfected with the T24 
oncogene (151). 
Since no gross differences could be detected between the T24 
oncogene and its normal cellular counterpart, the transforming 
element in the T24 oncogene was localized more precisely by exchang-
ing restriction enzyme fragments between the transforming and 
nontransforming gene and assaying the hybrid genomes for fo-
cus-forming ability. In this way. the transforming activity was 
localized to a small region encompassing the first exon (encoding 
the first 37 amino acids) and sequences immediately 5 1 and 3' to it 
(152-154). This region was subsequently sequenced. Only one essen-
tial change could be detected: in the codon for the twelfth amino 
acid, a T was found in the bladder carcinoma gene and a G in the 
normal gene, resulting in a valine at position 12 in the former and 
a glycine in the latter (152-154). Interestingly, Kirsten, Harvey 
and Balb MuSV also differ in the amino acid at position 12; v-Ha-ras 
has an arginine, v-bas has a lysine and v-Ki-ras has a serine. Like 
the normal human c-Ha-ras-1, rat c-Ha-ras-1 has a glycine at 
position 12 (153). The change of one amino acid residue can be 
detected on 
(collectively 
protein level; in 
described as p21) 
v-Ha-~-1 p21 specific antiserum. 
normal cells two proteins 
are im.munoprecipitated with 
In cells transfected by DNA of 
the EJ bladder carcinoma cell line, four proteins can be detected, 
two of which are identical to those found in normal cells. The 
other two migrate slightly slower on gels and are encoded by the 
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transforming allele of the c-Ha-ras-1 in the EJ cell line (152). 
Other studies have confirmed that only the single basepair change in 
the transforming oncogene distinguishes it from its nontransforming 
counterpart (155). 
An independent~ apparently spontaneous, mutation was found in 
an originally non-transforming c-Ha-ras-1 allele; it had become 
transforming after transfection to NIH 3T3 cells. In this case, a 
point mutation had also occurred in the twelfth codon, but the 
normally occurring glycine was replaced by an aspartic acid (156). 
A transforming c-Ha-ras-1 gene has also been cloned from a lung 
carcinoma cell line, Hs242. In contrast to the T24 oncogene, the 
transforming sequences were not localized to the region encoding 
amino acid residue 12, but to a region more to the 3' in the gene; a 
single basepair change had occurred in codon 6 l, resulting in the 
substitution of a leucine for a glutamine (41). 
Transfection experiments with DNA isolated from solid tumors 
has shown (157) that some of these also contain transforming 
oncogenes detectable through transfection; this gave answer to an 
important question, namely, if the transforming oncogenes in the 
cell lines could have been active in the original tumor and were not 
merely the result of an activation process during tissue culture 
propagation. However, only 5 of 28 DNA samples from solid tumors 
contained an oncogene, detectable with the transfection assay. DNA 
of second-cycle transformants were examined for similarity in 
restriction enzyme patterns after hybridization with total human DNA 
and for homology to a number of viral oncogenes. Many of these 
transforming DNAs contained similar sequences that had been 
transferred to the NIH 3T3 cells, sequences that hybridized to a 
v-Ki-ras probe (157). 
The oncogenes transmissable from the SH 480 colon carcinoma 
cell line and the small lung carcinoma cell line LX-1 apparently 
also are homologous to v-Ki-ras (158, 159). Since two v-Ki-ras 
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homologous loci exist in man (105), c-Ki-ras-1 and c-Ki-ras-2, each 
was examined for identity with the colon and lung carcinoma genes; 
these genes hybridized to a probe specific for c-Ki-ras-2, (159). 
The SW 480 sequences necessary for transformation stretch out over 
an extended region of DNA; c-Ki-~-2 is a very large gene (30-35 
kb) ~ comparable to human c-abl and human c-fms (160, 161). The 
normal c-Ki-ras-2 allele does not transform NIH 3T3 cells; the 
transforming gene has apparently undergone a point mutation (162). 
The transforming gene from the neuroblastoma cell line SK-N-SH 
has been molecularly cloned (163); the transforming activity is 
situated on two EcoRI fragments of 9.2 and 7.0 kb. This 
neuroblastoma oncogene seems to be related to the human ras gene 
family (163, 164). A part of the gene has been cloned from 
secondary transfectants of the fibrosarcoma cell line, HT-1080; it 
is apparently identical to the SK-N-SH transforming gene and can be 
demonstrated in transfectants of DNA from the cell lines RD 
(rhabdomyosarcoma) and HL-60 {a promyelocytic line); as this N-ras 
gene is located on chromosome 1, it is clearly distinct from the 
other members of the ~ gene family. RNA transcripts of 2.2 kb 
were detected in comparable amounts in HT-1080 cells, in EJ cells 
and in normal human fibroblasts {165). 
Tumorigenesis is generally regarded to be a multi-stage 
process, That members of the ras gene family are able to transform 
NIH 3T3 cells with single hit kinetics is an argument against the 
possibility that these cells are representative of actual target 
cells in vivo. The ras genes are not capable of transforming normal 
fibroblasts in the transfection assay; however, upon cotransfection 
with a myc gene or the polyoma large-T antigen normal fibroblasts 
can be made tumorigenic (166). A similar phenomenon was reported by 
others; neither the T24 oncogene (Ha-ras) nor the polyoma middle-T 
antigen can transform primary cells alone; however, co-transfection 
with adenovirus early region 1A yielded transformed cells (167). 
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Additionally, the EJ oncogene (Ha-~) can only transform normal 
fibroblasts after they have been immortalized by carcinogens (168). 
These results have led to the proposal that certain complementation 
groups exist among oncogenic sequences: large T-antigen, adenovirus 
early region lA and myc would belong to one group, inducing 
immortality. The ras gene family and polyoma middle-T would be 
implicated in events leading to anchorage independent growth and 
morphological change (166), 
2. CONCLUSION 
The connection between human oncogenes and cancer has to date 
not been clarified for any human oncogene. Since all viral 
oncogenes cause transformation, the potential to transform may be 
present in these particular homologous sequences in human. However, 
it is clear that the viral oncogenes are in no case identical to 
their own direct cellular progenitors: viral oncogenes lack all 
intervening sequences and in some instances exons present in their 
cellular counterparts. Point mutations and deletions further 
distinguish them from the cellular oncogenes (for a review, see 
169). However, similar critical pTocesses which may have changed a 
virally transduced, non-transforming sequence into a transforming 
gene may take place in an individual. Therefore, it is possible 
that every human oncogene is ultimately found to be connected with 
some kind of malignancy. Only a limited number of human oncogenes 
have been implicated to date in vivo in neoplastic diseases. 
Human c-myc appears to be closely associated with Burkitt 
lymphoma and with the type of APL represented by the cell line 
HL-60. In the first case, c-myc homologous RNA is not found in 
significantly higher amount, indicating that the transformation is 
not caused by elevated transcription. Moreover, no human c-myc RNAs 
of an abnormal size have been found in Burkitt lymphomas. Recently, 
it was shown that the c-myc allele translocated to chromosome 14 is 
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expressed, whereas the other allele is not; this led to the proposal 
that the translocated oncogene somehow escapes normal regulation as 
a consequence of the translocation (170). The breakpoints on both 
chromosome 8 and 14 seem to be variable: in some cell lines (such as 
Daudi) no breakpoint anywhere in the neighborhood of c-myc is 
detectable although it is translocated to chromosome 14. In the 
immunoglobulin locus, breaks in the variable region and in the 
switch region of the heavy chain have been reported. The mechanism 
by which human c-myc may cause transformation in Burkitt lymphoma 
may therefore be called unclear. However. the strong correlation 
between Burkitt lymphoma and the presence of a translocation of 
c-myc to chromosome 14 in the t(8;14) indicates that this oncogene 
must somehow be involved in this disease. 
The oncogenes detected by transfection do not provide a consis-
tent linkage between one type of malignancy and one type of 
oncogene; both c-Ha-ras and c-Ki-ras have been implicated in the 
transformation in bladder carcinomas. The N-ras gene has been 
activated in four different types of malignancies (see Table II). 
Some of these oncogenes are activated by single point mutations. 
How common such events are in vivo remains to be determined, as none 
of 10 primary bladder carcinomas, 9 colon carcinomas or 10 lung 
carcinomas had a point mutation in the codon for the twelfth amino 
acid (171), although a mutation in other codons may be possible. 
The involvement of human c-fes in human tumorigenesis is at the 
moment unclear. Since the fes gene has been "acquired" 
independently by four type C transforming viruses in chicken and two 
in cat, the oncogenicity of these sequences seems unquestionable. 
Nonetheless, it is possible that in the evolutionary period between 
man and cat, safeguards have evolved to prevent the human homolog 
from being expressed at the wrong moment. The highly conserved 
nature of fes suggests that it has an important function in the 
cell, but, since it has not been found expressed in any cell line 
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examined to date, could represent a gene activated only in a 
particular tissue and/or during specific developmental stages. 
Although involvement of human c-fes could be possible in APL because 
it is translocated from chromosome 15, others (172) have indicated 
that the critical chromosome in this disease is the 15q +. This 
would argue that possibly another oncogene originating from 
chromosome 17 has a major part in causing the malignancy. Moreover, 
the localization of c-fes to 15q25-26 does not coincide with the 
breakpoint on chromosome 15 in APL, 15q22. 
The connection between human c-abl and CML is much stronger; 
that the translocation between chromosome 9 and 22 resulting in the 
formation of the Ph' chromosome was reciprocal could only be 
detected using molecular hybridization techniques, because the piece 
of chromosome 9 translocated to chromosome 22 is too small to be 
visualized by cytogenetic means (paper IX). The relatively small 
size of this piece (in cytogenetic terms; it may be more than 1000 
kb long) and the fact that it contains human c-abl automatically 
places c-abl in the proximity of a chromosomal breakpoint. Indeed, 
Table II. 
Cell Line 
EJ/T24/J82 
Hs 242 
Calu-1 
SK-Lu-1 
SK-Co-1 
SW-480 
Lx-1 
Sk-N-SH 
HT-1080 
RD 
HL-60 
Type Line 
Bladder carcinoma 
Lung carcinoma 
Lung carcinoma 
Lung carcinoma 
Colon carcinoma 
Colon carcinoma 
Small cell lung carcinoma 
Neuroblastoma 
Fibrosarcoma 
Rhabdomyosarcoma 
Promyelocytic leukemia 
Activated 
Oncogene 
c-Ha-ras-1 
c-Ha-ras-1 
c-Ki-ras-2 
c-Ki-ras-2 
c-Ki-ras-2 
c-Ki-ras-2 
c-Ki-ras-1 
N-ras 
N-ras 
N-ras 
N-ras 
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we have found a chromosomal breakpoint in one CML patient located 
within 14 kb 5' from the most 5' v-abl homologous sequence (paper 
XI). That such a proximity is fortituous seems unlikely: recently, 
we have found a chromosomal breakpoint in a second CML DNA in the 
relative neighborhood of human c-abl (unpublished observations). If 
the break actually occurs in the human c-abl gene itself is at the 
moment unresolved; v-abl is approximately 3 kb long whereas v-abl 
homologous human RNA's of around 6 kb have been detected (unpublished 
observations), suggesting the presence of as of yet unidentified 
exons. Furthermore~ studies with the mouse c-abl gene have indicated 
that it contains sequences to the 5', not present in v-abl (173). If 
the break is outside the human c-abl locus itself, a similar 
situation is found as in Burkitt lymphoma, in which a breakpoint is 
not found in c-myc coding sequences. 
In contrast to the t(8;14) in Burkitt lymphoma, the "recipient" 
chromosome of the human oncogene in CML, chromosome 22, contains 
breakpoints within a narrowly defined region (4.2- 5.8 kb). Prelim-
inary results indicate that this region contains protein encoding 
sequences not related to the A immunoglobulin region. The breakpoints 
seem to occur within 
defined if they are 
these sequences. although we have not 
in exons or introns. All Ph '-positive 
yet 
CML 
patients seem to share a common breakpoint region on chromosome 22; 
Ph' -negative CML seems to be a different type of leukemia in this 
respect. 
We believe that at the moment we have a strong model system to 
examine the possible involvement of genetic sequences in the causa-
tion of human cancer: on chromosome 22 a region is present that 
consistently contains Ph' breakpoints and in addition c-abl is 
translocated into its relative vicinity, even in the DNAs of patients 
having complex translocations such as a t(9;11;22) and a t(1;9;22). 
The specific amplification in a human CML cell line of both the c-abl 
oncogene and chromosome 22 sequences in the breakpoint region (unpub-
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lished observations) further implies that these genetic sequences~ if 
any, may be responsible for the causation of CML. 
In general) it seems reasonable to expect that in the near 
future discoveries on the molecular basis of human cancer will result 
in the development of new technologies for early diagnosis and 
ultimately in new approaches to cure this disease. A great amount of 
attention has been focused on oncogenes in particular and this thesis 
is a reflection of the expectation, that oncogenes do have a role in 
human cancer. Obviously, the correlation between oncogene expression 
and human tumorigenesis has yet to be established firmly. The 
practical value of the knowledge~ that such a correlation exists, is 
large. 
In diagnostics, tests could be developed based on abnormal 
oncogene expression either at the mRNA (detecting overproduction of, 
or abnormal size of mRNA with Northern blot) or at the protein level 
(detecting products with monoclonal antibodies). DNA probes may be 
used for the detection of gross DNA rearrangements in specific types 
of human cancer: for example, in Ph'-positive CML the presence of the 
breakpoint on chromosome 22 and thus the Philadelphia chromosome can 
be detected with DNA probes. Possibly these tests could be used for 
diagnosis of cancer at a very early stage. Knowledge of the type(s) 
of oncogene(s) activated in a certain neoplastic disease could lead 
to more accurate prognosis. 
In patients with a certain type of cancer, identification of the 
oncogene responsible could result in a more specific treatment. If 
the biochemical pathway by which the oncogene causes cancer has 
become evident, very effective treatments may be possible. Even if 
such data were not available, monoclonal antibodies against specific 
oncogene products could be of potential value in controlling the 
disease and perhaps curing it. 
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In existing "cancer families". in which individual members have 
an increased probability of developing a certain type of cancer {such 
as hereditary retinoblastoma), identification of e.g. the 
retinoblastoma-causative oncogene(s) could be invaluable for genetic 
counselling • using DNA probes derived from these genes. If 
tumorigenesis requires the activation of more than one oncogene, some 
individuals could be members of a "high risk group 11 (e.g. highly 
susceptable to the development of lung cancer) because they were born 
with one activated oncogene. 
early and they could adapt 
These individuals could be identified 
their life-style (e.g. refrain from 
smoking) with the foreknowledge of an increased risk of developing 
that type of cancer. Even tumor-promoting substances in the environ-
ment could be identified based on their ability to mutate certain 
oncogenes (such as causing base-changes in the ras gene family). 
Taken together, the identification of oncogenes as the causative 
agents of tumorigenesis is not only valuable for improved cancer 
diagnosis, prognosis, treatment and cure, but also for a more pro-
found understanding of the mechanisms in the cell which dictate 
growth and differentiation. 
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SUMMARY 
The human oncogene field is a relatively new area investigating 
the molecular basis of human tumorigenesis, Since the discovery, 
that acute type C RNA transforming viruses have acquired sequences 
(oncogenes) of cellular origin, many human homologs of these viral 
oncogenes have been molecularily cloned. Although the viral 
oncogenes unequivocally have transforming activity, there is at the 
moment no definite proof available that human oncogenes cause human 
cancer. Because of their homology to the viral oncogenes, a con-
nection between these human cellular sequences and tumorigenesis is 
not unlikely and evidence that this may be the case is accumulating; 
this thesis forms a contribution to that evidence, 
A first step in the process of investigating the possible 
tumorigenic properties of human genetic sequences is their molecular 
cloning. In research presented in this thesis, we have molecularly 
cloned the human oncogenes c-abl, c-fes and c-fms from a human cosmid 
library using viral oncogene sequences as molecular probes. These 
oncogenes were further characterized by nucleic acid hybridization 
and restriction enzyme mapping. Nucleic acid sequencing of a 
homologous part of human c-abl and v-abl (from mouse) revealed a 
striking conservation on both nucleic acid and arninoacid level; a 
strong homology between the v-fes/v-fps, v-src oncogenes was also 
observed in the same region, as well as a more distant relatedness to 
the catalytic chain of the bovine cAMP protein kinase. 
Furthermore, v-fps (from chicken) and v-fes (from cat) were shown to 
be represented by one single locus in man, the human c-fes oncogene. 
Certain 
chromosomal 
types of human 
aberrations. To 
cancer are 
determine, 
strongly 
if the 
correlated with 
isolated human 
oncogenes could be connected with known chromosomal aberrations and 
to further characterize them, we determined the chromosomal locali-
zation of each; all three oncogenes were localized to different 
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chromosomes, c-abl to chromosome 9 band q34, c-fes to chromosome 15 
and c-fms to chromosome 5 band q34. Although human c-fes was found 
to be translocated from chromosome 15 in the t(15;17) associated with 
some forms of acute promyelocytic leukemia, we could detect no 
chromosomal breakpoint in the relative vicinity of this oncogene, 
Human c-ab! however, was consistently translocated to chromosome 
22 in the Philadelphia translocation occuring in the leukemic cells 
of a high percentage of all cases of chronic myelocytic leukemia 
(CML). The human c-sis oncogene, normally located on chromosome 22, 
was also involved in the translocation but was not situated in close 
proximity to the breakpoint on this chromosome. In one CML patient, 
a break on chromosome 9 had occurred only 15kb upstream of the most 
5' located v-abl homologous sequences. The isolation of a chimeric 
restriction enzyme breakpoint fragment containing sequences 
originating both from chromosome 9 and 22 enabled us to moleculary 
clone the breakpoint region of chromosome 22. Not only the DNA of 
the patient examined originally, but all Ph'-positive CML DNAs were 
found to contain a chromosomal breakpoint within a very limited 
region on chromosome 22. 
We have molecularly cloned human genetic sequences from both 
chromosomes involved in the Philadelphia translocation, immediately 
adjacent to the chromosomal breakpoints. It will therefore be 
possible to examine the significance of the Philadelphia translo-
cation in the development of CML on a genetic level. Similar 
approaches have been used by others to study human oncogenes, 
resulting in the strong implication of especially human e-ras and 
c-myc in human tumorigenesis. There is no doubt that the study of 
human oncogenes will result in a better understanding of cancer. 
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SAMENVATTING 
Ret onderzoek aan menselijke oncogenen is een betrekkelijk nieuw 
gebied, dat zich bezighoudt met de moleculaire basis van menselijke 
tumorgenesis. Sinds de ontdekking, dat acuut type C RNA 
transformerende virus sen sequenties van cellulaire oorsprong 
(oncogenen) hebben verkregen, zijn vele menselijke homologen van deze 
virale oncogenen gekloneerd. Alhoewel de virale oncogenen zonder 
twij fel transformerende activiteit bezitten is er momenteel geen 
definitief bewijs beschikbaar dat menselijke oncogenen kanker 
veroorzaken. Echter, vanwege hun homologie met de virale oncogenen is 
bet niet onwaarschijnlijk dat er een verband bestaat tussen deze 
menselijke oncogenen en tumorgenesis. Het a an tal aanwij zing en~ dat 
een dusdanig verband aanwezig is neemt toe en dit proefschrift !evert 
daarin een bijdrage. 
Het kloneren van deze menselijke DNA sequenties is een eerste 
stap van het onderzoek naar hun kankerverwekkende eigenschappen. rn 
het onderzoek beschreven in dit proefschrift hebben wij, 
gebruikmakend van de virale oncogen sequenties als moleculaire 
probes, de menselijke c-abl, c-fes en c-fms oncogenen gekloneerd uit 
een menselijke cosmide bank. Verdere karakterisatie van deze 
oncogenen vend plaats door middel van DNA hybridisaties en het in 
kaart brengen met restrictie enzymen. Na het bepalen van de 
nucleotide-volgorde van een homoloog gedeelte van het menselijke 
c-abl en het virale v-abl gen (dat van muis afkomstig is) bleek zowel 
de aminozuurvolgorde als de DNA sequentie sterk geconserveerd te 
zijn; oak de v-fes/v-~ en v-src oncogenen vertoonden in hetzelfde 
gebied een sterke homologie, evenals, in mindere mate, de 
katalytische keten van cAMP -afhankelijk protein kinase. Voorts kon 
er aangetoond worden, dat v-fps (uit de kip) en v-fes (uit de kat) 
voorkomen als een enkele genetische locus in de mens, het menselijke 
c-fes oncogen. 
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Er bestaat een sterke correlatie tussen bepaalde soorten 
menselijke kanker en de aanwezigheid van chromosomale afwijkingen, 
Wij hebben de chromosomale lokatie van elk der geisoleerde menselijke 
oncogenen bepaald, teneinde deze verder te karakteriseren en om te 
bepalen of er een verband kon worden gevonden met bekende 
chromosomale afwijkingen; elk oncogen kon worden geplaatst op een 
ander chromosoom, c-abl op chromosoom 9 band q34, c-fes op chromosoom 
15 en c-fms op chromosoom 5 band q34. Hoewel wij konden aantonen, dat 
c-fes in de t (15; 17) die voorkomt in sommige soorten van acute 
promyelocytic leukemie van chromosoom 15 naar chromosoom 17 wordt 
getransloceerd, konden wij geen chromosomale breukpunt vinden in de 
nabije omgeving van dit oncogen. 
Het menselijke c-abl oncogen werd echter consequent 
getransloceerd naar chromosoom 22 in de Philadelphia translocatie; 
deze translocatie vindt plaats in de leukemische cellen van een groat 
percentage van alle gevallen van chronische myeloide leukemie (CML). 
Ret menselijke oncogen c-sis, dat normaliter aanwezig is op 
chromosoom 22, was ook betrokken bij de translocatie maar bleek niet 
dichtbij bet breukpunt op dit chromosoom te liggen.In een CML patient 
werd de chromosomale breuk op chromosoom 9 slechts 15 kb 
stroomopwaarts van de meest 5' gelegen v-abl homologe sequenties 
gevonden. Dankzij de isolatie van een restrictie enzym fragment dat 
sequenties bevatte van zowel chromosoom 9 als 22, konden wij het 
breukpunt gebied van chromosoom 22 kloneren. Niet alleen het DNA van 
de patient, dat wij aanvankelijk hadden onderzocht, maar alle 
Ph'-positieve CML DNAs bleken een chromosomaal breukpunt te hebben 
binnen een zeer beperkt gebied van de gekloneerde DNA sequenties op 
chromosoom 22, 
Wij hebben menselijke sequenties gekloneerd die direct grenzen 
aan de chromosomale breukpunten van de beide chromosomen, die 
betrokken zijn bij de Philadelphia translocatie. Derhalve zal bet 
mogelijk zijn om de betekenis van de Philadelphia translocatie in bet 
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ontstaan van CML op een moleculair niveau te onderzoeken. Anderen 
hebben een soortgelijke benadering gebruikt om menselijke oncogenen 
te bestuderen, waardoor de betrokkenheid van vooral het menselijke 
e-ras en c-myc oncogen in menselijke tumorgenesis sterk wordt 
gesuggereerd. Zander twijfel zal de studie aan menselijke oncogenen 
leiden tot het beter begrijpen van kanker. 
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The integrated form of McDonough FeSV proviral DNA, including cellular flanking 
sequences, was molecularly cloned from nonproductively transformed Fisher rat cells. 
Acquired cellular-derived (v-fms) sequences within the cloned proviral DNA were mapped 
from between 2.6 and 5.5 kb from the 5' LTR. Upon transfection, the cloned proviral DNA 
was biologically active; it caused induction of the transformed phenotype and the result-
ing transformed cells expressed the major McDonough FeSV translational product, 
Pl70'"'~~1;,, at high level. Using a series of molecular probes representing subgenomic 
regions of the viral v-jms gene, a cosmid library of human lung carcinoma DNA was 
screened for v-jms homologous sequences. Three cosmid clones containing overlapping 
v-jms homologous cellular DNA inserts, representing a contiguous region of cellular DNA 
sequence of approximately 64 kb in length, were isolated. Within this region of human 
genomic DNA, v-jms homologous sequences are dispersed over a total region of around 
32 kb. These represent the entire human cellular homolog of v-jms, are colin ear with the 
viral v-jms transforming gene, and contain a minimum of four intervening sequences. 
At least 12 regions of highly repetitive DNA sequences have been mapped in close prox-
imity to c-jms coding sequences. 
INTRODUCTION 
Approximately 16 independent type C 
retrovirus "oncogenes" have now been de-
scribed (Coffin et al., 1981; Varmus, 1982). 
These were initially identified as trans-
formation-specific sequences within the 
genomes of various transforming retro-
virus isolates of both avian and mamma-
lian origin. The human cellular homologs 
of several such viral oncogenes have been 
molecularly cloned and studies initiated to 
determine their possible involvement in 
naturally occurring tumors of man (Klein, 
1982). Based on comparison to transform-
ing sequences identified by transfection 
techniques using in vitro cultured tumor 
cells as a DNA source, one oncogene, c-
rasHa, has been implicated in the induction 
of human bladder carcinomas (Der et al., 
1982; Parada eta!., 1982; Santos et al., 1982) 
while a second, c-rasK1, appears to be as-
sociated with carcinomas of the lung (Der 
et aL, 1982). Other cellular homologs of 
viral oncogenes, including c-fes (Dalla-
1 To whom reprint requests should be addressed. 
Faver a et aL, 1982; Heisterkamp et aL, 1982) 
and c-abl (Heisterkamp et al., 1982; de Klein 
et al., 1982), have been mapped on chro-
mosomes involved in translocations fre-
quently associated with human lymphoid 
neoplasms. These findings indicate that 
studies of cellular homologs of type C viral 
oncogenes may provide new insights into 
mechanisms involved in malignant trans-
formation. 
The McDonough strain of feline sar-
coma virus (FeSV) was initially isolated 
from a naturally occurring fibrosarcoma 
of the domestic cat (McDonough et al., 
1971). By molecular hybridization it was 
shown to represent a recombinant be-
tween feline leukemia virus (FeLV) and 
cellular sequences of cat origin (Donner et 
al., 1982). McDonough FeSV resembles the 
majority of other mammalian and avian 
transforming retroviruses in that it is rep-
lication-defective, requiring a helper virus 
for in vitro and in vivo propagation (Bar-
bacid et al., 1980; Van de Ven et al., 1980). 
The major McDonough FeSV transla-
tional product has been identified as a 
170,000 Mr polyprotein (P17()1Jar;·/m~· consist-
73 
ing of amino terminal FeLV gag gene en-
coded structural components, p15, p12, and 
p30, covalently linked to an acquired se-
quence encoded nonstructural component 
(Barbacid et aL, 1980; Van de Ven et aL, 
1980; Ruscetti et al., 1980). By tryptic pep-
tide analysis (Van de Ven et aL, 1980) and 
on the basis of immunologic criteria using 
both polyvalent (Barbacid et aL, 1980; 
Van de Ven et aL, 1980) and monoclonal 
antisera (Veronese et al., 1982; Anderson 
et al., 1982), the v-fms specific region of 
P17fY'aa-fms has been shown to be distinct 
from that encoded by v-fes, an oncogene 
common to the Snyder-Theilen and Gard-
ner isolates-of FeSV (Barbacid et al., 1980; 
Van de Ven et al., 1980; Fedele et aL, 1981). 
Analogous results has been obtained upon 
direct comparison of v-fms and v-fes by 
molecular hybridization (Donner et aL, 
1982). Functionally, P17QY<lfJ·/ms differs from 
the Gardner and Snyder-Theilen FeSV en-
coded transforming proteins in that it lacks 
tyrosine-specific protein kinase activity 
(Reynolds et al., 1981). 
We have recently applied a cosmid vec-
tor system to the molecular cloning of the 
human cellular homo logs of two retroviral 
oncogenes, v-jes (Groffen et al., 1982) and 
v-abl (Heisterkamp et aL, 1983). The use of 
a cosmid vector for this purpose was of 
particular value in the case of the human 
c-abl gene because of its overall size and 
relatively large intervening sequences. Us-
ing a similar approach in the present study 
we have molecularly cloned the Mc-
Donough FeSV proviral DNA from a 
transformed rat cell line and, by use of a 
v-jms specific probe, identified and isolated 
its cellular homolog from a cosmid library 
of human lung carcinoma DNA. Our re-
sults establish the c-fms gene to resemble 
c-abl in that it is distributed over a rela-
tively large region (>30 kb) of human ge-
nomic DNA and contains multiple regions 
of noncoding (intervening) sequence. 
MATERIALS AND METHODS 
Cells and viruses. Cells were grown in 
Dulbecco's modification of Eagle's medium 
supplemented with 10% calf serum. Cell 
lines include a highly contact inhibited 
74 
Fisher rat embryo line, FRE 3A, and sev-
eral previously described subclones of FRE 
3A nonproductively transformed by the 
McDonough strain of FeSV (Van de Ven 
et aL, 1980). A TK- rat cell line, Rat-2 
(Topp, 1981), was kindly provided by W. 
Topp. 
Bacteriophages and plasmids. AHF60, a 
recombinant of Charon 4A containing an 
EcoRI restriction fragment consisting of 
an entire infectious FeLV provirus (Gard-
ner-Arnstein B) with human host flanking 
sequences (Mullins et al., 1981), was a gen-
erous gift of J. L Mullins. A recombinant 
plasmid clone, designated pHEPSTH, con-
taining the complete Snyder-Theilen FeSV 
proviral DNA, including FRE 3A rat cel-
lular flanking sequences, within the 
Hindiii site of plasmid pREP, and other 
vectors used including AgtWESAB and 
pBR328, have previously been described 
(Groffen et aL, 1982). 
Gel electrophoresis and hybridization. 
Restriction enzymes were purchased from 
either New England Biolabs or Bethesda 
Research Laboratories (BRL) and were 
used according to the suppliers' specifi-
cations. DNAs were digested with restric-
tion enzymes, subjected to electrophoresis 
through 0.75% agarose gels and trans-
ferred to nitrocellulose (Schleicher and 
Schuell, PH79) as described by Southern 
(1975). Nick translation of probes and fil-
ter hybridization were as described (Ber-
nards and Flavell, 1980; Flavell et aL, 1978). 
Specific activity of probes was 2-5 X 108 
cpm/p.g. After hybridization, filters were 
exposed to XAR-2 film (Kodak) for up to 
5 days at -70° with Dupont Lightening 
Plus intensifying screens. 
Preparation of DNA probes. DNA probes 
were prepared by digesting 150 p.g of DNA 
with appropriate restriction enzymes, fol-
lowed by electrophoresis through low 
melting point agarose (BRL). Desired 
bands were excised from gels and brought 
into solution by heating at 65° for 30 min. 
Agarose was removed by two extractions 
with phenol equilibrated with 0.3 M 
NaOAc, pH 5.0, and one extraction 
with phenol:chloroform:isoamylalcohol 
= 25:24:1. DNA was precipitated with 
ethanol and 0.2 M NaOAc, pH 4.8, in the 
presence of 20 ,ug/ml Dextran T-500 as 
carrier. 
Isolation of human v-jms homologous se-
quences. For isolation of v-fms homologous 
cellular sequences, a previously described 
cosmid library of human lung carcinoma 
DNA partially digested with Mboi was 
used. This library is highly representative 
and contains relatively large (35-45 kb) 
cellular inserts. Construction of the cos-
mid library, as well as procedures for the 
screening, isolation, and growth of recom-
binants were as described (Grosveld et aL, 
1981). 
DNA-mediated transfection. Transfec-
tion of TK- Rat-2 cells was based on the 
methods of Graham and Vander Eb (1973) 
as modified by Wigler et al. (1978). 
RESULTS 
UrLTR Probe/or Detection of McDonough 
FeSV Proviral DNA 
As an initial approach to the identifi-
cation and molecular cloning of the 
McDonough FeSV proviral DNA from 
nonproductively transformed rat cells, a 
series of molecular probes containing 
FeL V -specific sequences were analyzed. 
These included Smai and Xhoi restriction 
fragments of around 3.7 and 5.0 kb, re-
spectively, from the 5' half of the FeLV 
genome (Mullins et al., 1981) and a probe 
corresponding to the complete Snyder-
Theilen FeSV proviral DNA containing 
both 5' and 3' FeLV-derived sequences 
(Groffen et al., 1982). The DNA restriction 
fragments were purified by preparative gel 
electrophoresis and 32P labeled by nicked 
translation as. described under Materials 
and Methods. To test the potential use of 
these probes for detection of the inte-
grated McDonough FeSV provirus, high-
molecular-weight DNAs were prepared 
from each of several independently trans-
formed and non transformed control FRE 
3A Fisher rat clones, digested with EcoRI 
and subjected to hybridization analysis by 
the method of Southern (1975). With all 
three :12P-labeled probes, multiple bands of 
hybridization were observed in DNAs from 
both transformed and control cells (data 
not shown), thus precluding their use for 
molecular cloning the McDonough FeSV 
provirus. 
As an alternative approach to identifi-
cation of the integrated McDonough FeSV 
proviral DNA, we undertook construction 
of a probe specific for the u3 region of the 
Snyder-Theilen FeSV LTR. We reasoned 
that the McDonough FeSV proviral DNA 
might hybridize strongly with this probe 
by virtue of the fact that it contains two 
copies of the LTR sequences. Moreover, an 
FeLV-derived probe of this nature was 
previously shown to be of value for the 
identification of newly integrated exoge-
nous FeLV proviral DNAs in cat cells 
(Casey et aL, 1981). As shown in Fig. 1, 
plasmid pHEPSTH, which contains a sin-
gle complete copy of Snyder-Theilen FeSV 
proviral DNA including both 5' and 3' cel-
lular DNA flanking sequences, was di-
gested with Kpni and religated generating 
a new plasmid, pHEPLTR, from which all 
of the Snyder-Theilen FeSV proviral DNA 
sequences, with the exception of a single 
LTR, had been eliminated. This construc-
tion was possible due to the presence of 
corresponding Kpni restriction sites within 
the 5' and 3' proviral LTRs, thus gener-
ating a single hybrid LTR in pHEPLTR. 
For preparation of a Us-LTR specific probe, 
pHEPLTR was digested with BamHI and 
Kpni, and a 0.9-kb restriction fragment 
containing the U3 region of the viral LTR 
and approximately 0.5 kb of mink cellular 
flanking sequence was purified by gel elec-
trophoresis. 
To test the potential use of the U3-LTR 
probe for detection of the integrated 
McDonough FeSV provirus, high-molecu-
lar-weight DNAs were prepared from each 
of five independently transformed and one 
control clone of FRE 3A rat cells, digested 
with EcoRI and subjected to hybridization 
analysis. As shown in Fig. 2, single U3-
LTR cross-reactive restriction fragments 
were observed at different molecular 
weights in DNAs from transformed clones 
which were not present in control FRE 3A 
cellular DNAs. These results are consis-
tent with those of a previous study in which 
the McDonough FeSV proviral DNA was 
shown to lack an internal EcoRI restric-
tion site (Donner et al., 1982). The differ-
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FrG. 1. Construction of U3-LTR probe: Plasmid pHEPSTH containing a single complete copy of 
Snyder-Theilen FeSV proviral DNA including cellular flanking sequences terminating in Hindiii 
restriction sites, was digested with Kpni and religated, generating pHEPLTR. The position of the 
Bami!Kpnl restriction fragment (U~-probe) used for cloning of the McDonough FeSV proviral 
DNA is indicated. 
ence in U3-LTR homologous EcoRI restric-
tion fragment sizes in the McDonough 
FeSV transformed clones thus reflects 
variations in the extents of cellular flank-
ing sequences. In contrast, upon digestion 
with Hindiii, an internal cutting enzyme, 
two U3-LTR homologous restriction frag-
ments were observed, a result consistent 
with the localization of LTRs at both the 
5' and 3' termini of the integrated proviral 
DNAs. These findings establish the suit-
ability of the U3-LTR probe for molecular 
cloning of the integrated McDonough FeSV 
proviral DNA and suggest that it may have 
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FIG. 2. ldentificationofv-frns homologous sequences in control and McDonough FeSV transformed 
FRE 3A rat cells. High-molecular-weight DNAs were prepared from SM-FeSV FRE 145-T (1}, SM-
FeSV FRE 60T (2) and control FRE 3A rat cells (3) digested with either EcoRI or Hindlll as 
indicated and electrophoresed through an 0.75% agarose gel. Following transfer to nitrocellulose, 
filters were hybridized with 32P-labe\ed probes including (A) U0-LTR, and (B) probe D described 
in Fig. 3. 9>-\abeled Hindiii digested ;:>., DNA was used as a molecular weight standard. v, v-Jrns; 
c, c-fms. 
EcoRI BamHI Kpnl Smal I '"i'' ( ,..---
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FIG. 3. Restriction endonuclease map of McDonough FeSV proviral DNA isolated from McD-
FeSV FRE 145T cells and cloned in AgtWESAB. The position of acquired cellular {v-fm.s) sequences 
is indicated by the solid box {B) in the center of the figure. The hatched {GJ) region at the 5' 
terminus of these sequences indicates that the v-frns region terminates at a position intermediate 
between the corresponding Srnai and Psll restriction sites. A series of five subgenomic probes 
isolated from the proviral clone are shown in the lower portion of the figure and include {Al Socii 
Sacl; {B) Hpai!Sacl; {C) Saci/Sacl; {D) Saci/Xhoi; and {E) Xhol!.X7wi restriction fragments. 
general application for the identification 
and molecular cloning of FeSV proviral 
DNAs. 
Molecular Cloning of McDonough FeSV 
Proviral DNA 
For further study, the UrLTR homol-
ogous EcoRI restriction fragment identi-
fied in one of the above clones, FRE 145-
T, was molecularly cloned in AgtWESAB, 
subcloned in pBR328, and subjected to de-
tailed restriction endonuclease analysis. 
On the basis of the data summarized in 
Fig. 3, a number of features of the molec-
ularly cloned proviral DNA are apparent. 
First, the overall length of the cloned 
EcoRI restriction fragment is 11.2 kb, thus 
corresponding to that of the U3-LTR cross-
reactive EcoRI restriction fragment dem-
onstrated in total FRE 145-T cellular DNA. 
Within the cloned DNA sequence, the pro-
viral DNA, as defined by the positions of 
the two LTRs, is 8.0 kb in length and is 
flanked by cellular sequences of 2.2 kb and 
1 kb at its 5' and 3' termini, respectively. 
Finally, the cloned sequence contains an 
internal Hindiii restriction site as would 
be predicted based on hybridization anal-
ysis of FRE 145-T total cellular DNA (Fig. 
2, lane A-1). 
As a means of localizing the acquired 
sequence-specific (v-fms) region within the 
molecularly cloned McDonough FeSV pro-
viral DNA, the viral genome was subjected 
to restriction enzyme digestion and var-
ious combinations of single and double di-
gested DNA fragments analyzed for ho-
mology to a 32P-labeled molecular probe 
corresponding to the complete FeLV pro-
virus. These results thus localize the 5' 
FeLV/v-fms junction site at a position in-
termediate between the Smai and Psti sites 
indicated by the cross-hat::hed box. By an 
analogous approach, the 3' v-fms/FeL V 
junction site was localized between Psti 
and JOwl sites also shown in Fig. 3. Be-
cause of the close proximity of these latter 
restriction sites to each other, the posi-
tioning of the 3' junction site is much more 
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FIG. 4. Restriction endonuclease analysis ofv-frns homologous sequences in human genomic DNA. 
Twenty micrograms of high-molecular-weight human DNA was digested with (1) EcoRI; (2) EcoRI 
and Hindiii; or (3) EcoRI and BamHI, electrophoresed through an 0.8% agarose gel, transferred 
to nitrocellulose, and analyzed by hybridization according to the method of Southern (1975). :rop_ 
labeled probes, prepared as described in Fig. 3, are defined on the top of each paneL 32P-labeled 
Hindiii digested A DNA is included as a molecular weight standard. 
precisely defined than that at the 5' ter-
minus of v-fms. 
Having identified the acquired sequence 
(v-fms) region within the McDonough 
FeSV proviral DNA, we proceeded to pre-
pare v-fms specific probes designated B, C, 
D, and E (Fig. 3). In addition, a somewhat 
larger probe, A, was generated encom-
passing both FeLV and v-fms specific se-
quences localized within the 5' region of 
the McDonough FeSV proviral DNA. These 
probes were hybridized to the same EcoRI 
and Hindiii digested cellular DNAs as ini-
tially analyzed using the Us-LTR probe. 
Representative results with one such probe, 
D, are shown in Fig. 2B. In addition. to the 
integrated McDonough FeSV provirus seen 
at the same position as with the U3-LTR 
probe, its rat cellular homolog, c-fms, was 
detected in both transformed and control 
cells establishing the specificity of each of 
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the v-fms probes for c-fms sequences. Al-
though analogous results were obtained 
upon analysis of Hindiii digested DNAs, 
only single McDonough FeSV proviral 
DNA restriction fragments hybridized 
with probe D, as would be expected on the 
basis of mapping data in Fig. 3. 
To test the biological activity of the 
cloned proviral DNA sequence and thereby 
confirm its identity as McDonough FeSV, 
transfection experiments were performed. 
Upon transfection to either NIH/3T3 or 
Rat-2 cells, the cloned proviral DNA in-
duced transformation at a specific activity 
of approximately 100 foci/~g (data not 
shown). For further analysis, trans-
formed cells from one such focus were bio-
logically cloned in microtiter plates, 
and tested by immunoprecipitation/SDS-
PAGE analysis for expression of the ma-
jor McDonough FeSV encoded polypro-
tein, P17fY'agfnw. High levels of expression 
of P11()flagfms and its major cleavage prod-
uct P120f""', was seen in cells transformed 
by the cloned proviral DNA but not in con-
trol FRE 3A cells (Reynolds et aL, data not 
shown). On the basis of these results the 
identity of the cloned proviral DNA was 
confirmed as McDonough FeSV. 
Human v-fms Cellular Hmnolog 
With the availability of a series ofv-fms 
specific probes, it was possible to test hu-
man cellular DNAs for v-fms homologous 
sequences. For this purpose, high-molec-
ular-weight human DNA from A431 cells 
was digested with EcoRI and analyzed for 
sequence homology to probes B, D, and E. 
As shown in Fig. 4, v-fms homologous re-
striction fragments were detected with all 
three probes. For instance, with probe B, 
cross-hybridizing restriction fragments 
were observed at molecular weights of 3.0 
and 13.0 kb (lane B-1). In contrast EcoRI 
restriction fragments of 13.0 and 16.0 kb 
hybridized with probeD (lane D-1), only 
the latter of which hybridized to probe E 
(lane E-1). These findings indicate that v-
fms homologous sequences can be identi-
fied within total human DNA using the 
above probes and that such sequences en-
compass, at minimum, EcoRI restriction 
fragments of 3.0, 13.0, and 16.0 kb. 
On the basis of the above considerations, 
a cosmid vector system appeared to pro-
vide the most practical approach to the 
isolation of human v-fms homologous se-
quences. We thus screened a previously de-
scribed cosmid library of Mboi partially 
digested human DNA for colonies hybrid-
izing to probe D. Three positive cosmid 
clones identified by this means were col-
ony purified, grown in culture, and their 
DNAs subjected to restriction endonucle-
ase analysis. As summarized in Fig. 5, in-
serts within the three cosmid clones con-
sisted of overlapping cellular sequences 
spanning a total region of 64 kb and ex-
hibiting homology to probes A through E. 
Representative hybridization data for two 
such cosmids, cos 13 and cos 10-2, using 
probes A, D, and E, is presented in Fig. 6. 
Because of the overlapping nature of the 
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FIG. 6. Identification of v-fms homologous restriction fragments in human cellular DNA inserts 
of cos 13 and cos 10-2. Cos mid DNAs (0.4 ..,g) were digested with EcoRI in combination with either 
Hindiii or BamHI, as indicated at the bottom of each gel panel, electrophoresed through 0.75% 
gels, transferred to nitrocellulose, and hybridized to (2) probe A, (3) probeD, or (4) probe E. The 
first lane of each panel shows the ethidium bromide staining patterns of restricted cosmid DNAs. 
Molecular weight standards are as shown in Fig. 4. 
cos mid inserts we were able to exclude the 
possibility of one or more internal frag-
ments being missed from the cloned se-
quence. Moreover, based on extents of hy-
bridization of restriction fragments within 
this cloned sequence to probes correspond-
ing to subgenomic regions of v-fms, the 
orientation of the human c-fms gene could 
be established as shown. 
To establish whether the complete hu-
man v-fms homolog was contained within 
the 64-kb cellular sequence represented by 
the above described cosmid cellular in-
serts, and that no rearrangements had 
taken place during the cos mid cloning, hu-
man cellular DNA was digested by EcoRI 
alone, as well as by EcoRI in combination 
with either Hindiii or BamHI, and ana-
lyzed by Southern blot hybridization using 
each of the above described probes (Fig. 
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5). On the basis of a comparison of v-fms 
homologous restriction fragments identi-
fied by this means (Fig. 4) to the composite 
human c-fms restriction map generated 
from analysis of the molecular cloned se-
quences, it is apparent that all of the ma-
jor v-fms homologous fragments are rep-
resented in the cosmid clones. For in-
stance, three of the four human v-fms 
homologous EcoRI fragments (2.5, 3.0, and 
13.0 kb) identified in total human cellular 
DNA are represented in cos 13, while the 
fourth restriction fragment (16.0 kb) is 
present in cos 10-2. The smallest of these 
hybridizes only with probe A and thus is 
not seen in Fig. 4. Additionally, cos 10-2 
contains 6.6 kb of the largest (13.0 kb) of 
the fragments in cos 13. These are iden-
tified by double digests using EcoRI in 
combination with either Hindiii or BamHI 
and hybridization with probes correspond-
ing to various regions of v-fms (Fig. 6). In 
addition, several minor restriction frag-
ments were observed which hybridized to 
much lesser extents with one or more of 
the v-fm.s specific probes. These weakly hy-
bridizing fragments could either reflect 
secondary loci within the human genome 
containing v-fms homologous sequences or 
may reflect low level cellular DNA con-
taminants of the v-fms probes. 
We have previously demonstrated large 
numbers of highly repetitive sequences 
within the human c-a,bl cellular homolog, 
using as a molecular probe, :32P-labeled to-
tal human cellular DNA (Heisterkamp et 
al., 1983). These have been primarily lo-
calized within the noncoding (intron) re-
gions of c-abl. To explore the possibility 
that c·-fms may contain analogous repeats, 
various combinations of restriction en-
zyme digests of each of the cosmid clones 
were assayed for sequence homology to to-
tal human cellular DNA. As summarized 
in Fig. 5, c-fm.s was shown by this means 
to contain a minimum of 12 separate re-
gions of repetitive sequence. Although the 
majority of these could be identified within 
non-v-frns homologous regions of the hu-
man c-fms locus, their precise localization 
will require further study. 
DISCUSSION 
In the present study we report the mo-
lecular cloning of a biologically active 
McDonough FeSV provirus from non pro-
ductively transformed Fisher rat embryo 
cells. This was accomplished by use of a 
probe specific for the U3 region of the Sny-
der-Theilen FeSV LTR. In addition, using 
a molecular probe prepared from the ac-
quired sequence-specific region of the 
McDonough FeSV genome (v-fms), the hu-
man cellular homolog of v-fms has been 
isolated. It is of interest that the Mc-
Donough FeSV proviral DNA isolated in 
our study, although similar to, shows sig-
nificant differences from a clone of Mc-
Donough FeSV described previously (Don-
ner et al., 1982). These differences are pri-
marily manifested with respect to numbers 
and positions of particular restriction sites. 
For instance McDonough FeSV proviral 
DNA isolated in the present study lacks 
one of the Hpai sites identified in the pre-
viously described clone and contains ad-
ditional Sacl, Pstl, and Bglii sites. Such 
variation may reflect evolutionary drift 
during the different passage histories of 
these virus isolates. With respect to their 
critical properties, however, the two clones 
appear highly related. Both are of the same 
overall size, the positioning of their ac-
quired sequence (v-fms) components is 
similar, and upon transfection to appro-
priate recipient cell lines, both induce 
morphologic transformation at high effi-
ciency. Moreover, both encode polyprotein 
gene products of the same size and im-
munologic properties. These include a ma-
jor translational product of around 170,000 
Mr and an acquired sequence specific cleav-
age product of 120,000 Mr. 
Using a subgenomic probe correspond-
ing to the acquired sequence-specific (v-
fms) region of the molecularly cloned 
McDonough FeSV proviral DNA, we have 
extended the above studies to molecular 
cloning of the human v-fms cellular ho-
molog. For this purpose a cosmid vector 
system was utilized because of the need to 
obtain cellular DNA inserts of relatively 
large (30-40 kb) size. The human c-fms gene 
isolated by this approach encompasses a 
total length of over 30 kb and contains nu-
merous regions of noncoding (intervening) 
sequence. Colinearity with v-fms was es-
tablished on the basis of relative extents 
of c-fms hybridization to subgenomic 
probes corresponding to different regions 
of the McDonough FeSV genome. It should 
be noted that the mapping procedure used 
provides an underestimate of the number 
of introns and overestimate of the size of 
v-fms homologous regions (exons) within 
the c-fms human locus. Moreover, when 
originally generated, the viral v-fms gene 
may have differed significantly from the 
cat c-fms and subsequently may have di-
verged further. Finally, differences in the 
cat v-fms and human c-fms gene may re-
flect differences in their species of origin. 
Thus conclusions regarding the positions 
and extents of human c-fms coding se-
quences must at present be considered 
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preliminary.lt is, however, of interest that 
the c-fms gene contains extensive regions 
of highly repetitive DNA within what ap-
pears to be the noncoding (intron) regions 
of the genome. Similar sequences have been 
reported within the noncoding regions of 
a number of other eukaryotic genes in-
cluding c-abl (Heisterkamp et aL, 1983). The 
nature of such sequences, their exact lo-
cations and significance will require fur-
ther study. 
With respect to overall size and extent 
of noncoding regions (introns), the human 
c-fms locus resembles c-abl which is also 
large (>25 kb) and consists of highly dis-
persed coding sequences (Heisterkamp et 
aL, 1983). Certain human cellular onco-
genes such as c-mos lack detectable non-
coding sequences (introns) (Prakash et al., 
1982; Watson et al., 1982). Although the 
human homologs of many other viral on-
cogenes, including c-rasKi, c-rasHa (Chang 
et aL, 1982), and c-fes (Trus et aL, 1982; 
Groffen et aL, 1982; Franchini et al., 1982), 
have been found to contain intervening se-
quences, the regions of homology have been 
localized within relatively small DNA 
fragments. Molecular cloning of each of 
the latter loci has been accomplished, us-
ing conventional A phage vector systems. 
This approach, however, proved difficult 
for c-abl and c-fms because of their size, a 
problem which was to a large extent cir-
cumvented by use of the cos mid vector sys-
tem. An additional advantage of the cos-
mid system for isolation of the cellular ho-
mo logs of these viral oncogenes is that 
relatively extensive regions are obtained 
at their 5' and 3' termini, thus strength-
ening the possibility that the complete cel-
lular homologs of the viral genes, includ-
ing putative regulatory sequences, are rep-
resented. The availability of molecular 
clones of c-fms should now make possible 
studies to explore the possible involve-
ment of this cellular oncogene in naturally 
occurring human tumors. 
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ABSTRACT 
A molecular probe was prepared >Nith specificity for the human cellular 
homologue of transforming sequences represented within the HcDonough strain of 
feline sarcoma virus (v-fms). By analysis of a series of mouse-human somatic 
cell hybrids containing--;ariable complements of human chromosomes it was 
possible to assign this human oncogene, designated c-fms, to chromsome 5. 
Regional localization of c-fms to band q34 on chromosome-s-was accomplished by 
analysis of Chinese hamster-human cell hybrids containing as their only human 
components, terminal and interstitial deleted forms of chromosome 5. The 
localization of c-fms to chromosome 5 (q34) is of interest in view of reports 
of a specific, apparently interstitial, deletion involving approximately two 
thirds of the q arm of chromosome 5 in acute myelogenous leukemia cells. 
INTRODUCTION 
A number of well defined genetic sequences, designated "oncogenes," have 
been identified within the human genome ( 1 ,2). Such sequences were demon-
strated by use of molecular probes corresponding to transforming sequences of 
oncogenic retrovirus isolates of various avian and mammalian species. In 
general, cellular oncogenes have remained highly conserved throughout 
vertebrate evolution although their functional significance is not known. The 
viral counterparts of many of the oncogenes studied to date are known to 
encode tyrosine specific protein kinases while enzymatic functions have not 
been ascribed to transforming proteins encoded by the others (3). Support for 
the possible involvement of cellular oncogenes in human cancer has recently 
been derived by the demonstraton that under certain conditions, members of the 
ras family, can transform cells in culture (4-7). Moreover, two other human 
cellular oncogenes, c-abl and c-myc, are involved in translocations associated 
with chronic myelogenous leukemia (8) and Burkitt's lymphoma (9,10), 
respectively. 
The human c-fms oncogene represents a cellular sequence initially 
identified on the basis of homology to the transforming gene (v-fms) of the 
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McDonough strain of feline sarcoma virus (11,12). We have recently applied a 
cosmid vector system for the molecular cloning of this gene (12). Although the 
c-fms gene product has not been identified, the corresponding viral gene, v-
fms, has been shown to encode a protein with transforming function (13,14) but 
lacking protein kinase activity (15). In the present study we have developed a 
specific probe for the human c-fms gene. Using this reagent, studies were 
performed to determine the chromosomal localization of c-fms and its relation 
to chromosomal deletions and/or rearrangements associated with specific forms 
of human cancers. 
MATERIALS AND METHODS 
Cells and Viruses: Cells were grown in Dulbecco's modification of Eagles 
medium supplemented with 10% calf serum and included NIH/3T3 mouse cells (15), 
A673 human cells (15) and the human-mouse somatic cell hybrids described in 
Table 1. A series of human-Chinese hamster cell hybrids, including HHW105 
containing chromosome 5 as its only human component and segregants of HHW105, 
designated HHW207, HHW'209, ffilW212, HHW213, HHW224, characterized by a variety 
of terminal and interstitial deletions of chromosome 5, have been described 
(16,17). 
Preparation of a Human c-fms Specific Probe: The isolation of a cosmid 
clone with a cellular insert of approximately 38 kb containing v-fms homo-
logous sequences (cos 13) from a library of human lung carcinoma DNA has been 
described (12). For use as a probe, an 0.9 kb Kpn-1 restriction fragment, was 
isolated from cos 13 according to previously described methods (12). 
Molecular Hybridization: Restriction enzymes were purchased from New 
England Biolabs and Bethesda Research Laboratories and were used according to 
the suppliers' specifications. DNAs were digested with restriction enzymes, 
subjected to electrophoresis through 0. 75% agarose gels and transferred to 
nitrocellulose essentially as described by Southern (18). Nick translation of 
were as described (19), Specific activity of probes and filter hybridization 
the probes was 2-5xl08 cpm/ug. After hybridization, filters were washed under 
high stringency conditions (0.1 xSSC,65°C) and exposed to XAR-2 film (Kodak) 
for up to 5 days at -70°C with Dupont Lightning Plus intensifying screens. 
RESULTS 
Identification of Human c fms Specific Sequences: As a means of 
discriminating human c-fms sequences from related sequences in the mouse 
cellular genome, a series of probes were prepared from cos 13 (Fig. 1), a 
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Figure 1 (Upper pannel) • Restriction endonuclease map of v-fms homologous 
human DNA sequences. The positions of v-fms homologous sequences, shown as 
solid boxes ( IBD) were determined as previously described (12). The position 
of sequences corresponding to the cellular insert in cos 13 and the 0.9 kb 
Kpn-1 restriction fragment used as a molecular probe for characterization of 
somatic cell hybrids are shown in upper portion of the figure. Single BamHl 
(B 4 0 ) and EcoRl (E 12 'l) restriction fragments detected by the c-frr:.s K0 9 proOe, are indicatedbe:Iow the restriction map. Restriction enzymes inclua:e: 
BamHl (B); tlindiii (H); EcoRl (E);and Kpn-1 (K). Panels I & II: Analysis of 
mouse, human and representative mouse-human somatic cell hybrid cellular DNAs 
for human c-fms sequences. BamHl (I) and EcoRl (II) digested cellular DNAs (25 
)..lg/lane) wer:e-electrophoresed on 0.7% gels, blotted to nitrocellulose and 
hybridized to the c-fms K0 9 probe. Cell lines include: I: NIH/3T3 mouse (A); A673 human (B); and mOuse-human somatic cell hybrids DT1.2R (C); Dur4R3 
(D); and Dur4R4 (E); II: A673 human (A); NIH/3T3 mouse (B); and mouse-human 
hybrid, MOG-2E5 (C). The positions of single human DNA specific K 
homologous BamHl (B 4 0 ) and EcoRl (E12 'i) restriction fragments are indica~ed to the right side Of the figure. "Hindiii digested :\DNA, included as a 
molecular weight marker is shown on the left. Panel III: Regional 
localization of c-fms on chromosome 5. BamHl digested DNAs of human A673 (A); 
Chinese hamster (B~ and human-Chinese hamster somatic cell hybrids including 
HHW213 (C); HHW207 (D); HHW209 (E); HHW224 (F); HHW212 (G); HHW105 (H) were 
analyzed for human c-fms specific sequences as above. 
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previously described cosmid clone containing v-fms homologous human cellular 
DNA sequences (12). One such probe, c-fms K0 , 9 was suitable for the purpose 
of the present study in that it lacked detectable repetitive sequences and 
hybridized specifically to single 4.0 kb BamHl and 12.5 kb EcoRl human DNA 
restriction fragments (Fig. l, Panels I & II). The sizes of both restriction 
fragments correspond to those predicted on the basis of restriction endonu-
clease map analysis of the v-fms homologous region of the human genome. No 
detectable cross-homology between this probe and mouse cellular DNA sequences 
was observed when high stringency washing conditions were used as described in 
Methods. 
c-fms Maps on Human Chromosome 5: To determine the chromosomal location 
of the human cellular homologue of v-fms, EcoRl and BamHl restriction 
endonuclease-digested cellular DNAs of human-mouse somatic cell hybrids were 
screened for human c-fms specific sequences. The above described c-fms K0 • 9 
probe was used for this purpose. These hybrids each contain a full complement 
of mouse chromosomes but have retained only limited numbers of human 
chromosomes. As shown in Fig, l, Panels I & II, it was possible, by this 
means, to distinguish between hybrids containing the human c-fms gene and 
those lacking such sequences, As shown in Table 1, six of the fifteen somatic 
cell hybrids analyzed contained c-fms K0 • 9 homologous sequences. Only four 
chromosomes (5 ,12 ,14 and 17) are common to all six c-fms positive hybrids. 
These findings localize c-fms to human chromosomes 5,12,14 or 17. To further 
localize c-fms we examined the chromosomal content of the series of nine 
hybrids which were non-crossreactive with the c-fms K0 • 9 probe. As summarized 
in the lower portion of Table 1, only human chromosome 5 was missing from each 
of these nine hybrids. This excludes the possibility of c-fms mapping on 
chromosomes 12,14 or 17, each of which were present in at least three of the 
c-fms negative hybrids, and thus localizes c-fms to human chromosome 5. 
Regional Localization of c-fms to Chromosome 5 (q34): The recent 
isolation of a series of segregants of Chinese hamster-human somatic cell 
hybrids expressing variable numbers of genes mapping on chromosome 5 (16 ,17) 
provided a means of regionally localizing c-fms. The majority of these 
segregants are characterized by terminal deletions involving well defined 
regions of the long arm of chromosome 5; these were isolated by positive 
selection for leuS, which maps on the p arm or very near the centromere on the 
q arm of the chromosome, and negative selection directed against markers on 
the distal half of the q arm (emtB and chr), DNAs prepared from Chinese 
hamster-human hybrid cells were analyzed for c-fms K0 • 9 homologous sequences 
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TABLE 1: ANALYSIS OF HUHAN~MOUSE SOMATIC CELL HYBRIDS FOR HUr1AN 
c fms SPECIFIC SEQUENCES 
Hybrid Ref Human Chromosomes c~fms 
l 2 3 4 5 6 7 8 9 10 ll 12 13 14 15 16 17 18 19 20 21 22 X 
CTP 3~a4 21 + + + [ + > + > + + + + + OUR 22 + + + + + + + + + + + DUR4R3 22 + + + + + + + + + MOG~2 4E5 19 + + + + + + + + + + + + + + + + + + + + + SIR-7 A2 19 + + + + + + + + + + + + + + + + 
t10G-2 Gl 19 + + + + + + + + + + + + + + + + NT + 
DTl. 2R 26 + + + + t + + t + + 
CTP41Pl 21 + + + + + + + + 
w Cl 25 + + + + + + + + h~c1Jcuz lO + + + + 
FlR5R3 23 + + 
DUR 4.4 20 + + + + + + + + + + 
SIR-7 Dl 19 + + + + + + + + + + + + + + 
SIR-7 Gl 19 + + + + + + + + + + + + + + 
MOG U/22 24 + + + + 
1The origins and details of the initial characterizations of the somatic cell hybrids are described in the references 
indicated in the second column. The human chromosomal contents were deduced from a combination of karyotypic, antigenic 
and enzymatic analyses. Karyotypic analysis was done by a combination of Gll staining and quinacrine banding. Analysis 
of hybrids for c-fms sequences was performed as described in the legend to Fig. !. Concordance beween the presence or 
absence of a particul~r chromosome from a hybrid and c-fms sequences is indicated by the open boxes. 
"' 
,.... 
105 213 209 212 224 207 
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Figure 2. Schematic representation of human chromosome 5 indicating the 
localization of breakpoints of segregants utilized in the present study and 
previously reported map positions of leuS, hexB, emtB and chr (16,17). 
Localization of c.-fms is based on the results or-the present study. In the 
right panel of thefigure the series of chromosome 5 deletion se6regants are 
shown diagramatically and indicated as c-fms positive ( +) or negative (-). 
Regions common to the three segregants containing human c-fms sequences are 
shown as solid bars. 
following BamHl. digestion (Fig. 1, Panel III). In contrast to human DNA, 
Chinese hamster cellular DNA lacked detectable homology with the c-fms K0 _9 
probe. Hybrid IDIW105, containing an intact chromosome 5 as its only human 
component, reacted strongly with 
localization of c-fms to human 
the c-fms 
chromosome 
probe, thus confirming th.e 
In contr~st, human c-fms 
sequences were absent from a segregant (HHW213) missing almost the complete q 
arm of chromosome 5 as well as from segregants HHW209 and HHW212 which have 
lost approximately 80% and 40% respectively, of the terminal portion of the q 
arm of chromosome 5. An additional segregant, HHW224, characterized by an 
apparent terminal deletion of chromosome 5 encompassing at most the q35 
terminal band corresponding to the chr marker, was positive for c-fms, thus 
localizing c-fms between q23 and q34. 
In a previous study (16), preliminary characterization of an additional 
segregant, HHW207, revealed a large interstitial deletion of chromosome 5 
encompassing both the hexB and emtB markers. Upon hybridization analysis, 
this segregant was found to have retained c-fms (Fig. 1, Panel III). In order 
to more precisely localize c-fms, it was necessary to subject HHW207 to more 
detailed karyotypic analysis. Upon examination of chromosome preparations from 
HHW207 under conditions which gave much better banding resolution than was 
achieved previously we were able to unequivocally localize the interstitial 
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deletion as encompassing the region of chromosome 5 mapping from ql2 to q33, 
As shown schematically in Fig. 2, these results est.<1blish the order of the 
individual markers on chromosome 5 as leuS, hexB, emtB, c-fms and chr and more 
specifically localize c-fms to band q34. 
DISCUSSION: 
In the present study ~e have utilized a panel of mouse-human somatic cell 
hybrids to map the human oncogene, c-fms, on chromosome 5, Additionally, the 
availability of a set of hybrids with well defined deletions in chromosome 5 
(16,17) has allowed regional localization of c-fms to band q34. The gener-
ation of sets of deletion hybrids, such as those used in the present study, is 
possible for any human chromosome for which appropriate positive and negative 
selection markers can be developed. By use of such hybrids in combination with 
Southern hybridization the localization of specific genetic sequences can be 
achieved v;rith much less ambiguity than is possible by use of alternative 
techniques such as in situ hybridization. 
The localization of c-fms on chromosome 5, in addition to the previous 
assignment of other human oncogenes to specific chromosomes, establishes the 
distribution of the known oncogenes among human chromosomes to be relatively 
random. In fact, the eight human oncogenes which have been mapped to date are 
distributed among seven different chromosomes. These include c-fes (20,21), c-
myb (21), c-abl (20), c-sis (22,23) and c-ras-H (24) which have been mapped to 
chromosomes 15, 6, 9, 22 and 11, respectively, c-fms localized in the present 
study on chromosome 5, and two human oncogenes, c-myc (9,10) and c-mos (25,26) 
both of which map on chromosome 8. 
Evidence for an association of human oncogenes w-ith translocations and 
deletions specific to various human cancers is accumulating. For instance, c-
ab! has been localized within a small terminal region of chromosome 9 (20) 
which is translocated to chromosome 22 in chronic myelogenous leukemia (9 ,10) 
while c-sis maps •,o1ithin the reciprocally translocated region of chromosome 22 
(27). Similarly, c-myc has been identified near the breakpoint of the segment 
of chromosome 8 which trans locates to chromosomes 2, 14 or 22 in Burkitt's 
lymphoma (9 ,10) and c-fes has been mapped within the region of chromosome 15 
which is translocated to chromosome 17 in acute promyelocytic leukemia (28). 
In other studies, c-ras-H has been mapped on chromosome 11, a human chromosome 
with a characteristic deletion in Wilms tumor (24). The mapping of c-fms on 
chromosome 5 is of interest in that deletions within the long arm of 
chromosome 5 are also frequently observed in patients with refractory anemia 
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(29) and acute myelogenous leukemia (30,31). Such deletions have been reported 
to appear to be interstitial, involving approximately t~>~o thirds of the long 
arm of chromosome 5, but not extending to band q34 (29,31). 
As one possible model, to account for their association with chromosomal 
rearrangements occurring in specific human cancers, cellular oncogenes, such 
as c-fms could map adjacent to chromosomal breakpoints possibly resulting in 
the juxtapositioning of potentially oncogenic sequences with cellular 
promoters. Such a model has been proposed to account for the trans locations 
associated with chronic myelogenous leukemia and Burkitt's lymphoma (8-10); in 
fact, in Burkitt's lymphoma the cellular sequences in the chromosome to which 
c-myc is translocated appear to be involved in immunoglobulin rearrangements 
(9 ,10). It will thus be of interest to accurately map the proximity of c-fms 
to chromosome Sq- deletions associated with acute myelogenous leukemia and to 
analyze tumors with the Sq- deletion for expression of c-fms gene products. 
Independent of its potential involvement in neoplasia, the localization of c-
fms provides a unique molecular marker for chromosome 5 which should be useful 
for identifying syntenic linkage associations among diverse mammalian species, 
ACKNOWLEDGEMENT: 
The authors thank G.T. Blennerhassett and P. Hansen for their excel-
lent technical assistance. This work was supported under Contract No, 
NOI-C0-76380 from the National Cancer Institute, Bethesda, Haryland, and 
by Public Health Service Grant No, GM-25339 from the National Institute of 
General Medical Sciences, Bethesda, Maryland. 
REFERENCES: 
l. Varmus, H.E. (1982) Science 216, 812-820 
2. Bishop, J.M. (1902) Retrovirus and Cancer Genes, In Adv. Cancer Res. 37, 
1-32 
3. Klein, G. (1982) Advances in Viral Oncology. New York, Raven Press. 
4, Parada, L.F., Tabin, C.J., Shih, C. and Weinberg, R.A. (1982) Nature 
297 ,474-478 
5. Santos, E., Tronick, S.R., Aaronson, S.A., Pulciani, S., and Barbacid, 
M. (1982) Nature 298, 343-347 
6. Der, C.J., Krontiris, T.G., and Cooper, G.t1. (1932) Proc. Natl. Acad, 
Sci. USA 79, 3637-3640 
7. Chang, E.H., Furth, M.E., Scolnick, E.M. and Lo~vy, D.R. (1982) Nature 
297, 479-483 
3. de Klein, A. Geurts van Kessel, A., Grosveld, G., Bartram, C.R., 
Hagemeijer, A., Bootsma, D., Spurr, N., Heisterkamp, N., Groffen, J. and 
Stephenson, J.R. (1982) Nature 300, 765-767 
9. Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R.C., 
Croce, C.M. (1982) Proc. Natl. Acad, Sci. U.S.A. 79, 7824-7827 
10. Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, s., 
Aaronson, S., and Leder, P. (1982) Proc, Natl. Acad. Sci. USA 79, 
7837-7841 
11. Donner, L., Fedele, L.A., Garon, C.F., Anderson, S.J., and Sherr, C.J. 
(1982) J. Viral, 41, 489-500 
94 
12. Heisterkamp, N., Groffen, J., and Stephenson, J.R. 
126, 248-258 
(1983) Virology 
13. Van de Ven, W.J.M., Reynolds, F.H., Nalewaik, R., and Stephenson, J.R. 
(1980) J. Viral. 35, 165-175 
14. Barbacid, M., Lauver, A.V., and Devare, S.G. (1980) J. Viral. 33, 196-
207 
15. Reynolds, F.l:L Jr., Van de Ven, W.J.M., Blomberg, J., and Stephenson, 
J.R. (1981) J. Vriol. 41, 1084-1089 
16. Dana, S., and Wasmuth, J.J. (1982) 
17. Dana, s., and Wasmuth, J.J. (1982) 
18. Southern, E.M. (1975) J. Mol. Biol. 
Malec, & Cell Biol, 2, 1220-1228 
Somatic Cell Gen. 8, 245-264 
98, 503-517 
19. Groffen, J., Heisterkamp, N., Grosve1d, F., Van de Ven, W., and 
Stephenson, J.R. (1982) Science 216, 1136-1138 
20. Heisterkamp, N., Groffen, J., Stephenson,J.R., Spurr, N.K., Goodfellow, 
P.N., Solomon, E., Garritt, B., and Bodmer, W,F. (1982) Nature 299, 
747-749 
21. Dalla-Favera, R., Franchini, G., Martionotti, s., Wong-Staa1, F., Gallo, 
R.C., and Croce, C.M. (1982) Proc. Natl.Acad, Sci, USA 79, 4714-4717 
22. Swan, D.C., McBride, O.W., Robbins, K.C., Keithley, D.A., Reddy, E.P., 
and Aaronson, S.A. (1982) Proc. Nat1.Acad. Sci. USA 79, 4691-4695 
23. Dalla-Favera,R., Gal1o,R.C., Gia1longo,A., and Croce, C.M. (1982) 
Science 218, 686-688 
24. McBride, O.W., Swan, D.C.,Santos, E., Barbacid, M., Tronick, S.R., and 
Aaronson,S.A. (1982) Nature 300, 773-774 
25. Prakash, K., McBride, O.W., Swan, D.C., Devare, S.G., Tronick, S.R., and 
Aaronson, S.A. (1982) Proc. Natl. Acad,Sci. USA 79, 5210 
26. Nee!, B.G., Jhanwar, S.C., Chaganti, R.S.K.,and Hayward, W.S. (1982) 
Proc. Natl. Acad, Sci. USA 79, 7842-7846 
27. Groff en, J., Heisterkamp, N., Stephenson, J .R., Geurts van Kessel, A., 
de Klein, A., Grosveld, G., and Bootsma, D. (1983) J. Expt. Med. 158, 
9-15. 
28. Sheer, D., Hiorns, L.R., Goodfellow, P .N,, Trows dale, J., Solomon, E., 
Swallow, D.A., Pavey, S., Heisterkamp, N., Groffen, J., and Stephenson, 
J.R. (1983) Proc. Nat!. Acad. Sci. USA (in press) 
29. Van den Berghe, H., Cassiman, J.J., David, G., Fryns, J.P., Michaux, 
J.L., and Sakal, G. (1974) Nature 251, 437-438 
30. Sakal, G., Michaux, J.L., Van den Berghe, H., Cordier, A., Rodhain, J., 
Ferrant, A., Moriau, H., de Bruyere, M., Sonnet, J. (1975) Blood 46, 
519-553 
31. Van den Berghe, H., David, G., Michaux, J.L., Sakal, G., and Verwilghen, 
R., (1976) Blood 48, 624-626 
32. Whitehead, A.S., Solomon, E., Chambers, S., Bodmer, W.F., Pavey, S., and 
Fey, G. (1982) Proc. Nat!. Acad. Sci, USA 79, 5021-5025 
33. Solomon, E., Bobrow, M., Goodfellow, P.N., Bodmer, W.F., Swallow, D.M., 
Pavey, s., and Noel, B. (1976) Somat. Cell Genet, 2, 125-140 
34. Jones, E.A., Goodfellow, P.N., Kennett, R.H., and Bodmer, W.F. (1976) 
Somat, Cell Genet. 2, 483-496 
35. Solomon, E., Bobrow, M., Goodfellow, P.N., Bodmer, W.F., Swallow, D.~ •• 
Pavey, s., and Noel, B. (1976) Somat. Cell Genet. 2, 125-140 
36. Hobart, M.J., Rabbits, T.H., Goodfellow, P.N., Solomon, E., Chambers, 
S., Spurr, N., and Pavey, S. (1981) Ann. Hum. Genet. 45, 331-335 
37. Pavey, S., Jeremiah, S.J., Barker, R.F., Hopkinson, D.A., Robson, E., 
Cook, P .. J.L., Solomon, E., Bobrow, M., Carrot, B., and Buckton, K.E., 
(1980) Ann. Hum. Genet. 43, 241-248 
38. Nabholz, M.,Miggiano, V., and Bodmer, W.F. (1969) Nature 223, 358-363 
39. Swallow, D.M., Solomon, E., and Pajunen, L. (1977) Cytogenet. Cell 
Genet. 18, 136-148 
95 

APPENDIX PAPER III 

Isolation of Human Oncogene Sequences (v-fes Homolog) 
from a Cosmid Library 
Abstract. To define the human homolog (or homologs) of transforming sequences 
(v-fes gene) common to Gardner (GA) and Snyder Theilen (ST) isolates of feline 
sarcoma virus (FeSV), a representative library of human lung carcinoma DNA in a 
cosmid vector system was constructed. Three cosmid clones v.:ere·isolated contain-
ing GAIST FeSV v-fes homologous cellular sequences, within 32- to 42-kilobase 
cellular inserts representing 56 kifobases of contiguous human cellular DNA. 
Sequences both homologous to, and colir;ear with, GA or ST FeSV 1{-fes are 
distributed discontinuously over a region of up to 9.5 kilobases and contain a 
minimum of three regions of nonhomology representing probable introns. A thymi-
dine kinase sele.ction system was used to show that, upon transfection to RAT-2 cells, 
the human c-fes sequence lacked detectable transforming activity. 
That RNA transforming viruses con-
tain acquired cellular ge_nes accounting 
for their capacity to transform cells in 
culture and induce tumors of various 
histological classes in vivo is well estab-
lished(/). Although such ceiiular derived 
"oncogenes" have been described only 
in animal model systems (!), their exis-
tence makes possible the isolation of 
related human genomic sequences. Ex-
tensive noncoding sequences within the 
cellular homologs of many such viral 
transforming genes (2, J) represent a 
major difficulty for their cloning in con-
ventional phage and plasmid systems. 
Because of this problem and the desir-
ability of obtaining such genes with suffi-
ciently extensive flanking sequences for 
studies of cellular regulatory controls 
influencing their expression, we used a 
ABCDEFGH 
Fig. 1. Restriction patterns of cellular homo-
logs of transformation-specfic DNA se-
quences common toGA and ST FeSV. (A) 
High molecular weight DNA "s were prepared 
from kitten lung embryo cc:lls; (B) CCL64 
mink lung cells; (C) NlH/3T3 mouse embryo 
cells; (D and G) nonnal human lung tissue; 
and (E, F, and H) human lung carcinoma 
tissue. DNA samples (20 IJ-g) were digest<:d 
with Eco Rl (A to E), Bam HI {F), or Kpn I 
(G and H), separat<:d by electrophoresis on 
0.75 percent agarose gels, transferred to nitro-
cellulose, and analyzed by hybridization ac-
cording to previously described procedurc:s 
(19). nP-Labe!ed DNA digested with Hind Ill 
is included as a molecular weight standard. 
cosmid cloning vector (4-6) in our study. 
This system involves the use of plasmids 
containing lambda cos sequences (cohe-
sive ends) permitting insertion of large 
DNA fragments, in vitro packaging, and 
transduction to Escherichia coli. 
To define the cellular homolog of the 
GAIST transforming (v-fes) gene, we 
used a molecular probe corresponding to 
a 0.5-kb Pst I restriction fragment within 
the ST FeSV (feline sarcoma virus) ac-
quired sequence (v-fes Sd (2, 7). By 
Southern blot analysis (8), single bands 
of hybridization were observed at molec-
ular. weights of between 7.0 and 12.5 kb 
in cat, mink, mouse, and human Eco RI 
restricted DNA's (Fig. I, A to E). Re-
striction of DNA's from both normal 
human lung and human lung carcinoma 
with Bam HI or Kpn I resulted in gener-
ation of single bands hybridizing at 3.8 
kb (Fig. I F) and 2.4 kb (Fig. 1, G and H), 
respectively. 
A cosmid library was constructed and 
screened for v-fes homologous se-
quences (Fig. 2). Three clones were ini-
tially selected on the basis of hybridiza-
tion to v-fes SL and were propagated for 
restriction endonuclease analysis. Two 
of the clones contained a 12.0-kb Eco RI 
restriction fragment with hofnology to 
both v:fes SL and v-jes SR. while only the 
9.8-kb 5' region of this fragment was 
represented in the third clone. Further 
restriction enzyme analysis indicated 
that sequences within these clones were 
overlapping and represented a 58-kb 
contiguous region of the human genome. 
The orientation and positioning of the 
cellular inserts within these clones, both 
relative to each other and to the cosmid 
vector, are summarized in Fig. 3. For 
purposes of fine structure mapping, the 
above described 12.0-kb Eco RI v-fes 
homologous restriction fragment was 
subcloned in plasmid pBR328. 
As a prerequisite to further analysis of 
the above described clones it was first 
necessary to isolate and prepare molecu-
lar probes corresponding to the complete 
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acquired cellular sequences of both GA 
and ST FeSV. The ST FeSV genome 
was cloned in phage Charon 9 as a 6.6-kb 
fragment of Hind Ill restricted DNA iso-
lated from the nonproductively trans-
formed mink cell line, ST-FeSV 64 C!4l. 
Similarly, GA FeSV was isolated as a 14-
kb Eco RI restriction fragment from 
the mink-transformed clone, G-FeSV 64 
F3, in phage ;l..gtWES;~..B. 32P-Labeled 
DNA's corresponding to the entire GA 
and ST FeSV genomes were prepared 
(Fig. 3). 
The results of fine structure mapping 
of the 12.0-kb Eco Rl restriction frag-
ment containing GA and ST FeSV ho-
mologous sequences are summarized in 
Fig. 3. The indicated regions of hybrid-
ization are based on identification of 
restriction fragments hybridizing with 
each of the four indicated probes. These 
encompass a total of 4.5 kb of homology 
distributed discontinuously over a 9.5-kb 
region. No additional homology with ei-
ther GA or ST FeSV was observed with-
in the entire 58 kb of human DNA repre-
sented within the three cosmid clones. 
The similarity in arrangement ofhomolo-
Eca I 
gous sequences within the viral and cel-
lular DNA's establishes colinearity be-
tween v-fes and its human homolog. 
These findings thus provide a maximum 
estimate of human DNA sequence ho-
mology to the GA and ST FeSV genomes 
and a minimal estimate of the number of 
nonhomologous regions representing 
probable introns. 
From a comparison of the results sum-
marized in Fig. 3, to the analysis of total 
human lung carcinoma DNA (Fig. 1), the 
major Eco RI, Kpn I, and Bam HI re-
striction fragments homologous to the v-
Bo SV40 origin Apr ' Bam HI lk Eoa I B. "' Cia I pHEP Bam HI 
" 
Fig. 2. Construction of a human lung carcinoma DNA library in a cosmid vector 
system. High molecular weight cellular DNA was purified from human lung 
carcinoma ti~sue and partially digested with Mbo I and the fragments were 
separated by sucrose gradient (5 to 20 percent) fractionation. The DNA's of 
plasmids pOPFI 19 and pHEP were digested with Eca I and Cia I. respectively, 
treated with calf intestine phosphatase, and redigested with Bam HI. A I: t 
molar ratio (1.0 ,_..g each) of the restricted plasmid DNA's and restricted cellular 
DNA fragments (30 to 50 kb) were ligated. packaged in vitro, and transduced 
into E. coli ED8767 (5. 6). Ampicillin-selected bacteria containing recombinant 
DNA were grown on nitrocellulose (Millipore HA WP) at a density of approxi-
mately 15.000 colonies per filter. Approximately 250,000 individual colonies 
were obtained representing three to four times that required for representation 
of the entire human genome, 
sr-F.sv 
GA-v-fes 
ST-v-fes 
v-fes-Sl 
Eco Rl 
"" '(" origin ·' 
j "" Phosphatase Bam HI j Cia I 0:::~~~"" "' "' " 
T4llgue 
ONA fragmenl> (SO 10 50 kb) 
SV40 
cos or111in 1~ Apr 
~ .. ·)(~==~---~r-~-~ 
Mbo I Sam HI Sam HI Mb<> I 
Eco Rl 
Fig. 3. Restriction map of human cellular 
sequences homologous to acquired cellular 
oequences represented within GA and ST 
FeSV. Open boxes {D) within the viral ge-
nomes represent the relative positions of their 
respective acquired cellular sequences, while 
feline leukemia virus cross-reactive se-
quences are shown as solid lines (•). The 
positions of long terminal repeats (fll!l) and 
cellular flanking sequences(.....,) are also indi-
cated. The 12.0-kb Eco RJ DNA restriction 
fragment shown in the center of the figure 
contains the entire human homolog of the GA 
and ST FeSV acquired cellular sequences. 
Restriction fragments containing sequences 
homologous to the complete GA-FeSV 
genome (GA-v-fe•). the ST-FeSV genome 
(ST-v-fes). v-Jes S~. and v-fes s,. are indicat-
ed. The lower portion of the figure shows the 
position of the 12.0-kb Eco Rl fragment with· 
in a 58-kb contiguous sequence of human 
cellular DNA: the restriction map of this 58-
kb sequence was deduced as a composite of 
individually mapped overlapping cellular se-
quences represented within the cosmids 
shown at the bollom. The relative positions of 
the thymidine kinase gene (lk). cos site, and 
SV40 restriction fragment within the 9-kb 
vector are shown for purposes of orientation. 
Restriction enzymes are abbreviated as fol-
lows: Ava I (A). Bam HI (B). Eco Rl (EJ. Kpn 
I (KJ. Hind Jll {H}. and Pst I (PJ 
~::::::;::::;::::;::::;::::;:::;::::::=::;:::;::;::;:::::;::::::/::::;::::;::::;:::;:= Eco Rl sites 
- Kpn I sites 
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10 kb 
fes S1.. probe are seen to correspond. 
~imilarly, correspondence was observed 
between v-fes S~t homologous restriction 
fragments as determined by genomic 
blots of total cellular DNA and the isolat-
ed human homolog of the GAIST v-fes 
gene. The human v-fes homolog showed 
no detectable transforming activity when 
transfected to RAT-2 cells by means of a 
thymidine kinase selection system. Mo-
lecularly cloned GAIST FeSV were in-
cluded as positive controls. 
The molecular cloning of human geno-
mic sequences hQmologous to GAIST 
FeSV v-fes is of particular interest be-
cause (i) the c-fes gene is highly con-
served and {ii) It is subject to frequent 
recombination with type C retrovirus 
sequences resulting in the generation of 
transforming viruses (7, 9). Virus iso-
lates of this class of not only mammalian 
(feline) but also avian (chicken) origin 
contain related cellular derived trans-
forming sequences (10). A common "fea-
ture of the major gene product of these 
recombinant transforming viruses is an 
associated tyrosine-specific protein ki-
nase (11-13). In addition, the GA and ST 
FeSV gene products exhibit binding af-
finity for a 150,000 molecular weight 
cellular phosphoprotein {12, 14) and 
transformation by these viruses leads to 
abolition of epidermal growth factor 
binding (15, 16) and production of a low 
molecular weight transforming growth 
factor (I 7). 
The finding of only a single genetic 
locus exhibiting significant homology 
with the GA and ST FeSV acquired 
sequences establishes that the highly re-
lated transforming sequences within the 
genomes of these independently isolated 
viruses were originally derived from the 
same cellular gene. Conversely, molecu-
lar probes specific for acquired cellular 
sequences represented within the Abel-
son MuL V genome, an independent 
RNA transforming virus.with associated 
protein kinase activity (I J, 18), recog-
nized different human DNA restriction 
fragments and lacked detectable homolo-
gy with sequences represented within 
any of the three cosmid isolates (data not 
shown). Thus there must exist at least 
two independent loci within the human 
genome homologous to viral genes with 
associated tyrosine-specific protein ki-
nase activities. 
The human carcinoma DNA cosmid 
library generated in our study provides a 
specific reagent for the molecular clon-
ing of cellular homologs of viral trans-
forming genes. In particular, the avail-
ability of this library should be of value 
for the isolation of those human trans-
forming genes with extensive intervening 
sequences. An important feature of this 
system is the presence of a functionally 
active thymidine kinase gene that allows 
for selection of minority populations of 
eukaryotic cells containing such cosmids 
after transfection. In addition, SV40 
DNA sequences situated in one of the 
cosmid arms have been shown to exert a 
positive influence on transcription in the 
~-globin system (6). If this sequence 
similarly influences expression of cellu-
lar homologs of viral transforming genes, 
its presence may be important for identi-
fication of the translational products of 
these sequences and a determination of 
their transforming potential. 
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APPENDIX PAPER IV 

Transforming Genes of Avian (v-fps) and Mammalian (v-fes) Retroviruses 
Correspond to a Common Cellular Locus 
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The Gardner (GA) and Snyder-Theilen (ST) isolates of feline sarcoma virus (FeSV) 
represent genetic recombinants between feline leukemia virus (FeLV) and transforma-
tion-specific sequences {v-fes gene) of cat cellular origin. A related transforming gene 
(v-fps), common to the Fujinami, PRC II, and UR 1 strains of avian sarcoma virus has 
also been described. Translational products of each of these recombinant virus isolates 
are expressed in the form of polyproteins exhibiting protein kinase activities with spec-
ificity for tyrosine residues. In the present study, v-fes and v-fps homologous sequences 
of GA-FeSV, ST-FeSV, and Fujinami sarcoma virus (FSV) are defined and these inde-
pendently derived transforming genes are shown to correspond to a common cellular 
genetic locus which has remained highly conserved throughout vertebrate evolution. 
Several independent acute transforming 
retrovirus isolates have been shown to en-
code as their major translation products 
tyrosine-specific protein kinases which are 
closely associated with their transforming 
function (12). Such viruses can be sepa-
rated into six classes on the basis of their 
cellular "oncogenic" sequences. Acquired 
cellular "oncogenes" and representative 
virus isolates of each group include: v-src 
(RSV) (6, 20, 22), v-fes (STand GA FeSV) 
(3, 12-14,27-29, 33-35), v-fps (FSV, PRCII, 
URI) (10, 18,23-25,30, 36), v-yes (Y73, Esh) 
(15, 21, 30, 39), v-ros (UR2) (11, 30), and v-
abl (A MuLV) (5, 16, 26, 38). Two of these 
genes (v-fes and v-abl) are of mammalian 
cellular origin while the remaining four 
(v-src, v-fps, v-yes, and v-ros) were derived 
from naturally occurring avian tumors. 
Earlier studies indicating low levels of se-
quence homology between the v-fes and v-
fps genes (31), and both immunologic (2) 
and structural relatedness (.4) between 
their translational products, raised the 
possibility that these either represent re~ 
lated genes or alternatively that they cor-
respond to a common cellular locus which 
1 To whom reprint requests should be addressed. 
has remained highly conserved through-
out vertebrate evolution. Precedence for 
the first model was derived from the re-
latedness of Harvey and Kirsten strains 
of rat sarcoma virus (8). The present study 
was undertaken to resolve these alterna-
tive possibilities. 
To determine the extent of relatedness 
of FSV v-fps to the GA and ST FeSV v-
fes genes, molecular probes corresponding 
to the complete GA-FeSV and ST FeSV 
genomes, designated GA-v-fes and ST-v-
fes, respectively, and to 0.5-kb Psti 
subgenomic fragments of ST-FeSV, des-
ignated v-fes SL and v-fes SR (Fig.l), were 
utilized (13, 17). Each was tested for hy-
bridization by Southern blot analysis to a 
series of restriction fragments of a pre-
viously described (30) molecular clone of 
FSV in Agt WES-AB. As shown in Fig. lA, 
the extent of v-fps homology with the in-
dividual v-fes probes varies in a manner 
colinear with their arrangement in the STM 
and GA-FeSV genomes. For instance, ho-
mology to v-fes SR was restricted to the 
Psti-Smai fragment at the 3' region ofFSV 
v-fps, while v-fes-SL lacked homology with 
the 3'-terminal BamHI-Smai fragment 
and v-fes SL homology extended much fur-
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FIG. 1. Homology between FSV-v-fps and acquired cellular sequences (v-fes) of the Gardner and 
Snyder-Theilen strains of FeSV. (A) An Sstl restriction fragment, representing the entire molec-
ularly cloned FSV genome, was purified from recombinant phage lambda-FSV-1 by gel electro-
phoresis (17). Restriction maps of DNA sequences mapping within the Snyder-Theilen (ST-v-fes) 
and Gardner (GA-v-fes) FeSV acquired cellular sequences, shown in the upper portion of the figure, 
have been previously described (17). Following digestion with the indicated restriction enzymes, 
hybridization was performed using previously described 32P-labeled probes (13, 17) including GA-
v-fes, ST-v-fes, v-fes-~, and v-fes-SR. Extents of hybridization of FSV-v-fps with each of the four 
probes is shown as negative (0); weak (0); intermediate (D); and strong (•). Restriction endonu-
cleases include BamHI (B); Kpni (K); Psti (P); Pvul (PI); Pvuii (PII); Smai (Sm); and &tl (Ss). 
The 4.7-kb FSV Sst! restriction fragment shown in the center of the figure was digested with either 
Psti and Kpnl (A, D, G) or Pstl alone (B, E, H), electrophoresed on a 1.0% agarose gel, transferred 
to nitrocellulose, and hybridized to the indicated probes. In addition, a 2.6-kbPvui/Smal restriction 
fragment was isolated from the FSV clone by preparative gel electrophoresis, further digested 
with Pstl, and analyzed for hybridization to the same series of these probes. 
ther into the 5' region of FSV v-fps. The 
most extensive homology was observed 
with GA-v-fes which included all but the 
extreme 5' region of v-fps. The strength of 
homology between v-fes and v-fps was 
most pronounced at their 3' ends. Repre-
sentative hybridization data are shown in 
the lower panel of Fig. lB. In contrast to 
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FIG. 2. Comparison of v-fes and v-fps homologous sequences in human (A, B), cat (C, D), mouse 
(E, F), and rat (G, H) cellular DNAs. DNAs (20 ~g) from cell lines of each species were digested 
with EcoRI, separated by electrophoresis on 0.75% agarose gels, transferred to nitrocellulose, and 
hybridized to either v-fes-SL (A, C, E, and G) or the 2.6-kb Pvui-Smai FSV-v-Jps probe (B, D, F, 
and H). 
the homology between the acquired cel-
lular transforming genes of GA -FeSV and 
FSV, no detectable cross-hybridization was 
observed between the structural genes of 
these viruses. 
The above results demonstrate exten-
sive homology between v-fes and v-fps and 
establish co linearity in their structural or-
ganization. To resolve whether these viral 
transforming sequences correspond to the 
same, or alternatively, to related but ge-
netically distinct cellular genes, high-mo-
lecular-weight DNAs of several mamma-
lian species including human, cat, mouse, 
and rat were analyzed for sequence ho-
mology to v-fes- and v-fps-specific probes. 
In each case, single 9.0- to 12.0-kb EcoRI 
DNA restriction fragments hybridized to 
probes specific for both viral transforming 
genes (Fig. 2). Although the intensity of 
hybridization is much greater with the v-
fes than with the v-fps specific probe, no 
additional v-fps homologous restriction 
fragments were observed. With both con-
trol and human lung carcinoma DNA, this 
fragment is 12.0 kb in length and corre-
sponds to the previously described (17) 12.0-
kb restriction fragment containing the 
complete v-fes human homolog. The lack 
of identifiable DNA restriction fragments 
exhibiting exclusive or preferential hy-
bridization with either v-fes- or v-fps-spe-
cific probes strongly argues for the in-
volvement of a common cellular genetic lo-
cus in derivation of viruses containing 
these genes. 
To accurately define regions of sequence 
homology of the v-fps gene with the hu-
man cellular homologue of v-fes, a series 
of three cosmid clones containing the 
above-described 12.0-kb v-fes homologous 
EcoRI restriction fragment within a total 
of 56 kb of contiguous human DNA se-
quences, were examined (Fig. 3). Hybrid-
ization with FSV v-fps was restricted to 
a single 12.0-kb EcoRI restriction frag-
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FIG. 3. Comparison of v-fes and v-fps homologous sequences within the c-fes/c-fps human genetic 
locus. The 12.0-kb EcoRl restriction fragment shown in the center of the figure contains all de-
tectable v-fes and v-fps homologous human DNA sequences. Restriction fragments hybridizing to 
GA-v-fes, ST-v-jes, and FSV-v-fps are indicated as solid bars in the upper portion of the figure. 
The position of the 12.0-kb EcoRI fragment within a 58-kb contiguous sequence of human cellular 
DNA, represented within three independent overlapping cosmid clones, is indicated by the dotted 
diagonal lines. EcoRI restriction fragments within the inserted cellular sequence of one such cosmid 
clone (cos-5) are designated at the bottom of the figure and the spedfic hybridization of the 12.0-
kb fragment with '9>-labeled GA-v-fes (B) and the 2.6-kb Pvui-Smal FSV-v-fps (C) probes are 
shown on the right side. The diagonal line near the 5' terminus of cos-5 represents the junction 
between the vector arm and inserted cellular sequences. Restriction enzymes are abbreviated as 
follows: A val (A); BamHI (B); EcoRI (E); Hindiii (H); Kpnl (K); Pstl (P); Smai (Sm); Sst! (Ss); 
Xba.l (Xb); and XMI (Xh). 
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ment containing v-fes homologous se-
quences. Following subcloning, the 12.0-kb 
EcoRI fragment was digested with the in-
dicated combinations of restriction endo-
nucleases and analyzed for hybridization 
to v-fes- and v-fps-specific probes (Fig. 4). 
FSV v-fps homology to human DNA most 
closely resembled that of GA FeSV v-fes. 
However, the 3'-terminal v-fes homolo-
gous region of human DNA common to ST-
and GA-v-fes did not hybridize to a de-
tectable extent with the FSV v-fps probe. 
ST v-fes homologous sequences differ from 
those of both GA v-fes and FSV v-fps in 
that they are not represented within the 
5'-terminal region hybridizing to the other 
two. Finally, two regions of human DNA 
homology unique to FSV-v-fps were iden-
tified in the 5' half of the 12.0-kb human 
EcoRI DNA fragment. Thus, although all 
three viral "oncogenes" appear to be en-
tirely represented by homologous se-
quences within a single c-feslc-fps human 
genetic locus, the exact positions at which 
regions of homology map differ among the 
individual viral transforming genes. The 
lack of detectable hybridization of v-fps 
with the 3' region of the c-fes/c-fps locus 
could reflect evolutionary divergence. Al-
ternatively, there may exist within the v-
feslv-fps locus, sequences not necessary 
for transformation which were lost, either 
in the generation of FSV and the two FeSV 
isolates, or by subsequent deletions. Thus 
a comparison of the 5'-terminal position of 
ST-v-fes, and 3' position of FSV-v-fps ho-
mologous sequences within the human c-
fes!c-fps locus, indicated by the dotted 
lines, may provide a minimal estimate of 
those sequences required for transforma-
tion. 
The larger size of the FSV v-fps gene 
(2.6 kb) (30) as compared to that of GA-v-
fes (1.8 kb) (9) may be accounted for by 
regions of the human c-feslc-fps locus 
which are uniquely hom<>logous with FSV 
v-fps. These FSV v-fps unique sequences 
can be explained by one of several alter-
native possibilities. For instance such se-
quences may have been initially repre-
sented within GA-v-fes but deleted during 
passage of GA-FeSV subsequent to its ini-
D E F 
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FIG. 4. Restriction endonuclease analysis of human 
cellular sequences hybridizing to 32p-labeled GA-v-
fes and FSV-v-/ps probes. DNA from a variant of 
pBR328, containing the 12.0-kb human cellular EcoRI 
fragment from cos-5 (pBR328 cos-5), was digested ei-
ther with Avo:I (A-C); or Psti (E-F), separated by 
electrophoresis on 0.75% agarose gels, and stained 
with ethidium bromide (A, D). Following transfer to 
nitrocellulose, hybridization was performed accord-
ing to previously described (17) procedures. 32p-la-
beled probes include the 2.6-kb Pvui-Smai FSV-v-
fps fragment (B, E) and GA-v-fes (C, F). Restriction 
fragments which hybridized to either the FSV-v-fps 
or GA-v-fes probes and correspond to the 12.0-kb 
EcoRI insert of pBR328 cos-5, are indicated by ar-
rows; additional hybridizing restriction fragments in 
lanes C and F correspond to pBR328 plasmid se-
quences. The 0.3-kb Avai restriction fragment, al-
though not visible in this figure, was found upon lon-
ger exposure to hybridize to both probes. 
tial derivation. Alternatively, the differ-
ences in sequences in these viruses may 
reflect differences in the positions of cod-
ing and noncoding regions of the c-feslc-
fps RNA transcripts of the divergent host 
species from which they were isolated. Fi-
nally, mechanisms of incorporation of cel-
lular oncogenic sequences in retroviral ge-
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names may be imprecise and the resulting 
insert within the viral genomic RNA not 
necessarily correspond exactly to the cel-
lular mRNA from which it was derived. 
Either the first or third possibilities ap-
pear most probable in that one of these 
must be envoked to explain the differences 
between the acquired cellular sequences of 
GA- and ST-v-fes (9, 17). Resolution of 
these alternative models may provide in-
sight into mechanisms by which cellular 
oncogenes become stabily associated with 
the genomes of retroviruses. 
The present findings establish that the 
v-fes and v-fps sequences correspond to a 
common cellular genetic locus which has 
been highly conserved throughout verte-
brate evolution. Thus, tyrosine-specific 
protein kinase activities associated with 
the translational product of such se-
quences, have probable functional signif-
icance to their host. Although the mam-
malian homologues of other avian retro-
virus encoding tyrosine-specific protein 
kinases have not been characterized, the 
human homolog of the mouse v-abl gene 
has been shown to be independent of the 
c-feslc-fps locus (19). By analysis of ap-
propriate somatic cell hybrids, c-fes/c-fps 
has been localized on human chromosome 
15 (7, 19). 
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Chromosomal localization 
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:> MRC Human Biochemical Genetics Unit. Galton Lahornton. 
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Acute transforming RNA tumour viruses represent genetic 
recombinants between type C retroviral sequences and transfor-
mation-spedlic sequences of cellular origin. Of the known 
mammalian cell-derived transforminj! genes (oncogenes), two 
have been shown to encode proteins with either intrinsic or 
highly associated tyfosine-specilic protein kinase activity. One 
such gene, c-fes, is of ~at cellular origin, while the second, c-ab/, 
was derived from mouse cellular sequences. We now show that 
the human equivalents of c-fes and c-ab/ are localized on human 
chromosomes 15 and 9, respectively. These lindings e:>eclude 
the possibility that these transformation-related genes are 
clustered at a single locus within the human genome. It is of 
interest that both of these chromosomes are involved in specific 
rearrangements found in certain forms of human cancer. 
Two mammalian and four avian cell-derived viral oncogene" 
encoding proteins with tyrosine-specific protein kinase activity 
have been described'. One of these, c-fes. is represented within 
the genomes of two independent isolates of feline sarcoma '"iru~ 
(FeSV), Gardner and Snyder-Theilen. both of which represent 
genetic recombinants between feline leukaemia virus and cel-
lular lc-fes) sequences of cat origin''. c-[<"s is closely related 
to c-fps, a transforming gene common to several independent 
avian transforming retrovirus isolates-'·'. The second cell-
derived viral oncogene of this class. t·-abl. has so far been 
identified as a transforming component only of the Abelson 
strain of murine leukaemia virus I MuL V). This virus is a genetic 
recombinant between Moloney MulV and mouse cellular !c-
ab/) sequences". The primary translational products of these 
two cell-derived viral oncogenes are polyproteins containing 
amino-terminal structural proteins encoded by the gag gene, 
covalently linked to acquired cellular sequence-encoded com· 
ponents7·'". Tyrosine-specific protein kinase activities associ-
ated with such polyproteins 1 ,_., have been implicated in trans-
formation through the analysis of transformation-defective viral 
mutants"·-'". Recently, transforming sequences isolated from 
a human bladder carcinoma cell line have been shown to exhibit 
homology with acquired transforming !oncogenic) sequences 
of the Harvey strain of murine sarcoma virus'"'". Because of 
the potential involvement of the cellular homologues of viral 
oncogenes in human cancer, we decided to investigate the 
human genetics of these sequences and to test the possibility 
that chromosomes containing c-fes and c-ab/ might correspond 
to those with known translocations or other rearrangements 
associated with certain human cancers 
To determine the chromosomallocation of the human celluiH 
homologue of ~·-fes, we initially screened restriction endonu-
clease-digested cellular DNAs from a serie> of mouse-human 
somatic cell hybrids by molecular hybridization. These hybrids. 
which contained a full complement of mouse chromosomes. 
but retained limited numbers of different combinations of 
human chromosomes, were analysed for the presence of the 
human ~·-fes-cross-reactive EcoRI restriction fra!!ment. 
Identification of the human chromosomes present in the hybrids 
was based on isoenzyme, antigenic and chromosome analysis 
!Table 11. For identification of c-fes sequences, we used a 
"P-labelled probe corresponding to a 0.5-kilobase ikbi Psrl 
restriction fragment localized within acquired sequences of the 
Snyder-Theilen FeSV genome, designated v-fes P"·'· This probe 
has he en described previously'' 1 and is shown diagrammatically 
in Fig. I. A single 12.0-kb EcoRI restriction fragment of human 
Dl" A could he distinguished from the major 8.5·kb ~·-/es-cross­
hybidizing EcoRI fragment in mouse cellular DNA which 
migrated at a position close to that of a much less cross-reactive 
restriction fragment of mouse DNA at -11.5 kb !Fig. 11. In 
preliminary experiments using this probe, the human c-fes was 
identified only in those hybrid clones containing human 
chromosome 15 !Table 1). 
To obtain a molecular probe having increased specificity for 
the human c-[fs gene, two 0.5-kb Kpnl human restriction 
fragments I c-[fs K" .) were isolated from a previously described 
wsmid clone containing the complete 12.0-kb c-fes EcoRI 
restriction fragment. Use of these restriction fragments as 
molecular probes considerably improved detection of the 
human c-fn 12.0-kb EcoRI restriction fragment in DNA both 
from human cells and from mouse-human somatic cell hybrid 
clones I Fig. Llanes c-111. As shown for representative hybrids 
in Fig. 1 and summarized in Table 1, the 12.0-kb EcoRI 
c-J<'s-homologous restriction fragment identified in this way was 
ngain observed only in DNA isolated from hybrid clones .:on-
taining human chromosome 15. 
Particularly compelling was the positive reaction with 
Horl9D2 hybrid DNA with the 0.5-kb Kpnl human c-fcs probe 
1Fig. L lane:·). This hybrid contains human chromosomes 11, 
15 and X as its only human conTribution. Segregants of the 
l--!orl9D2 containing only the X chromosome 1Hor19Xillane 
hI or only chromosome 11 (Horl 9D2RI; lane [J failed to react 
"With the probe. The segregant Horl-1 which retained hu[11an 
chromosome 15 and a human-mouse translocation which 
includes part of the long arm of chromosome 11, also reacted 
strongly with the c-fcs K,, {lane g) and ~--{es p,, !Table 11 
probes. The results of further restriction endonuclease analysis 
of DNA from segregant Horl-1 are shown in the right panel of 
the upp~r gel in Fig. 1. Two major BamHl restriction fragments 
of the human c-fn gene which hybridize with the c-fn K", 
probe Iiane h 1 are both identified in segregant Hori-1. Similarly, 
two Sst fragments of 3.6 and 7.5 kb were identified in human 
DNA Iiane hJ and in the Horl-1 segregant Iiane cl, but not in 
DNA of mouse IIane a J origin. 
An analogous approach was pursued to establish the chromo-
somal localization of the human cellular homologue of ~--abl 
In this case £caRl-restricted DNAs from a similar series of 
mouse-human somatic cell hybrids were analysed. The 
molecular probes used included a Bam HI fB, ,J restriction 
fragment containing all but the 3'-terminal portion of the 
Abelson M'.!LV genome and a 1.7-kb Pst! (p, 7 ) restriction 
fragment localized within the Abelson MuL V -acquired cellular 
lr-abl) sequences IFig. 1). A total of seven £coR! restriction 
fragments of human DNA, ranging in size from 2.5 to 12.0 kb, 
and several of mouse DNA, were identified, each of which 
hybridized to the P, _, probe. The five lower molecular weight 
human fragments were completely separated from mouse c-ab! 
EcoRl restriction fragments, thus providing a means of identify-
ing hybrid clones containing the human c-ab/ gene. The results 
of a typical analysis are shown in the lower left panel of Fig. 
1 IIanes a-cr. In other studies the complete human l·-abl cellular 
homologue has been cloned from a cosmid library and at least 
six of the seven EcoRI restriction fragments map to a single 
position. As an independent means of identifying hybrids con-
taining the human c-ab/ gene, a 0.6-kb BamHI probe was 
prepared from the second lowest molecular weight 12.9 kbi 
EcoRI human restriction fragment and used as a probe. Rep-
resentative data obtained with this probe are shown in the right 
panel of Fig. 1. 
As summarized in Table 1, complete concordance was 
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observed between the presence of the five v-abl cross-reactive 
EcoRl restriction fragments in the 2.5-5.0-kb size range and 
human chromosome 9, while each of the other chromosomes 
could be excluded by one or more examples of discordance. 
For example, human c-abl-specific restriction fragments were 
present in hybrid F4Sc13 Cl12 which contained only four 
human chromosomes: 1, 9, 14 and X. Of these, all but chromo-
some 9 were present in at least one hybrid which lacked the 
human c-ab/ gene, thus by elimination identifying chromosome 
9 as the location of human c-ab/. Finally, a series of four 
previously described hamster-human somatic cell hybrids were 
analysed for human c-ab/ sequences. As summarized in Table 
1 and shown in the lower portion of Fig. 1 (lanes h-k ), only 
one done, ClOb, contained human c-abl-specific sequences. 
Interestingly, this hybrid was positive for each of three isoen-
zyme markers for human chromosome 9, cytoplasmic soluble 
cis-aconitase {A CONs), AK3 and AKl. A subclone of ClOb, 
designated Cl0b2BU, lacked detectable human c-ab/ 
sequences and by isoenzyme analysis was positive for only 
ACONs and AK3, both of which are localized on the short 
arm of chromosome 9. The third marker, AKl, which was not 
detected in this hybrid, is in contrast, localized to the long arm 
of chromosome 9. The remaining two hybrids were nonreactive 
in enzyme assays for all three markers for chromosome 9 and 
lacked detectable sequences hybridizing to the human c-ab! 
B,,_,; probe. 
These findings establish the independent chromosomal 
localization of human cellular homologues of two viral trans-
forming genes, both of which encode tyrosine-specific protein 
kinases. The possibility that these functionally similar genes are 
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Fig. I !dentificanon of human chromosomes containing v-[es- and v-abl-
homologous sequences. Molecular clones of the ST-FeSV and human c-{e.< 
sequences. shown diagrammatically at the top of the figure. are based on 
pr"'·iously published data'. The Open box IDJ within the vnal genome 
represonts the position of the acquired cellular sequences. while the feline 
leukaemia virus cross-reactive sequences are shown as solid lines 1-)_ The 
positions of tile long terminal repeats 111.'ll). cellular flanking sequences iU I 
and the 0.5-kb Psi I restriction fragment used as a probe IP, ,) are also 
shown. The organi<ation of the human c-fes llas been pubHsiled previously' 
For rderence, the posllions of previously identified restriction fragments 
of t'le humon :-f.,s g~n~ with hnmology to ST-FeSV. GA-FeSV and the 
Fuiianami strain of avian sarcoma virus. as well as two 0.5-kb Kpnl restric-
tion fragments which wore co-purified and used as a probe IK.,,J. arc 
shown_ Restriction patterns of cellular sequences hybddizin~ to tile ''-fes 
and c-fes probes are shown in the uppermost gel. Cell lines from which 
r>NAs were prepared arc described in detail in Table I legend and include 
in the left panel: b. d. N!H/3T3(-I mouse; a. c. A673 human(+!'" and 
mouse-human hybrids;<. Hori9D2i+l; {. Hori9D2Rli- I; g. Horlli+i; h. 
Horl9xt-)-. in right panel. a. NIH/3T31-I mouse; h, A67.1 human! t-1; c. 
mouse-human hybrid Horl[] + )_ 1+ Indicates a posillve assignment: - indi-
cates absence of the particular chromosome.) Molecular probes and restric-
tion enzymes are dS indicated. Molecular clones of the Abelson MuL V 
lA-MuL Vi genome and a region of human c•-ab/-!10mologous <equences 
are shown diagrammatically in tile centre of the figure. RestrictiOn fragments 
used as hybridization probes. including 1.7-kb Pslli,•-abJ P, ,I and 3.5-kb 
BamHiic•-abl B, ,J restriction fragments »well as a 0.6 kb BamHI (c-ab! 
B,") restriction fragment mapping withm the 2.9-kb EcoRI human c-abi 
r<striction fragment, arc mdicated. RestTJction patterns of cellular DNA 
sequences hybndizing to the o-aM B, _, and c-ab! B.," probes are shown 
in the lower portion of the figure. Cell lines shown in the left panel include: 
a, A673 humani+l; b. :--IIH/3T3 mouse(-): c. mouse-human hybricl 
F4sci3Cl 121+ ). Those in !ile right panel include: a, NIH/JT3 mousc1-1; 
b. A673 llumani+l. mouse-human hybridso c. F4sci:IC1121~J: d, 
FIR5R3(-I: <, F4sd3C19i-l; f. F4sc1Kli21TJ: g. hamster: hamster-
human hybrid<: 11. Dl$201-·1; i. C10b2BL"I-I; j, C4al-l: k. ClOb(+l_ The 
derivations of these cell lmes and the<r complements of human chromosomes 
are described in detail 1n Table I legend. Followin~ hybridization with the 
P, -'' B,. and P,, probes. filters were washed with 2.5 x SSC at 65 'C; 
ustng K .. , and B,," probes. was he< were performed using 0.3 x SSC ao 
65T •coording to the method of Bernards and Flavell''. RestrictLM 
enzymes are abbrevtated as follows· E. EcoRI; H. Hindlll; P.- Ps<l. K. 
Kpnl; A. Ac•al; Ss. S"L Hindlll·digested A DNA is included as" molecular 
weight >tandard 
all organized in a cluster such as that observed for the y-globi n, 
immunoglobulin or histocompatibility gene families is thus 
ruled out. Although the exact number of human genes encoding 
proteins with tyrosine-specific protein kinase activity remains 
to be determined, transforming proteins encoded by each of at 
least four independent avian type C viral oncogenes with such 
activity have been identified t. One of these, v-{ps, is structurally 
related to and maps at the same human cellular locus as the 
c-fes gene analy~ed here4 ·'. Further study will be required to 
determine whether human cellular homologues of any of the 
three other avian viral oncogenes map to the same positions 
as either c-fes or c-ab!. 
In other studies, the mouse c-ab/ gene has been assigned to 
mouse chromosome 2 (S." P. Goff, P. D'Eustachio, F. Ruddle 
and D. Baltimore, personal communication). It is interesting 
that the human homologues of several linked markers assigned 
10 mouse chromosome 2 are found on the long arm of human 
chromosome 9, indicating that these are, at least in part, 
homologous linkage groups". The present results obtained 
from analysis of the hamster-human hybrids suggest that c-ab! 
could be on the long arm of human chromosome 9. 
Our findings are of interest in that both c-fes and c-ab/ map 
on chromosomes which are frequently involved in specific trans-
locations associated with human neoplasms23 •24 • For example, 
a high percentage of human chronic myelogenous leukaemias 
(CML) involve translocations of the distal portion of the long 
arm of chromosome 22 to chromosome 9. The resulting abnor-
mal form of chromosome 22 has been called the Philadelphia 
chromosome. The long arm of human chromosome 9 which is 
specifically involved in this rearrangement is the region of 
Table I Hybridization of DNA from human-mou<e and human-ham<tcr <omatic <ell hybrid; with c-aM- and c-fes-specific probes 
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The origin and detail; of the initial characteril.ation of the somatic cell hybrids listed in column 1 are described in the references indicated in the second column. 
Sumc of these hybrid; ha,·e been subcloned after the initial characterization. iC10b2BU is bromodcoxyuridine-selccted <ubclone isolated from C!Ob. F4Sc13 Cl9 and 
F4Scl3 Cll2 were subdones. the original cells were a gift from Dr H. Koprowski. These hybrids were isolated from a fusion of human fibroblasts and RAG mou.e 
cell<. Hori9D2 is a clone or Horl9 'fef 321 with an identical karyotype. Hori9D2Rl. Horll and Hori9X arc •ubcloncs of Hor19D2 J Four of the hybrids described. 
indudin~ DlS20. C10b2BU. C4a and C10b. represent human-hamster somatic cell hybrids; all remaining arc human-mouse hybrids. The chromosomal content was 
deduced I rom a combination of karyotypic. antigenic and enzymatic analy5es. karyotypic analysis was done by a combination of G II >taining and quinacrine banding·'"·". 
Techniqu., and morkers for antigenic analyses are reviewed in ref. 38. Assays for human en>ymes were performed usmg >tandard methods". Analysis of hybrids for 
c-fes and c-ob! sequences wa. performed a< described in Fig. I legend using u-fes B,, and c-fes K,., probes in a and u-abl B, and c-ab! B,.,. probes in b 
D isconcordance between the presence of any one chromosome and hybridization with pr~bc; for either locus i.< shown by open boxes. Karyotypic analysis of F4Scl3C I 1 2 
indicates that only about 4% of the cells <Ontain chromosome I NT. not tc•ted 
human chromosome 9 that appears to correspond to mouse 
chromosome 2. Similarly, a translocation involving the long 
arm of chromosome 15 has been observed in cells of patients 
with acute promyelocyticleukaemia (APL)'·'·'·. Abelson MuL V 
was initially derived from a spontaneously occurring lympho-
sarcoma of the mouse and induces lymphoid tumours in 
l'ivo inoculation25 • Although c-fes was derived from a fibrosar-
coma of the cat25 , the possibility that its disease spectrum in 
natural conditions and in the human population may be very 
different from that as a recombinant virus must be considered. 
It will thus be of interest to examine levels of expression of 
c-fes and c-ab/ in tumour cells with translocations involving 
chromosomes 15 and 9, respectively. and to establish by in situ 
annealing techniques whether these genes are, in fact, near the 
specific translocations points found in chromosome 9 for CML 
and in chromosome 15 for APL. 
Since this work was completed, Dalla-Favera et al."" have 
assigned c-fes to chromosome 15. 
We thank Gail T. Blennerhassett and Pam Hansen for tech-
nical assistance, Karina· Stanley for karyotype analysis, Sue 
Povey, Dallas Swallow and Mohamed Parker at the Galton 
Laboratories for enzyme analyses and Alan Tunnacliffe for 
deriving the clone HORLI. This work was supported under 
PHS contract NOI-C0-75380 from the NCI. 
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ABSTRACT Somatic cell hybrids have been constructed be-
tween a thymidine kinase-deficient mouse ce!l line and blood leu-
kocytes from a patient with acute promyelocytic leukemia showing 
the 15q+;l7q- chromosome translocation frequently assodated 
with this disease. One hybrid contains the 15q+ translocation 
chromosome and very little other human materia!. We have shown 
that the cjffs oncogene, which has been mapped to chromosome 
15, is not present in this hybrid and, therefore, probably is trans-
located to the l7q- chromosome. Analysis of the genetic markers 
present in this hybrid has enabled a more precise localization of 
the translocation breakpoints on chromosomes 15 and 17. Our ex-
periments also have enabled an ordering and more precise map-
ping of several genetic markers on chromosomes 15 and 17. 
Several oncogenes. each of which was initially detected by use 
of transfonning retrovirus-derived molecular probes, have been 
identified within the human genome (1). :O.fany of these human 
sequences have been molecularly cloned, and studies have been 
initiated to determine their possible relationship to oncogenici-
ty in man. At least tv:o sequences, c-rasKi and c-rasHa, trans-
form :'-IIH 3T3 mouse cells in culture upon direct isolation from 
speci fie tumor cell lints (2-4). In other studies, human c-rasH• 
sequences have been isolated that lack such activity but do 
transform cells when linked to retrovirus promoter sequences 
l51. Similar results have been obtained with c-rrws, the mouse 
cellular homologue of the :O.Ioloney murine sarcoma virus on-
cogene (6), whereas activation of the mouse c-rrws gene by a 
transposition event resulting in its positioning adjacent to an 
insertion sequence (ISHike element has been described more 
recently (7) 
By somatic cell hybridization, many of the known oncogenes 
have been assigned to specific human chromosomes (8-15). Al-
though the distribution of such sequences appears somewhat 
random. many of the chromosomes to which these genes have 
been localized are involved in translocations associated with 
specific human neoplasms. For instance, c-abl has been local-
ized in a small terminal fragment of the long arm, q, of chro-
mosome 9, which is translocated to chromosome 22 in chronic 
myel"Jgenous leukemia (CYIL) (16), whereas c-sis maps within 
the region of chromosome 22 (qll to qter), which translocates 
to chromosome 9 in CY!L (17). In other studies, c-myc has been 
identified within a fragment of human chromosome 8, which 
is translocated to chromosomes 2, 14, or 22 in Burkitt lym-
phoma (8. 9). Of potential significance. each of the chromo-
somes to which c-ab/ or c-myc are translocated in CML and 
Burkitt lymphoma, respectiv~ly, contain immunoglobulin se-
The publication ~011> of this article were defrayed in part by ~.age cha;ge 
payment. This article must therefore be hereby marked ad~ert•se­
men{' m accordance w1th 18 U. S.C. §1734 solely to mdicate th1s fact. 
quences that map at the position of the translocation break-
points (9, 18, 19). 
The human cellular homologues of the feline sarcoma virus 
v-fes gene and of v-fps, a transforming gene shared by several 
independent isolates of avian sarcoma viruses. correspond to a 
common cellular locus, c-fr:s (20, 21), mapping on human chro-
mosome 15 (13, 22). Functionally, v-fes and vfps are also re-
lated in that both encode transforming proteins with tyrosine-
specific protein kinase activity (23-27). The present study was 
undertaken to ascertain whether c-fes is involved in the 
15q+;l7q- chromosome translocation frequently associated 
with acute promyelocytic leukemia (APL) (28-31). This trans-
location occurs as a reciprocal exchange of the distal segments 
of the q arms of chromosomes 15 and 17. We also have been 
able to map more precisely the translocation breakpoints rel-
ative to known genetic markers on these chromosomes. 
MATERIALS AND METHODS 
Cells. Frozen blood leukocytes from a 26-yr-old male patient 
(J.D.) l'.'ith the typical"":0.-13'" form of APL (32) were cultured for 
48 hr in RF:-.H 1640 medium containing 20% fetal rcalf serum 
before karyotyping. The growth medium was supplemented with 
filtered supernatant from a 7-day culture of phytohemagglu-
tinin-stimulated normal blood lymphocytes to give a final con-
centration of 10%. A subclone of the 3T3 mouse cell line (33), 
which is deficient for thymidine kinase (TK), was used for prep-
aration of somatic cell hybrids. 
Somatic Ce!l Hybridization. Frozen blood leukocytes from 
patient J.D. were fused with 3T3 (TK-) cells by using poly-
ethylene glycol (34). TK+ hybrids were selected in HAT me-
dium [RPYII 1640 medium containing 20% fetal calf serum and 
HAT (100 ,u.:-.1 hypoxanthine/10 ,u.YI methotrexate/16 ,u.YI thy-
midine)] (35, 36). The unfused 3T3 cells die in HAT medium 
as they lack TK activity, whereas normal leukocytes are unable 
to grow in culture without mitogenic stimulation. Back-selec-
tion of TK- variants was carried out by growing hybrids in me-
dium with 60 p.g of BrdUrd per ml (37, 38). 
Genetic :\farkers. Genetic markers previously mapped to 
chromosome 15 were analyzed by published immunologic and 
electrophoretic procedures (39-42). These were genes for /32-
microglobulin (B2M) (39), hexosaminidase a (HEXA) (41), man-
nosephosphate isomerase (:-.tPI) (42), pyruvate kinase-3 (PKYI2) 
(42), and a cell surface antigen of apparent M, 95,000 encoded by 
Abbreviatiom: APL, acute promyelocytic leukemia; CML. chronic 
myelogenous leukemia; TK, thymidine kinase; HAT. hypoxanthine/ 
methotrexate/thymidine; B2M, {3~ microglobulin; HEXA, hexosamin-
idase tr; MPI, mannosephosphate isomerase; PKM2, pyruvate kinase-
3, CALK. galactokinase; CAA, acid a-glucosidase, kb. ki!obase(s). 
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the gene MIC7 (40). As an independent means of identifying 
B2M, DNA Southern blot hybridization analysis was performed 
with a molecularly cloned eDNA probe provided by B. Wallace 
(43). Human c-fes sequences were identified by DNA Southern 
blot hybridization with a 0.5-kilobase (kb) Kpn c-fes probe (des-
ignated c-fes Ko.s) as described (44). Of the genetic markers 
mapped to chromosome 17, galactokinase (CALK) and acid a-
glucosidase (GAA) were assayed by starch gel electrophoresis (45); 
the presence of the gene MIC6 coding for a cell surface antigen 
of apparent M, 125,000 (46) was measured by radioimmunoas-
say. The presence of the collagen al(I) gene COLlAl was mea-
sured by DNA Southern blot hybridization with a human 15-kb 
genomic DNA probe designated pga1H-l. This probe was iso-
lated and provided by D. Rowe (University of Connecticut). 
Chromosome Analyses. Chromosomes were prepared by 
standard procedures. Leukocytes from. the patient J.D. were 
karyotyped by using G-banding (47) and Q-banding (48). Hu-
man chromosomes were identified in the hybrids by using G-
11 (49}, Q-banding, and G-banding techniques. 
RESULTS 
Karyotypic Analysis of Cultured Leukocytes from the APL 
Patient. A karyotype of 46,XY,t(l5q+;l7q-) (t designates 
translocation) was found in 18 of 20 cells examined, with no evi-
dence for additional chromosome rearrangements. A repre-
sentative partial karyotype is shown in Fig. 1 Left. By G-band-
ing and Q-banding techniques, the translocation is characteristic 
of that previously described in APL (28-31}. 
Breakpoint in Chromosome 17 Relative to the TK and CALK 
Genes. To isolate somatic cell hybrids suitable for further stud-
ies of the 15q+;l7q- translocation, peripheral blood leuko-
cytes from the patient described above were fused with TK-de-
ficient 3T3 mouse ce!!s (33). Of a total of 12 hybrid clones 
examined, 7 were found to contain chromosome 17 in the ab-
sence of either ISq+ or 17q-. Four hybrids contained chro-
mosome 17, both l5q+ and 17q- chromosomes in a small pro-
portion of the cells, and 16-30 other human chromosomes. 
Finally, a single hybrid clone, PJT2/A1 (Fig. l Right), con-
tt A~ 
1S 15qo- 11 17q-
tained the 15q+ translocation chromosome in 37 of 40 cells ex-
amined, chromosome 21 in 9 of 40 cells, and a marker chro-
mosome that did not appear to be related to either chromosomes 
15 or 17 inS of 40 cells. The presence ofTK in the hybrid PJf zl 
A1 localizes the lSq+ ;17q- translocation breakpoint proximal 
to or within band 17q210-220. This localization is supported by 
our finding that this hybrid also expresses CALK, which maps 
to 17q210-220 (SO). 
Genetic Markers Translocated from Chromosome 17 to 
I5q+. Fig. 2 shows the regional localization of previously de-
scribed genetic markers on chromosome 17 (46, 50, 53-56). As 
predicted on the basis of its mapped position (54}, GAA is ex-
pressed in PJTziAI hybrid cells. Additionally, the PJTJ A1 hy-
brid contains the MIC6 gene (Fig. 3), thus establishing its 
localization within the segment of chromosome 17 that is 
translocated to the 15q+ chromosome in APL. Another locus, 
COLIAl, coding for the a( I) chain of type I collagen, has been 
mapped dire<:tly on chromosome 17 by molecular hybridization 
analysis (56). By using a 15-kb genomic probe for this gene, this 
assignment was confirmed with hybrids containing chromo-
some 17 as their only human material (unpublished data). We 
used this probe to show that the gene is present in PJT2/A1 
hybrid cells (Table 1). This latter observation is consistent with 
results mapping a type I collagen gene to 17q2I-q22 (55). 
Regional Localization of cjes and Other Loci on Chro-
mosome 15. The availability of PJT~/A 1 hybrid cells also en-
__ abled a more precise localization of several genetic markers 
previously mapped on chromosome 15, including c-fes (13, 22) 
and B2M (51). As shown in Fig. 4 Left, the human cellular ho-
mologue of vjes (lane B), seen as Sst I restriction fragments of 
around 4.0 and 7.0 kb, was readily distinguishable from the 
mouse c-fes gene (lane A) by using a 0.5-kb cjes-specific mo-
lecular probe (designated c-fes Ko.s). Human c-fes sequences 
were present in hybrid HORL-I (22), which contains chro-
mosome 15 and a fragment of chromosome 11 as its only karyo-
typically detectable human material (lane C), and in hybrid 
DT2.12 (41), which contains a translocation between the long 
arms of chromosomes IS and X (lane E). The absence of de-
tectable human cjes-specific sequences in hybrid DT2.1R3, a 
FIG. 1. Karyotypic analysis of the 15q+;l7q- chromosome translocation in APL. (Left) Partial karyotype of a representative cell from APL 
patientJ.D. alight) G-banded metaphase spread of hybrid PJT z/ Al showing 15q + translocation chromosome. Chromosome 21 and the unidentified 
mLU"ker chromosome are not present in this cell. 
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15 15q+ r.t,- 17 
FIG. 2. Schematic representation oft(l5q+;17q-). Translocation breakpoints are placed in bands l5q22 and 17q21 on the basis of both genetic 
and cytogenetic data (see text). Localizations of genes Wsted in the hybrid PJT.; A1 including B2M (51); MIC7 (40), MPI (52), PKM2 (52), c·fes (13, 
22), MIC6 (46), GALK {50}, TK (53), GAA (54), and COLlAl {55, 56) are shown on the normal chromosomes 15 and 17 (solid lines). Those genes 
absent from hybrid PJT2/ A1 are shown to the right of the nonnal chromosome 15 (broken line). Those genes present in hybrid PJTzf A1 are shown 
on the l5q+ translocation chromosome. 
derivative of DT2.1R (41} lacking the 15/X translocation chro-
mosome, confirms the earlier assignment of c-fes to chromo-
some 15 (lane F) (13, 22). Finally, the absence of human c-fes 
sequences in hybrid PJT2/A! (lane D) establishes that c{es is 
not present within the ISq+ translocation chromosome and 
strongly suggests that these sequences map within the region 
of chromosome 15 that is translocated to chromosome 17. 
The results in Fig. 4 Right show that, in contrast to c-fes, 
human B2M sequences are present not only in hybrids con-
taining chromosome 15 but also in hybrid PJT2/A1 (lane D), 
localizing B2M on chromosome ISq+ and, thus, proximal to 
the translocation breakpoint of chromosome 15. These are seen 
as a series of three Sst I restriction fragments of 3.0, 7 .0, and 
12.0 kb. Two additional markers, "MPI and PKM2, previously 
mapped within the long ann of chromosome IS {52), were not 
detected in hybrid PJT2/A1, while a third chromosome 15 
marker, MIC7, was present {Table 1). These findings allow a 
more precise regional localization of each of these markers on 
chromosome 15 (Fig. 2). Analysis of HEXA, previously local-
ized to 15q22-q25.1 {61), gave ambiguous results. 
PJT~/A 1 Revertant Lacking the 15q+ Chromosome. To 
confirm the above assignments of various genetic markers to 
the 15q+ translocation chromosome, PJT2/A1 hybrid cells were 
c. p.m. 
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back-selected by growth in medium containing 60 }Lg of BrdL'rd 
per mi. Cells containing the human TK gene iilcorporate BrdL'rd 
and, thus, should be killed under these conditions (37, 38}. One 
back-selected hybrid isolated by this approach, designated PJT2/ 
A1R, was shown by karyotype analysis to have lost the human 
15q + translocation chromosome and the unidentified marker 
chromosome. This hvbrid also was found to have lost B2M, MIC7, 
CALK, GAA, and MIC6. These results confirm our assignment 
of each of these markers as well as the human TK and CALK 
genes to the 15q+ translocation chromosome. 
DISCUSSION 
Although there is evidence for a specific association of the 
15q+;l7q- chromosome translocation with APL (28-31}, the 
breakpoints in this translocation are difficult to localize and have 
been placed at different positions by various groups of inves-
tigators-e.g., 15q22 and 17q21 (29), 15q25-26 and 17q22 (28), 
and 15q22-23 and l7ql2 (30). The approach used in the present 
study allowed more precise determination of these breakpoints 
in one patient. For instance, the presence of TK and CALK in 
hybrid PJT2/A1 establishes the breakpoint on chromosome 17 
at a position proximal to that previously shown for these loci 
. 
~ :t 
~ ;; ,.; • ~ ~ ~  re ~ • 
HEB7A 
"' 
F1c;... 3. Radioimmunoassay to detect the presence of B2M, MIC6, and MIC7 genes by using monoclonal antibodies BBMl (ref. 39l, H207 (ref. 
461, and 28.3.7 (ref. 40), respectively. Control monoclonal antibody is P3.X63.Ag8 (ref. 157). Binding of monoclonal antibody to cells visualized using 
'
25!-rabbit anti-mouse !g. Human control cells are HEB7A (ref. 58). Mouse control cells are 3T3 (ref. 33}. 
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Table L Identification of chromosome 15 and 17 genetic markers on the 15q+ translocation chromosome* 
Chromosome 15 markers Chromosome 17 markers 
Hybrids Human chromosomes MICJ HEXA MPI PK c-fes B2M MIC6 TK GALK COLlAl GAA 
Horl-I 15, llq + + + + 
DT2.12 t(15/Xl, 2, 10, 11, + NT NT NT NT NT 
12, 13, 17' 21, 22 
DT2.1R3 2, 10, 11, 12, 18 NT NT NT NT NT 
PJT2fA, 15q+, 21, marker + ± + 
PJT2/A1R 21 NT NT NT NT 
NT, not tested. 
*Details concerning the derivation and chromosomal characterization of Horl-I, DT2.12, and DT2.1R3 somatic cell hybrids has been reported (22, 
41). PJTzf A, and PJT2f A1R are described in the present study. 
(q210-220) (50, 53). This information combined with a karyo-
typic analysis of the translocation chromosomes suggests that 
the breakpoint on chromosome 15 is within 15q22. These 
breakpoints are consistent with those proposed most recently 
by Rowley, who used extended chromosome preparations from 
several patients-i.e., l5q22.2 and l7ql2-2l (J.D. Rowley, 
personal communication). On the basis of these considerations, 
in the schematic representation of the t(l5q + ;l7q-) in Fig. 2, 
the breakpoints are shown in bands l5q22 and 17q21. 
Our results also allow a more precise ordering of the genes 
on human chromosome 15. For instance, MIC7 and B2M have 
been localized proximal to the translocation breakpoint on chro-
mosome 15, whereas l\-JPI, PKM2, and c-fes are distal to this 
position. Furthermore, we have localizedMIC6 to the long arm 
of chromosome 17, probably distal to band q2IO. 
The absence of cjes from the human l5q+ translocation 
chromosome strongly argues for its localization within the frag~ 
ment of chromosome 15 that translocates to chromosome 17 in 
APL. The possibility that cjes sequences are simply deleted or 
are localized within a small undetected fragment of chromo-
some 15 that is translocated to a third human chromosome, al-
though unlikely, cannot be rigorously excluded. If translocation 
of cjes from chromosome 15 to 17 is relevant to APL, chro-
mosome 17q- would be predicted to be the critical chromo-
some. Some evidence suggesting that chromosome l5q+ is the 
critical chromosome has been obtained from two cases of APL 
with complex translocations involving a third chromosome (62, 
A B C 0 E 
63). In both these cases, the constant recombinant is the 15q+ 
translocation chromosome derived from the proximal segment 
of 15q and the distal segment of 17q. Further studies of this 
nature are required. 
The demonstration of 82M sequences within the 15q+ 
translocation chromosome, in combination with earlier data po· 
sitioning B2M distal to 15q2l (51), maps these sequences at or 
near the breakpoint in chromosome 15. In other studies, im" 
munoglobulin sequences have been mapped at the breakpoints 
of chromosome 22 in the Ph1 translocation associated with C:O.'iL 
and in the regions of chromosomes 14 and 22 that are trans-
located to chromosome 8 in Burkitt lymphoma (9, 19). Simi-
larly, the breakpoint in mouse chromosome 12leading to trans-
locations associated with lymphoid tumors has been shown to 
~ map within immunoglobulin heavy chain sequences (64-66). 
Although B2M is of functional significance primarily with re-
spect to expression of HLA antigens and shows no evidence for 
structural rearrangements in development, it does exhibit some 
structural resemblance to immunoglobulins (67); therefore, its 
mapping near the breakpoint in chromosome 15 may be rele-
vant to the Ei;l7 translocation associated with APL. 
The possible involvement of c-fes in the 15q+;l7q- trans-
location in APL is of interest in view of accumulating evidence 
for the mapping of human cellular oncogenes within chr(lmo~ 
somal fragments subject to highly specific translocations as-
sociated with particular classes of tumors (8-10, 16). :\loreover, 
the availability of somatic cell hybrids containing the l-5q + and 
' ' ' ' ' 
-human 
---human 
-human 
.__mouse 
-human 
-o-human 
2.2-
1.8--
.... $ ---mouse 
FIG. 4. Localization of c-fes andB2M relative to the breakpoint on human chromosome 15. Sst !-digested cellular DNA~ (25 p.g per lane) were 
electrophoresed on 0.7% agarose gels, blotted to nitrocellulose, and hybridized to either c-fes Ko~ (Left) or B2M (Right). Cell lines are: mouse, 1R 
(ref. 59; lanes A); human, LNSV (ref. 60; lanes BJ; HORL-1 (ref. 22; lanes CJ; PJTzfA1 Oanes DJ; DT2.12 (ref. 41: lanes E), and DTZ.lR3 (ref. 41: 
lanes F). The positions of mouse and human specific restriction fragments are as indicated. Hindiii-digested phage A DNA fragments are the size 
markers in kb (Left). 
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17q- translocation chromosomes should facilitate studies of the 
breakpoints in this translocation and a determination of the 
proximity of c{es to the translocation breakpoint. 
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APPENDIX PAPER VII 

The Human v-abl Cellular Homologue 
Nora Heisterkamp, John Groffen, and John R. Stephenson 
Laboratory of Viral Carcinogenesis, National Cancer Institute, Frederick, Maryland, U.S.A. 
Summary: A contiguous region of cellular DNA sequence, 64 kb in 
length and representing overlapping cellular inserts from three inde-
pendent cos mid clones, has been isolated from a representative library 
of human lung carcinoma DNA partially digested with Mba I. Within this 
region of the cellular genome, v-abl homologous sequences are dis-
persed over a total region of around 32 kb. These sequences represent 
the entire v-abl human cellular homologue, are colinear with the viral 
v-abl transforming gene, and contain a minimum of seven intervening 
sequences. At least eight regions of highly repetitive DNA sequences 
have been shown to map in close proximity to c-abf coding sequences. 
In addition to the major c-ab! human locus, three regions of human 
DNA sequence, corresponding to only portions of the v-abl gene, have 
been identified. Two of these have been molecularly cloned and shown 
to be distinct from the primary human c--ab/locus. Upon transfection to 
rat embryo fibroblasts in culture, none of the cosmid DNAs containing 
v-abl homologous sequences exhibited transforming activity. These 
findings identify and map a single genetic locus of human DNA, c-ab!, 
representing the complete v-abl homologue, and demonstrate the ex-
istence of additional human DNA sequences corresponding to more 
limited, subgenomic regions of v-abl. Key Words: v-ab/-Human c-
ab/-Oncogenes-Malignant transformation. 
RNA tumor viruses have been shown to rep-
resent recombinants between nontransforming 
type C viruses and cellular genetic sequences 
(oncogenes) (1,2). One approach to the iden-
tification of cellular genes with potential in-
volvement in naturally occurring tumors has 
involved the molecular cloning of cellular 
homologues of such "acquired" viral trans-
forming genes (2). Alternatively, efforts have 
been made to isolate cellular oncogenic se-
Received August 18, 1982; revised November 15, 1982; 
accepted December 7, 1982. 
Address correspondence and reprint requests to John R. 
quences directly from total transformed cell 
DNA by a combination of transfection and 
molecular cloning procedures (3-5). In one 
case involving transformation-specific se-
quences associated with human bladder car-
cinoma cells, these independent approaches 
have led to the identification of the same cellu-
lar sequences (3-5). Thus, these methods pro-
vide the possibility of identifying human genes 
that may be involved in expression of the 
transformed phenotype and thereby represent 
powerful approaches for determining the mo-
lecular basis of malignancy. 
Stephenson, Laboratory of Viral Carcinogenesis, National 
Cancer Institute, Frederick, Maryland 21701, U.S.A. 
The oncogenic retrovirus considered in the 
present study, Abelson murine leukemia virus 
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(Abelson MuLV), is a recombinant between 
mouse cellular sequences (v-abl) and Moloney 
MuLV .(6,7). Abelson MuLV is of particular 
interest in that, in contrast to other mammalian 
transforming viruses, it transforms lymphoid 
cells in vitro (8)' and induces a rapid B-ee!! 
lymphoma in vivo (9). The major Abelson 
MuL V translational product has been iden-
tified as a 120,000-Mr polyprotein (P12~a~:·abl) 
containing Moloney MuL V gag gene-encoded 
structural proteins (p 15 and p 12) and a carboxy 
terminal transformation-specific component 
(10,11). P12~ag.abJ is one of several viral en-
coded transforming proteins with tyrosine-
specific protein kinase activity (12-15). By use 
of a series of transformation-defective mutants, 
the P120gag.abl enzymatic activity has been 
shown to be required for Abelson MoLY-
induced transformation ( 14, 16) and for the pro-
duction of a 7600-Mr transforming growth fac-
tor (TGF) closely resembling TGFs produced 
by a number of human tumors (17,18). 
As an initial step in efforts to determine the 
potential involvement of human v-abl homolo-
gous sequences in naturally occurring tumors, 
we undertook their identification and molecu-
lar cloning. Because of our preliminary results 
indicating the presence, within human genomic 
DNA, of numerous v-abl homologous restric-
tion fragments, and evidence for extensive in-
tervening sequences within the cellular homo-
logues of certain other viral transforming genes 
(2), a cosmid vector system was used (19,20). 
By this means, the isolation of relatively large 
(35-45 kb) v-abl homologous DNA fragments 
is possible, thus facilitating efforts to deter-
mine the structural organization of such se-
quences within the human genome. Using 
this approach, we have isolated a single human 
locus (c-abl) that contains sequences corre-
sponding to the complete v-abl gene distributed 
over a region of around 32 kb, including multi-
ple noncoding (intervening) sequences. Other 
human sequences corresponding to less exten-
sive subgenomic regions of v-abl are also iden-
tified, and a possible model that may account 
for their origin is considered. 
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METHODS 
Gel Electrophoresis and Hybridization 
Restriction enzymes were purchased from 
either New England Biolabs or Bethesda Re-
search Laboratories (BRL) and were used ac-
cording to the suppliers' specifications. DNAs 
were digested with restriction enzymes, sub-
jected to electrophoresis through 0.75% agarose 
gels, and transferred to nitrocellulose (Schleicher 
and Schuell, ph79) essentially as described by 
Southern (21). Nick translation of probes and 
filter hybridization were as described (22,23). 
Specific activity of the probes was 2-5 x lOS 
cpm/ fLg. After hybridization, filters were ex-
posed to XAR-2 film (Kodak) for up to 5 days 
at -70°C with Dupont Lightning Plus intensify-
ing screens. 
Preparation of DNA Probes 
DNA probes were prepared by digestion of 
150 fLg of DNA with appropriate restriction en-
zymes, followed by electrophoresis through 
low-melting-point agarose (BRL). Desired 
bands were excised from gels and brought into 
solution by heating at 65°C for 30 min. Agarose 
was removed by two extractions with phenol 
equilibrated with 0.3 M NaOAc, pH 5.0, and 
one extraction with phenoUchloroform/isoamyl 
alcohol (25:24: l). DNA was precipitated with 
ethanol and 0.2 M NaOAc, pH 4.8, in the pres-
ence of 20 fLg/ml Dextran T-500 as carrier. 
Isolation of Human v-abl 
Homologous Sequences 
For isolation of v-abl homologous cellular 
sequences, a previously described cosmid li-
brary of human lung carcinoma DNA partially 
digested with Mbol was used. This library is 
highly representative and contains relatively 
large (35-45 kb) cellular inserts. Construction 
of the cosmid library, as well as procedures for 
the screening, isolation, and growth of recom-
binants, was as described (19). 
Subcloning 
Plasmid vector pHEP (20) was digested with 
Bam HI and treated with alkaline phosphatase 
(Boehringer) prior to ligation with the insert 
to prevent reannealing of the vector arms. The 
phosphatased DNA was extracted once with 
phenol/chloroform/isoamyl alcohol (25:24: I) 
after addition of EDTA to a final concentration 
of 10 rnM. The DNA was precipitated with 
ethanol in the presence of 20 ,ug/ml Dextran 
T-500 (Pharmacia) as carrier and 1/1o volume of 
2M NaOAc, pH 4.8. The phosphatase treated 
vector was ligated with Bam HI-digested A-AM-
I (a clone of AgtWES AB containing a 7.8-kb 
cellular insert corresponding to the complete 
Abelson MuL V proviral DNA, generously pro-
vided by P. Reddy, NCI; 24) in a molar ratio 
of, respectively, 5: I. Transformation of E. coli 
HB 101 to ampicillin resistance was as described 
previously (25). 
DNA-Mediated Transfection 
Transfection of TK- Rat-2 cells (26) was 
based on the methods of Graham and Vander 
Eb (27) as modified by Wigler et al. (28) with 
the exception that carrier DNA was omitted. 
RESULTS 
Isolation of v-abl Homologous Sequences 
from a Cosmid Library of Human 
Cellular DNA 
For use as a molecular probe, a 3.5-kb 
BamHI restriction fragment encompassing all 
but a short region of the Abelson MoL V provi-
ral DNA was excised from A-Am-1 (24) and 
subcloned into pHEP. Transfection of the 
newly generated plasmid, pHEP-Ab, to Rat-2 
cells resulted in comparable numbers of trans-
formed foci as observed with A-AM-I DNA, 
thus establishing the Bam HI restriction frag-
ment to include the complete v-abl transform-
ing gene. A DNA probe prepared from pHEP-
Ab by digestion with BstEII and Bam HI con-
tained, in addition to v-ahl, approximately 0.6 
FIG. 1. Identification of v-abl homologous sequences in 
human and mouse cellular DNAs. High molecular weight 
DNAs (20 !'g) were prepared from mouse dense N (lane B) 
and human A431 cells (Lane C), digested with EcoRI, and 
electrophoresed through a 0.75% agarose gel. After transfer 
of DNA to nitrocellulose. fllters were hybridized with a "P· 
nick·translated v-ab/ 8stEII/8amHI probe, indicated in the 
lower part of the figure. The boxed areas indicate the viral 
long terminal repeats; the solid bar represents the acquired 
cellular v-abl sequences of Abelson-MuLV. "P-Labeled 
Hindlll-digested !..DNA is included as a molecular weight 
standard (lane A). All molecular weights are in kb. 
kb of sequence derived from the Moloney 
MuLV gag gene (Fig. 1). For identification of 
v-abl homologous human sequences, high mo-
lecular weight mouse and human cellular 
DNAs were digested with EcoRI, electro-
phoresed, transferred to nitrocellulose fil-
ters, and hybridized to the v-abl BamHI!BstEII 
probe. As shown in Fig. 1, lane C, v-abl ho-
mologous human DNA restriction fragments of 
ll, 7.2, 5.0, 4.0, 3.4, 2.9, and 2.5 kb were clearly 
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resolved. As discussed below, the 4.0-kb re-
striction fragment actually corresponds to two 
v-abl homologous sequences of similar size 
(4.0 and 4.1 kb), which are not resolved in this 
figure. The demonstration of numerous human 
DNA EcoRI restriction fragments hybridizing 
to v-abl, which itself encompasses a region of 
only 3.0 kb, argues that the human v-abl 
homologue must contain extensive intervening 
sequences. It is also apparent from the data 
presented in Fig. 1 that although strength of 
homology of human and mouse cellular DNAs 
with v-abl is comparable, the restriction pat-
terns are distinct. 
To facilitate further characterization of v-abl 
homologous human DNA sequences, we uti-
lized a previously described (20) cosmid li-
brary of human lung carcinoma DNA. Upon 
screening with the v-abl BamHI/BstEII probe, 
ten positive cosmid clones were identified. 
None of these exhibited detectable hybridiza-
tion with a subclone of pBR322 containing the 
complete Moloney MuLV proviral DNA (data 
not shown). For further characterization of 
these clones, a series of probes with specificity 
for subgenomic regions of v-abl was prepared. 
As shown in Fig. 2, digestion of plasmid 
pHEP-Ab with Psti and Bam HI yielded a 5' 
probe of 1.7 kb (v-abl P1.7), which, in addition 
to v-abl sequences, contained around 0.6 kb of 
Moloney MuL V sequences. Two probes corre-
sponding to the central portion of v-abl (P0 _25 
and P 0 _7) and a fourth probe specific for the 3' 
region (v-abl P0.85) were also prepared. Of the 
nine v-abl homologous cosmid clones isolated, 
FIG. 2. Restriction enzyme map of the human c-ab/ region. In 
the upper portion of the figure the Bam HI subclone of Abel· 
son MuLV is indicated. The hatched box represents the long 
terminal repeat; the solid bar the acquired cellular se-
quences. Directly beneath the Abelson-MuLV genome, sub-
genomic restriction enzyme fragments, used as probes in 
this study, are indicated. Human DNA restriction fragments 
homologous to v-abt sequences are represented as solid 
boxes; below each region probes that exhibit homology are 
shown. Boxed areas directly below the restriction enzyme 
map show repetitive sequences found in the human c-ab/ 
region. Hatched boxes represent regions with intermediate 
homology; solid boxes represent regions with strong homol-
ogy. Beneath the map, cellular DNA inserts within cos 6. 15, 
and 16 are shown. Bg, Bg/!1; B, Bam HI; H, Hindllt; E. EcoRI; 
K, Kpnl. 
TABLE 1. Homology of human DNA EcoR! restriction fragments with v-ab! subgenomic probes 
and distribution among individual cosmid isolates 
Extent of hybridization to the following subgenomic probes 
Co' co, co, EcoRI restriction 
fragments Pu Po.2o Po.ao Po.7 sl.l S0.45 S2_o 8, 15,18 4,5,7,16 2,3, 10 
12.0 w w + 
11.0 M M 
7.2 s s + 
5.0 w w s s + 
4.0 s w M M + 
3.4 s M + 
2.9 s s + 
2.5 M w w + 
4.1 M s + 
High molecular weight DNAs (20 p.g) were prepared from human A43l cells, digested with EcoRI, electrophoresed 
through a 0.75% agarose gel, transferred to nitrocellulose, and hybridized to the indicated v-abl subgenomic probes. 
Extents of hybridization are designated as strong (S), medium (M), weak (W), and negative ( -). The panels on the right 
portion of the table indicate the three separate series of cosmid clones isolated in this study and the v-abl homologous 
Eco RI restriction fragments represented in each series collectively. 
three, cos 8, 15, and 18, hybridized to the origi-
nal v-abl BamHI/BstEII probe to a much 
greater extent than the others; in addition, each 
hybridized to at least two of the more specific 
v-abl subgenomic probes (Fig. 3). Cos 15 
containedEcoRI fragments of7.2, 3.4, 2.9, and 
2.5 kb hybridizing to the v-abl Pu probe. Cos 
18 contained EcoRI fragments of 4.0 and 3.1 kb 
homologous to P1.1, one of which, the 4.0-kb 
fragment, also hybridized to the v-abl P0 _25 
probe, and a fragment of 5.0-kb homologous 
to v-abl P0 _25 , P0 _7 , and P0 _85 , whereas the third 
clone, cos 8, contained v-abl homologous 
EcoRI fragments of 7.2, 5.0, 4.0, 3.4, and 2.5 
kb. Finally, as shown in Fig. 3, these three 
clones exhibited considerable sequence cross-
homology with each other. 
Restriction maps of v-abl homologous se-
quences within cos 8, 15, and 18 were gener-
ated using various combinations of EcoRI, 
Kpni, Bam HI, Hindiii, and Bg!II. As summa-
rized in Fig. 2, the three cosmid clones contain 
overlapping cellular sequences corresponding 
to a single contiguous region of human cellular 
DNA of around 64 kb. Based on hybridization 
with the four individual subgenomic v-abl 
probes, a minimum of seven distinct regions of 
v-abl homology (exons), interspersed by six 
nonhomologous regions representing probable 
intervening sequences (introns), was identified. 
In addition, colinearity of sequences within 
the human v-abl homologue and the viral 
v-abl gene itself is established, 
Cos 8, 15, and 18 Contain i:he Complete 
v-abl Homologue 
To establish whether the complete human 
v~abl homologue is represented within the cos 
8, 15, and 18, and whether rearrangements 
might have occurred during cloning, the com~ 
posite restriction map of the cloned sequences 
was compared with that of v-abl homologous 
sequences in human cellular DNA. The latter 
were identified on the basis of hybridization to 
individual v-abl subgenomic probes. As shown 
in Fig. 4, digestion of human DNA withEcoRI 
and subsequent hybridization to the v-abl Pu 
probe yielded fragments of 11.0, 7.2, 4.0, 3.4, 
2.9, and 2.5 kb, whereas the v-abl P0.7 probe 
hybridized to a single fragment of 5.0 kb. Upon 
digestion of human cellular DNA, together 
with a small amount of DNA from cos 15 and 
18, and hybridization to Pu, all v-abl homolo-
gous fragments in cos 15 and 18 comigrated 
with those in human genomic DNA (Fig. 5). 
The extra fragment of 3.1 kb represents a trun-
cated 3.4-kb fragment located at the very 5' end 
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FIG. 3. Homology of cosmid clones 8, 15, and 18with v-abl P,_,, v-abl P0_7, and clone 15. Cosmid DNAs (0.4p.g} were digested with 
EcoRI, electrophoresed through 0.75% agarose gels, and transferred to nitrocellulose. Lane A, ethidium-bromide stained gel; 
lane B, hybridization with the v-abl P,_, probe; lane C, hybridization with v-abl P0•7 probe; lane 0, hybridization with cos 15. A 
Hindlll digest of IlONA is included as a molecular weight standard in the extreme left lane. 
of clone 18. Kpnl digestion of cellular DNA 
generated restriction fragments of 18.6, 14.2, 
5.6, and 2.8 kb hybridizing to v-abl P~, 7 , 
whereas BamHI digestion yielded 24.0- and 
3.4-kb fragments hybridizing with v-abl P1.1 
and a 7.3-kb v-abl P0 _7 homologous fragment 
(Fig. 4). These results are in concordance with 
the mapping and hybridization data on the 
cloned DNA shown in Fig. 3, arguing against 
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the possibility that major rearrangements of the 
c-ab! locus might have taken place during 
cloning. 
It should be noted that the 4.1- and 11-kb 
Eco RI fragments identified on digestion of total 
human DNA and hybridization with v-abl Pu 
are missing from the cloned human c-abl se-
quence represented in cos 8, 15, and 18 (Table 
1). Since the v-abl P1.1 probe corresponds to 
FIG. 4. Restriction endonuclease analysis of 
v-ab/ homologous sequences in human 
genomic DNA. Twenty micrograms of high 
molecular weight human A431 DNA was di-
gested with enzymes as indicated, elec-
trophoresed through 0.75% gels, and hy-
bridized with either v-abl P,,, (lane A) or v-abl 
P,_, (lane B). 
FIG. 5. Comparison of v-abl homologous EcoRI restriction 
fragments in total A431 human DNA with those of the molec-
ular cloned human c-ab/ gene. Twenty micrograms of high 
molecular weight human DNA (lane A) or 0.3 ng of a mixture 
of cosmid 15 and 18 DNAs plus 20 J.>g of high molecular 
weight human DNA (lane B) was digested with EcoRI, elec-
trophoresed through a 0.75% gel, transferred to nitrocel-
lulose, and hybridized to the v-abl P,_1 probe. 
the 5' region of v-abl, the possibility was con-
sidered that these missing fragments might rep-
resent DNA sequences at the extreme 5' end of 
the human c-abl region, not present in these 
clones. Alternatively, detection of these se-
FIG. 6. Comparison of restriction endonu-
clease patterns of human genomic DNA and 
molecularly cloned v-abl homologous se-
quences in cosmid 15. Twenty micrograms of 
high molecular weight A431 human DNA {A) 
or 0.41-'g of DNA from cosmid clone 15 {B) was 
digested with EcoRI, electrophoresed 
through a 0.75% agarose gel, and blotted 
onto nitrocellulose. Probes used are indi-
cated above each lane. The first lane in {B) 
shows the ethidium bromide-stained gel of 
cosmid 15 DNA. 
quences in total human DNA after hybridiza-
tion could reflect the fact that v-abl P1_7 probe 
contains approximately 0.6 kb of Moloney 
MuLV gag sequences. To test these pos-
sibilities, probes were prepared from plasmid 
pHEP-Ab by digestion with Smal, BstEII, and 
Bam HI (Fig. 2). In this way, the v-abl P1.1 re-
gion was subdivided into different domains. 
Hybridization of each of these probes to 
EcoRI-digested high molecular weight human 
DNA (Fig. 6, panel A) to cos 15 (Fig. 6, panel B), 
and cos 18 (data not shown) confirmed that all 
EcoRI fragments except the 4.1- and 11-kb 
fragments were present in the clones. In the 
total cellular DNA, however, the 4.1- and 
11-kb fragments lacked detectable homology to 
a probe specific for the 5' part of v-abl and the 
0.6 kb of Moloney MuLV sequences (v-abl 
Su), but did hybridize to the v-abl S0 _45 probe. 
The possibility that the 4.1- and 11-kb frag-
ments are Moloney MuLV specific is thus 
excluded. Furthermore, these latter fragments 
cannot represent 5' c-ab! sequences located 
upstream from the major c-abl locus, because 
they do not hybridize to the v-abl S~.~ extrem_e 
5' probe. We therefore conclude that cosmid 
clones 8, 15, and 18 encompass a DNA se-
quence representing the complete v-abl human 
135 
FIG. 7. Repetitive DNA sequences in the human c-ab/ region 
Cosmid 15 and 18 DNAs (0.4 J.<.g each) were digested with Bg/11 
and EcoRI, electrophoresed through a 0.75% agarose gel, and 
transferred to nitrocellulose. Lane A, ethidium bromide-
stained gel: lane B, hybridization to "P-Iabeled DNA of a pre-
viously described cosmid clone containing a 35-kb cellular 
insert representing the complete human c-fes gene: lane C, 
hybridization to a "P-Iabeled probe of total human DNA. High 
molecular weight human DNA was digested with EcoRI and 
size fractionated on a 10-40% sucrose gradient in 20 mM 
Tris-HCI, pH 8.0, 5 mM EDTA, i M NaCI. DNA (300 ng) in the 
size range 4-5 kb was nick translated. "P-Labeled Hind Ill-
digested ADNA is included as a molecular weight standard in 
extreme left lane. 
homologue and that the 4.1- and 11-kb v-abl 
homologous EcoRI restriction fragments cor-
respond to separate genetic loci. 
Human c-abl Locus Contains 
Repetitive Sequences 
There is accumulating evidence for the pres-
ence of repetitive DNA sequences mapping in 
proximity to cellular coding sequences {exons) 
(29,30). To test the 64-kb c-ab! homologous re-
gion for such sequences, restriction fragments 
were analyzed for hybridization to a probe of 
total human cellular DNA. As shown in Fig. 7, 
lane C, several EcoRI/Bglll restriction frag-
ments in cos 15 and 18 were found to hybridize 
to this probe. Moreover, as shown in lane B, 
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each of the repetitive sequences within the 
c-ab! locus also hybridized to a cosmid clone 
(cos 5), containing the entire human homologue 
of v-fes, a second cellular oncogene whose 
viral counterpart encodes a tyrosine-specific 
protein kinase. The extra positive restriction 
fragments seen in lane B reflect hybridization 
of vector sequences common to the c-ab! and 
c-fes cosmid clones. Upon further restriction 
mapping analysis, the positions of these repeti-
tive sequences within the region of c-abf have 
been determined (Fig. 2). Repeats mapped at 
essentially the same positions, regardless of 
whether the total DNA or c-fes probe was used 
for their detection. 
Identification of v-abl Related Sequences 
(Sn.4~ Homologous) in Cosmid Clones 
2, 3, and 10 
To determine the relationship of the 4.1- and 
11-kb v-abf homologous EcoRI restriction 
fragments to the major c-ab! locus, additional 
cosmid clones were analyzed for v-abl Srui; 
homologous sequences. Although none of the 
six clones screened contained the 11-kb re-
striction fragment, three clones were found 
to contain a 4.1-kb restriction fragment with 
homology to the v-abl S0 .4 5 probe (Fig. 8). The 
lack of detectable overlapping restriction frag-
ments between the cellular inserts in these 
clones and the major human c-abf locus indi-
cates the existence, within human genomic 
DNA, of at least two independent regions with 
homology to one of the v-abl internal restric-
tion fragments, v-abl Su.~5 . The relationship of 
these sequences both to each other and to the 
major c-abf locus remains to be established. 
Cos 4, 5, 7, and 16 Contain v-abl P0 _7 
Homologous Sequences 
In contrast to the above-described cosmid 
clones, the four remaining clones isolated in 
the initial screening (cos 4, 5, 6, and 16) hy-
bridized exclusively to the v-abl P11 •7 probe 
(Table l). As these clones exhibit extensive 
FIG. 8. Identification of v--abl homologous sequences in cos 
3 and cos 7. Cosmid DNAs (0.41-'g) were digested with £coAl, 
electrophoresed through a 0.75% agarose gel, and trans· 
ferred to nitrocellulose. Lane A, ethidium bromide-stained 
gels: lane 8 (left), hybridization to v-abl $ 0 • .,; lane B (right), 
hybridization to v-abl Po.>· ' 2P-Labeled Hindlll-digested ADNA 
is included as a molecular weight standard in extreme left 
lane. 
homology to one another, they appear to repre-
sent a single contiguous DNA region. All 
contain, in part or in whole, a 12.0-kb EcoRI 
restriction fragment with homology to v-abl 
P0. 7 • The fact that this particular fragment was 
not detected in £caRl-digested total cellular 
DNA using the same probe argues that the ex-
tent of v-abl homology within the sequence 
represented in these four cosmid clones is 
much less than that described above for cos 5, 
15, and 18. To exclude the possibility that the 
12.0-kb EcoRI fragment might represent an ar-
tifact generated during cloning, a probe of 0. 7 
kb representing an internal Ava I restriction 
fragment of the 12.0-kb cloned v-abl homolo-
gous sequence was prepared. Using this latter 
probe, a 12.0-kb £caRl fragment could be 
demonstrated in total human cellular DNA 
(data not shown), establishing that the v-abl 
Po. 7 homologous sequences in cosmid clones 4, 
5, 7, and 16 are representative of nonrear-
ranged cellular sequences. 
Although cos 4, 5, 7, and 16 showed some 
cross-homology to clones 8, 15, and 18, even 
when posthybridization washings were per-
formed under stringent conditions, no overlap-
ping restriction fragments were detected. Since 
the human c-abl locus contains numerous re-
petitive sequences, this hybridization is proba-
bly due to repeats common to these clones. 
Thus the v-ab/-related sequences represented 
in cos 4, 5, 7, and 16 appear to represent a 
different region of human genome from the 
primary c-ab! locus. Moreover, if the se-
quences in cos 4, 5, 7, and 16 are contiguous 
with sequences at the 3' end of clone 18, they 
must be separated by at least 26 kb. 
Transfection Analysis of Molecularly 
Cloned Human c-abl Sequences 
Since the cos mid vector used for the cloning 
of v-abl homologous sequences in humans con-
tains the TK gene, transfection of these clones 
to a recipient TK- Rat-2 cell line was possible, 
using a HAT selection system to ensure that the 
transfection was successful. Upon such analy-
sis, using molecularly cloned v-abl (pHEP-Ab) 
as a positive control, none of the three cosmids 
containing inserts representing portions of the 
major c-abl locus exhibited detectable trans-
forming activity. Similarly, cos mid clones con-
taining either v-abl SoAs (2, 3, and 10) or P0.7 
(4, 5, 7, and 16) homologous sequences were 
analyzed and found to lack transforming ac-
tivity. 
DISCUSSION 
A cos mid library constructed of human lung 
carcinoma DNA has been applied to the molecu-
lar cloning and restriction endonuclease analy-
Sis of human cellular sequences (c-ab!) homolo-
gous to the Abelson MuL V transforming gene 
v-abl. A contiguous human DNA sequence, 64 
kb in length, represented by overlapping cellu-
lar inserts of three independent cos mid clones 
was identified and shown to contain v-abl ho-
mologous sequences distributed discontinu-
ously over a region of 32 kb, as compared with 
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the v-abl gene, which is approximately 3 kb in 
length. This region of human genomic DNA 
exhibits homology with probes representing 
the complete acquired sequence region (v-abl 
gene) of the Abelson MuLV genome. Similarly, 
mouse cellular c-abl homologous sequences 
are spread over a region of 11-20 kb (7). Based 
on hybridization with probes corresponding to 
subgenomic regions of v-abl, the arrangement 
of human c-abl sequences is shown to be colin-
ear with that of the viral v-abi gene. 
On the basis of extent of hybridization with 
32P-labeled probes corresponding to the com-
plete v-abl gene, six regions of nonhomology 
(intervening sequences) are identified within 
the human c-abl gene. This, however, is based 
on hybridization to restriction fragments and 
thus represents a probable overestimation of 
the extent of homology and an underestimation 
of the number of intervening sequences. 
Moreover, the degree to which v-abl resembled 
the mouse c-ab! gene at the time of the initial 
recombination event invo.lved in its derivation, 
the extent of modification of the v-abl gene 
subsequent to recombination with Moloney 
MuL V, and the degree to which the mouse and 
human c-abl genes have diverged relative to 
each other are unknown. For instance, in addi-
tion to the Abelson MuL V isolate utilized in 
the present study, a second variant has been 
described that contains around 0.8 kb of addi-
tional acquired cellular sequence and encodes a 
somewhat larger polyprotein, P160 (3l). Pre-
sumably, the smaller form of v-abl represents a 
deletion of the larger variant. On the basis of 
these considerations, it is clear that coding and 
intervening sequences of the human c-abl gene 
cannot be accurately defined strictly on the 
basis of homology to v-abl. A more precise 
determination of the exact positions of the 
human c-abl coding sequence will require 
identification and characterization of its 
mRNA transcript(s). It is apparent, however, 
based on a comparison to v-abl, that >90% of 
the human c-abl gene represents probable non-
coding sequence. 
The present findings indicate differences in 
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the extent of hybridization between different 
regions of the v-abl and human c-ab! genes. 
Although probes corresponding to two of the 
v-abf Pstl fragments, v-abl P1.1 and v-abl P0 .7 , 
exhibit strong homology with c-ab!, the two 
others, v-abl P0.25 and v-abl P0.85 , hybridize to 
much lesser extents. As one possible explana-
tion of these observations, regions ofv-abl cor-
responding to the latter two probes may not be 
required for Abelson MuL V -induced transfor-
mation and consequently may be subject to 
much greater rates of evolutionary divergence. 
The possibility that at least one of these probes, 
v-abf P0.85 , may correspond to a region non-
essential for expression of transformation is 
indicated by the isolation of viral mutants with 
deletions in the 3' region of v-abl that retain 
transforming activity (3l). 
The demonstration of extensive regions of 
DNA repetitive sequences within the human 
c-ab! locus is consistent with recent reports by 
others indicating the frequent existence of 
DNA repeats in close proximity to celluiar 
coding sequences (29,30). It is not known, 
however, whether the repetitive sequences ob-
served in the present study correspond to mul-
tiple copies of a single sequence or alterna-
tively represent diverse members of a broader 
family of repetitive sequences. If the latter pos-
sibility should prove to be the case, the finding 
that each of the restriction fragments contain-
ing repetitive sequences, as measured by a 
total cellular DNA probe, also contains one or 
more repeats in common with the 35-kb human 
c:fes-containing cellular sequence may be of 
significance. 
In addition to cosmid clones representing the 
major human c-ab! genetic locus, evidence for 
as many as three other regions of v-abl homol-
ogy is presented. These include a 12.0-kb 
EcoRI restriction fragment that hybridizes ex-
clusively to a probe corresponding to a single 
0. 7-kb Psti restriction fragment mapping within 
the 3' half of v-abf (P0 .7 ) and fragments of 4.1 
and 11.0 kb with homology to v-abl S0 .45 . Al-
though the relationship of these secondary re-
gions of homology to the primary c-abl gene is 
unclear, a number of possibilities can be con-
sidered. For instance, _the secondary regions 
may correspond to highly divergent indepen-
dent loci that arose because of transposition of 
portions of, or even the complete, c-ab/locus, 
and as such may represent pseudogenes. Al-
ternatively, the homology of these secondary 
sequences to v-abl may reflect relatedness of 
distinct but functionally analogous cellular 
genes. As an example of the latter possibility, 
one or more of the secondary v-abl homologous 
sequences could correspond to other cellular 
oncogenes with tyrosine-specific protein 
kinase activity·. Finally, it is not resolved as to 
whether these secondary v-abl homologous se-
quences map in close proximity to each other 
or are randomly distributed throughout the 
human genome. 
None of the above-described c-abl contain-
ing cos mid clones exhibit transforming activity 
on transfection to Rat-2 cells. This does not 
rule out the possibility that the human c-abl 
gene has such activity, since two of the clones, 
8 and 18, are missing 5' regions that are likely 
to contain promoter sequences. Clone 15 is 
truncated and lacks sequences homologous to 
the 3' terminal of the v-abl gene. Each of the 
remaining cosmid clones contains sequences 
corresponding to only limited regions of v-abl, 
and thus their lack of transforming activity is 
not unexpected. Although on molecular clon-
ing from normal tissues the Harvey murine sar-
coma virus e-ras gene lacks transforming ac-
tivity (32), an active form of the gene is found 
in certain bladder carcinomas cell lines (3~5); 
even by appropriate in vitro modification, the 
inactive molecularly cloned e-ras gene can be 
converted to an active form (32). Similarly, the 
human c-abl gene may have oncogenic poten-
tial that becomes realized only subsequent to 
specific modification. 
Acknowledgments: The authors thank F. Gros-
veld for helpful discussions and G. T. Blennerhas-
sett and P. Hanson for their excellent technical as-
sistance. This work was supported under Contract 
No. NOl-C0-76380 from the National Cancer In-
stitute, Bethesda, Maryland. 
REFERENCES 
J. Fischinger PJ. Type C RNA transforming viruses. In: 
Stephenson JR, ed. Molecular biology of RNA 111mor 
viruses. New York: Academic Press, 1980:162-94. 
2. Klein G. Advances in viral oncology. New York: 
Raven Press, 1982. 
3. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human 
EJ bladder carcinoma oncogene is homologue of 
Harvey sarcoma virus ras gene. Nature 1982;297: 
474-8. 
4. Der CJ, Krontiris TG, Cooper GM. Transforming 
genes of human bladder and lung carcinoma cell lines 
are homologous to the ras genes of Harvey and 
Kirsten sarcoma viruses. Proc Nat! Acad Sci USA 
1982;79:3637-40. 
5. Santos E, Tronick SR, Aaronson SA, Pulciani S, 
Barbacid M. T24 human bladder carcinoma on-
cogene is an activated form of the normal human 
homologue of BALB- and Harvey-MSV transform-
ing genes. Narure 1982;298:343-7. 
6. Scolnick EM. Howk RS, Anisowicz A, Peebles P, 
Scher CD, Parks WP. Separation of sarcoma virus-
specific and leukemia virus-specific genetic se-
quences of Moloney sarcoma virus. Proc Nat/ A cad 
Sci USA 1975;72:4650-4. 
7. GoffSP, Gilboa E, Witte ON, Baltimore D. Structure 
of the Abelson murine leukemia virus genome and 
the homologous cellular gene: Studies with cloned 
viral DNA. Cell 1980:22:777-85. 
8. Rosenberg N, Baltimore D, Scher C. In vitro trans-
formation of lymphoid cells by Abelson murine 
leukemia virus. Proc Nat/ Acad Sci USA 1975;72: 
1932-6. 
9. Abelson HT, Rabstein LS. Lymphosarcoma virus-
induced thymic independent disease in mice. Cancer 
Res 1970;30:2213-22. 
10. Reynolds FH Jr. Sacks TL, Deobagkar DN, 
Stephenson JR. Cells nonproductively transformed 
by Abelson murine leukemia virus express a high 
molecular weight polyprotein containing structural 
and nonstructural components. Proc Nat/ Acad Sci 
USA 1980;75:3974-8. 
II. Witte ON, Rosenberg N, Paskind M, Shields A, Bal-
timore D. Identification of an Abelson murine 
leukemia virus-encoded protein present in trans-
formed fibroblasts and lymphoid cells. Proc Nat! 
Acad Sci USA 1978;75:2488-92. 
12. Van de Yen WJM, Reynolds FH Jr, Stephenson JR. 
The nonstructural components of polyproteins en-
coded by replication-defective mammalian trans-
forming retroviruses are phosphorylated and have 
associated protein kinase activity. Virology 1980: 
101:185-97. 
13. Witte ON. Dasgupta A, Baltimore D. Abelson murine 
leukemia virus protein is phosphorylated in vitro to 
form phosphotyrosine. Nature 1980;283:826-31. 
14. Reynolds FH Jr, Van de Yen WJ, Stephenson JR. 
Abelson murine leukemia virus transformation· 
defective mutants with impaired P120-associated 
139 
protein kinase activity. J Viral 1980;36:374-86. 
15- Sefton BM, Hunter T, Raschke WC. Evidence that 
the Abelson virus protein functions in vivo as a pro-
tein kinase that phosphorylates tyrosine. Proc Nat/ 
Acad Sci USA 1981;78:1552-6. 
16- Witte ON, Goff S, Rosenberg N, Baltimore D. A 
transformation defective mutant of Abelson murine 
leukemia virus lacks protein kinase activity. Proc 
Nat/ Acad Sci USA 1980;77:4993-7. 
17. Blomberg J, Reynolds FH Jr, Van de Yen WJM, 
Stephenson JR. Abelson murine leukemia virus 
transformation involves loss of epidermal growth 
factor-binding sites. Nature 1980;286:504-7. 
18. Twardzik DR, Todaro OJ, Marquardt H, Reynolds 
FH Jr, Stephenson JR. Abelson MuLV induced 
transformation involves production of a polypeptide 
growth factor. Science 1982;216:894-7. 
19. Grosveld FG, Dahl H-HM, de Boer E, Aavell RA. 
Isolation of .B-globin-related genes from a human 
cosmid library. Gene 1981;13:227-37. 
20. Groffen J, Heisterkamp N, Grosveld F, Van de Ven 
WJM, Stephenson JR. Isolation of human oncogene 
sequences (v-fes homolog) from a cosmid library. 
Science 1982;216: 1136-8. 
21. Southern EM. Detection of specific sequences among 
DNA fragments separated by gel electrophoresis. J 
Mol Bioi 1975;98:503-17. 
22. Bernards R, Flavell RA. Physical mapping of the glo-
bin gene deletion in hereditary persistence of foetal 
haemoglobin (HPFH). Nucleic Acids Res 1980;8: 
152!-34. 
23. Flave!l RA, Kooter JM, de Boer E, Little PFR, Wil-
liamson R. Analysis of the .B-S-globin gene loci in 
normal and Hb Lepore DNA: Direct determination 
140 
of gene linkage and intergene distance. Cell 1978; 
15:25-41. 
24. Srinivasan A, Reddy EP, Aaronson SA. Abelson 
murine leukemia virus: Molecular cloning of infec-
tious integrated proviral DNA. Biochemistry 
1981;78:2077 -81. 
25. Morrison DA. Transformation and preservation of 
competent bacterial cells by freezing. In: Wu R, ed. 
Methods in enzymology, vol 68. New York: 
Academic Press, !980:326-31. 
26- Topp WC. Normal rat cell lines deficient in nuclear 
thymidine kinase. Virology 1981;113:408-11. 
27. Graham FL, Vander Eb AJ. Transformation of rat 
cells by DNA of human adenovirus 2. Virology 
1973;54:536-9. 
28. Wigler M, Pellicer A, Silverstein S, Axel R. Bio--
chemical transfer of single-copy genes using total 
cellular DNA as donor. Ce/l1978;!4:725-3L 
29. Shen C-KJ, Maniatis T. The organization of repeti-
tive sequences in a cluster of rabbit .B-Iike globin 
genes. Cell 1980;19:379-91. 
30. Jelinek WR, Toomey TP, Leinwand L, et al. Ubiq-
uitous, interspersed repeated sequences in mamma-
lian genomes. Proc Nat/ Acad Sci USA 1981;77: 
1398-402. 
31. Ziegler SF, Whitlock CA, Goff SP, Gifford A, Witte 
ON. Lethal effect of the Abelson murine leukemia 
virus transforming gene product. Ceil 1981 ;27: 
477-86. 
32. Chang EH, Furth ME, Scolnick EM, Lowy DR. 
Tumorigenic transformation of mammalian cells in-
duced by a normal human gene homologous to the 
oncogene of Harvey murine sarcoma virus. NaJure 
1982;297:479-83. 
APPENDIX PAPER VIII 

Homology between phosphotyrosine 
acceptor site of human 
c·abl and viral oncogene products 
John Grotfen, Nora Heisterkamp, Fred H. Reynolds Jr 
& John R. Stephenson 
Labo-ratory of Viral Carcinogenesis. National Cancer !nstitute-
FCRF. Frederick, Maryland 11701, USA 
The human homologues of several independent viral 
oncogenes, each of which encodes tyrosine-specific protein 
kinases, have been identified'·'. Of -these, three (v-src, v-~es 
and v·fes/fps) are known to exhibit considerable seque~ce 
homology, particularly in the regions of their phosphorylation 
arceptor sites"-'. In the present study, sequences encoding the 
tyrosine phosphorylation acceptor sites of the Abelson murine 
leuk:aemia virus oncogene, v-abl, and its human cellular 
homologue, c-ab/, have been identified and their nucleic acid 
seq11ences determined. Our results establish extensive 
homology between this region of c-ab/ and acceptor domains 
of the v-src'·", v-yes• and v·fes{fps 4 ·' family of viral oncogenes, 
as w-ell as more distant relatedness to the catalytic chain of the 
mammalian cyclic AMP-dependent protein kinase7 • These 
findings suggest that, of the homologues of retroviral oncogenes 
with tyrosine protein kinase activity examined to date, all were 
probably derived from a common progenitor and may represent 
members of a diverse family of cellular protein kinases. 
We have described previously the application of a cosmid 
vector system to the molecular cloning of the human cellular 
homologue of acquired cellular (v-abl) sequences of the 
Abelson strain of murine leukaemia virus". v-abl homologous 
sequences were found to encompass six separate coding regions 
(exons) distributed over a total of 32 kilo bases (kb)" localized 
on human chromosome 9(q34) (refs 9, 10). Figure I shows the 
positioning of such sequences, as delineated by restriction 
endonuclease and hybridization analysis. HybridizatiorJ of 
individual exor1s to a series of Smal restriction fragments 
corresponding to specific regions of v-abl is also indicated. By 
transfection analysis, v-abl-specific sequences required for 
transforming activity have been localized to the 5' half of the 
acquired region within the viral genome". Moreover. a variant 
of Abelson-MuL V characterized by an in-phase interstitial 
deletion mapping within the 5' region of the v-abl acquired 
sequence has been shown to lack transforming activity 12 • Since 
this latter deletion approximates that of a 0.45-kb Sma! restric-
tion fragment of v-abl, shown in Fig. I, we reasoned that human 
(-abl sequences homologous to the S".-'' probe might corre-
spond to its phosphotyrosine acceptor site. As shown in Fig. 1, 
Fig. 1 Schematic representation of Abelson-
MuLV proviral DNA and the human v-abl 
homologous lc-ab/1 sequence. Positions of long 
terminal repeats I [II), acquired cellular sequen-
ces tBI, region of the acquired sequences 
ncce~'ary to retain transforming activity IIIII I, 
a deletion within a transformation-defective 
variant of Abelson MuLV (E!;l), and a series of 
three Smal restriction fragments li.J) used as 
probes for analysis of c-ab/ sequences, are 
sbown in the upper portion of the figure. v-abl 
homologous sequences, shown as solid boxes 
in the human c-ab/ genetic locus, were 
,, 
most (>[ the S".4 ·' homologous sequences could be locali:zed to 
a single 3.4-kb EcaRI restriction fragment encompassing por-
tion> of three exons and mapping within the middle of the 
human v-abl homologous region. Subdoning in pBR328 and 
fine mapping revealed that this fragment contained a 0.14-kb 
Bg!II/At•al restriction fragment which hybridized strongly to 
the$,_.~ probe. 
In view of its homology to the transformation-specific region 
of v-ab/ and consequently the possibility that it might corre-
spond to the active region of the c-ab/ prutein kinase, the 
0.14-kb Bgi!I/AL•al restriction fragment was subjected to 
nucleic add sequence analysis. Figure 2 shows that of the three 
possible reading frames, the first contained six termination 
codons, the second contained a single TGA stop codon near 
the middle of the sequence, not followed by any obvious splice 
acceptor site, while the third lacked any termination codons 
and thus appeared to represent the authentic coding sequence 
for the c-ab/ gene product. To extend this analysis, we sub-
sequently sequenced the coding region of an adjacent down-
stream A(.•al/A~:al c-ab/ restriction fragment, and by an 
analogous approach, the corresponding region of v-abl. The 
predicted amino acid sequences corresponding to each of these 
regions of nucleic acid sequence are shown in Fig. 2. The 
predicted amino acid sequences of the internal 61 residues were 
identical based on either the v-abl or c-ab/ nucleic acid 
sequence. Sixteen additional amino-terminal and 18 carboxy-
terminal residues correspond to regions for which only v-abl 
sequence was determined. 
We investigated whether the deduced c-ab!/ v-abl amino acid 
sequence correspor1ds to phosphotyrosine acceptor site regions 
common to the v-src-. v-res- and v-[es/fps-encoded transform-
ing proteins by comparing relevant sequences. As shown in Fig. 
3. the c-ablfv-abl sequence contains 38 out of 96 residues in 
common with all four of the viral acceptor site regions 
examined. Additional relatedness with individual viral sequen-
ces appears rather random; some c-abl/v-ab/ residues are com-
mon to either v-res or v-src while others are shared only with 
the v-fes and v-fps gene products. The c-abl/v-abl-encoded 
proteins also contain a tyrosine residue at the position corre-
sponding to the previously identified tyrosine acceptor sites of 
each of the other oncogene-encoded products examined. In 
addition, there is considerable homology (28 of 96 residues) 
between c-ab/ and the catalytic sun unit of the mammalian cyclic 
AMP-dependent protein kinase IBOY-PK), although the 
tyrosine acceptor residue of c-abl/v-abl is replaced by a tryp-
tophan residue in BOV-PK. Interestingly, this substitution is 
directly adjacent t0 a threonine residue known to represent 
one of two phosphorylation sites previously identified in BOV-
PK'. 
To establish whether the putative c-ab/ tyrosine phosphoryla-
tion site is recognized by functionally active viral protein 
kinases, a synthetic peptide with the sequence NH,-Ser-Arg-
' ~ ···' 
~~l~n:~~dm~e~~~~;c~~~ri~~~aot~:~l:~•:ly~:~e~ i--tF- ----~~ 
described previously" Specific v-abl probes, to "' 1 "' 1 
which the individual c-ab/ exons hybridize, are also shown A restriction map of the phosphotyrosine acceptor site region of c-ab/ is shown 
in more detail directly below the c-ab/ map; extents of hybridization to the$,_., probe are indicated as negative I'JJ. weak lrn), medium 
Iilii. or strong iBJ, 
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Lcu-\1et-Thr-Giy-Asp-Thr-Tyr-Thr-Aia-His-Aia-Giy-Aia-
Lys-COOH was chemically synthesized and purified by HPLC. 
On addition of Abelson-MuLV P120 to immunoprecipitates, 
the c-ab/ acceptor peptide was phosphorylated 10-fold more 
dficiently than in the same reaction conditions using 
[Val']angiotensin I! as substrate". Following re-purification of 
the labelled peptide by HPLC and subsequent two-dimensional 
phosphoamino acid analysis, "P incorporation by the synthetic 
c-ab/ acceptor site peptide was found to be exclusively in 
tyro•;~ne 
Table I summarizes the relatedness of the amino acid sequen-
ces within the acceptor regions of representative tyrosine-
'Pe<:ific protein kinases and the corresponding nucleic acid 
sequences from which these were deduced. Although c-ab/ is 
'mmcwhat more related to v-src especially with respect to 
nucleic acid sequence. than to the other viral oncogene 
sequences ~xamined. it is less related to v-src than is v-yes. 
Interestingly. of the five oncogene acceptor sequences analysed, 
<:-11hi is mo>t closely related to BOY -PK. It is also apparent that, 
in general, the oncogene acceptor site regions are much Jess 
conserved with respect to nucleic acid sequence than in the 
amino ~cids they encode, indicating that much of the nucleic 
acid >equencc divergence reflects third position or other silent 
nuclcutide <.:hanges not resulting in an altered gene product. 
The present findings establish the evolutionary relatedness of 
c-abl/v-abl to four retroviral oncogenes. each of which contains 
transformation-specific sequences with tyrosine-specific protein 
kinas<' ;~<:tivit). In fact. despite its human cellular origin, the 
phosphotyro~m<' acct'ptor site region of c-ab! is as closely 
related to analogous regions of the v-src, v-yes and v-fesjv-fps 
vital oncogenes as these are to each other. Although an addi-
tional rdro-viral oncogene, v-ros. with similar enzymatic activity 
has heen described, its relationship to those genes examined in 
the present study is unknown 14 • Human c-ob!. c-src and c-fes/c-
!P-' arc sufficiently diverged to lack detectable cross-hybridizing 
sequences and have been mapped to different human 
chromosomes"·'"·"'" The mammalian v-fes and avian v-fps 
genes. although indt'pendently identified. correspond to a com-
mon mammalian cellular genetic locus, c-fesjc-fps' 7 ·'". The 
human homologue of I he fourth viral oncogene, v-yes, remains 
poorly ddlned 
Evid~nce that the c-ab/ phosphotyrosine acceptor site 
identified in the present study is functionally active derives from 
it> in n'rr:~ phosphorylation by the v-abl protein kinase. 
\-lorcovcr, the iGcntity of this sit:: to that of v-abl. and its close 
mol glo ''' leo Oh• '" ''' ·"" OM '" hi> ••O 
~-~-~-~~----~---
o'>P IC<I ·"0 .F.O 010 loo ool gl'/ glu "" h" "" "' ''' 
-··==---==----~=--··=----==----~=-
"'"" gl1 •,eo "'9 '"" mel lh• gly O>P lhl 1y1 lh• 
••••=n•=••=-~~----~= 
~••-n•===-~~----~-
ql\ OM 010 ''' lVI otp 1hl '~ P~ 91" •~ 
=~=-•cr-~=~--===-= 
,;CC CAT ~C\ CC" Oct r,<G r fC CCL AYC AAA fC~ ACT GCA CCC GAG AGC 
CTG CCC lAC AAC AAG ttl: <tC AlC AAG 'CC GAC 01C fOG GOT AAG GGC 
lop O'o l1• ~~~ moo '" p•o ''' P•O 
Fig. 2 Nucl"ic aci<.l s~qucncc and prcdtctcd amino acids of the 
,_a!JI and human ·-·-abl phmphotyrosine acceptor site regrons. 
Both <trands of appropriate restriction fragme11ts were labelled 
with [ y ''P]A TP and <cquenced according to the method of Maxam 
and Gilhen" 
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Fig. 3 Comparison of the deduced amino acid sequem:e uf th" 
v-abl and human c-ab/ phosphotyrosine acce~tor sites to 
analogous regions of the v-fes''- {ref. 4), v-fps- , v-src-' and 
v-yes-' encoded transforming proteins and to the catalytic subunit 
of the mammalian cyclic AMP-dependent protein kinase'. Amino 
acids common to each of the oncogene-encoded acceptor domains 
are shown in open boxes, while those residues shared by the 
c-abl-encoded sequence and BOV-PK are indicated in the lower 
portion of the figure. The position of the putative phosphotyrosine 
acceptor residue (*) is also shown. A, alanine; G, glycine; T. 
threonine: C. cysteine; P, proline; M, methionine: V. valine; I. 
isoleucine: L. leucine: Y, tyrosine; F, phenylalanine; W, tryp· 
tophan: D. aspartic acid: E. glutamic acid; R, arginine; K, lysine: 
H. histidine:· S. '~rine: N, asparagine; Q, glutamine. 
resemblance tu th~ well characterized v-src, v-yes and v-fes/v-
fps tyrosine phosphorylation acceptor sites strongly favour~ the 
possibility that this site has functional activity. The major in ~itro 
and in vivo phosphorylated tyrosine residue of v-abl has been 
localized seven residues distal to a trypsin cleavage site'"·"", 
consistent with the positioning of the v-abl and human c-ab/ 
tyrosines seven amino acids distal to arginine residues. An 
analogous approach was first used to identify the acceptor sites 
common to the v-src, v-yes and v-fes/v-fps gene products"-24 • 
Although the requirement for a functionally active tyrosine-
specific protein kinase for v-ab/-associated transformation 
has been demonstrated using transformation-defective 
mutants"-'". the involvement of the major tyrosine acceptor in 
this process remains to be determined. 
The conservation of phosphotyrosine acceptor sequences 
throughout vertebrate evolution, and the finding that most of 
the observed divergence between different genes encoding such 
sequences involves silent base substitutions, argues that each 
confers on its host some essential biological function. Presum-
ably, divergence of these sequences occurred early in vertebrate 
evolution before separation of avian and mammalian classes. 
The possible involvement of tyrosine-specific cellular protein 
kinases in human cancer remains to be determined. However, 
the high frequency with which recombinant transforming 
Table 1 Segment comparison scores of human c-ab/ and representa-
ti,·e viral "neogene phosphotyrosine acceptor sites and BOY -PK 
SD units 
Sequence c-ab! v-/es v-fps V•\'eS 
c-ab/ 
v-(es 17.616.71 
v-fps t5.6{7.8) 19.51 16.9) 
18.911 1.4) I 1.9{3.2) 13.6{3.0) 
"-yes 17.1[5.2) 15.7(0.21 9.8{1.6) 42.5(15.8) 
BOV-PK 7.61-t 5.4(-) 4.8(-) 5.7{-) 4.5{-) 
Extents of relatedness of amino acid sequences designated 17-64 in 
Fig. 3 and corresponding nucleic acid sequences from which they w~re 
derived. Resul!s are expressed in SO units based on 20-residue segm~nt 
lengths according to the Relate program as described by Barker and 
Dayhoff" A score of >5 SO indicates evolutionary relatedness of two 
proteins and scores between 3 and 5 SD support relationship if there 
are other indicattons such as a similarity of function". 
viruses containing such sequences have been isolated and the 
recent localization of c-ab/ within a small fragment of human 
chromosome 9 which is translocated to chromosome 22 in 
chronic myelogenous leukaemia"·'", would seem to favour such 
a modeL 
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A cellular oncogene is translocated to 
the Philadelphia chromosome 
in chronic myelocytic leukaemia 
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The transforming genes of oncogenic retroviruses are 
homologous to a group of evolutionary conserved cellular one 
genes'. The human cellularbomologne (c-ab!) of the transform· 
iog sequence of Abelson murine leukaemia virus (A-MoL V) 
was recentJy shown2 to be located on chromosome 9. The long 
IHJD of this chromosome is involved in a specific translocation 
with chromosome 22, the Philadelphia translocation (Ph'), t(9; 
22) (q34, qll), which occurs in patients with chronic myelocytic 
leukaemia (CML)~. Here we investigate whether the~ c-abl 
gene is included in this translocation. Using c-abl and ..,.abf 
hybridization probes on blots of somatic ceU hybrids, positive 
hybridization is found when the 22cC (the Philadelphia chromo-
some), and not the 9q.,. deri11ttive of the translocation, is present 
in the ceU hybrids. From this we conclude that in CML, c-abl 
sequences are translocated from chromosome 9 to chromosome 
22q~. This finding is a direct demonstration of a reciprocal 
exchange between the two chromosomel and suggests a role 
for the _c-ab/ gene in the generation of CML. 
The human c-ab/ sequences represent a cellular homologue 
of the transforming component of A-MuLV. This retrovirus is 
a recombinant between Moloney MuL V and mouse cellular 
c-abl sequences' and induces lymphoid tumours on in vivo 
inoculation of the mouse~·". The major A-MuLV translational 
product has been identified as a poly-protein, P120 .. """"b1, con-
sisting of amino-terminal structural proteins encoded by the 
Ab~lson-MulV 
•· o.bl probe 
v·abl hybr•dizong 
sequenou 
c-o.bl probes 
sozes ol c-abl 
EcoRI frognHMS 
" I.J 
" " 
M-MuLV gag gene, linked to an acquired cellular sequence 
encoded carbox:y-terminal component'"·". This protein is one 
of several virus-encoded transforming proteins with tyrosine-
specific protein kinase activityn-ls. Similar oncogenic sequences 
of Harvey and Kirsten sarcoma virus are homologous to trans-
forming sequences (c-Ha-ras, c-Ka-ras) isolated from human 
bladder and lung carcinoma cell lines'.,._'". Both these sequences 
induce transformation of mouse NIH 3T3 cells after transfec-
tion, establishing that the human genes have potential trans-
forming activity. Recently, the human c-ab/ gene has been 
cloned in cosmids19• Using v-abl DNA as a probe, several clones 
containing overlapping sequences representing the entire c-ab£ 
gene were isolated from a human lung carcinoma cosmid library. 
The restriction enzyme map of the human v-abl cellular 
homologue, presented in Fig. 1, identifies areas of the gene 
which hybridize to v-abl sequences. The gene is distributed 
over a region of 40 kilobases (kb) of human DNA and contains 
multiple intervening sequences. On transfection of Rat-2 cells 
with the c-abl cosmids, no transforming activity was detected, 
not unexpectedly, as none of the cosmid clOnes tested contained 
the entire c-abl gene19• 
By Southern blot analysis of a series of somatic cell hybrids, 
the human c-ab/ gene has been localized on chromosome 9'. 
This finding is of interest because of the involvement of the 
long arm of chromosome 22 (band 22qll) in a specific translo-
cation with the long arm of chromosome 9 (band 9q34), the 
Philadelphia translocation (Ph'), occurring in human CML'·•. 
The abnormal chromosomes are designated 9q• and 22q-; of 
these, the 22q· chromosome is observed in 92% of CML cases'. 
We investigated the chromosomal location of the human c-abl 
gene in cases of CML, where the Philadelphia translocation is 
present. Southern blot analyses with c-ab/ and v-abl probes 
were performed on EcoRI-digested DNAs from somatic cell 
hybrids segregating the 9q• and 22q- chromosomes. 
The cell hybrids used here contain a full complement of 
mouse or Chinese hamster chromosomes and a limited number 
of human chromosomes. The hybrid cell lines have been 
obtained by fusion of cells from mouse (Pg 19 and 'WEHI-3B) 
or Chinese hamster (E36 and a3) origin with leukocytes from 
different CML patients and from a normal donor"·'". The human 
chromosome content of these cells is summarized in Table I 
and is based on chromosome analysis. In addition, the hybrid 
cells were tested for the ex:pression of human adenylate kinase-1 
(AKl) enzyme activity, a marker localized proximal in band 
8omHf BamHl I :;II P~l Pill I 
s· . ~I -1 . , J" 
"' 
Psll Psll 
P1.7 
~
30 .. 175 
" ' w 
F'ti.l Restriction enzyme map of the human c-ab/ region 10 • The upper line of the figure shows the BamHI subdone of A-MuL V; the hatched 
box presents the long terminal repeat, the solid bar the acquired cellular sequences. Directly beneath the A-MuLV genome, a subgenomic Psr 
1.7-kb fragment, used as a probe in this study, is shown. Human c-ab/ DNA restriction fragments homologous to v·abl sequences are indicated 
as black boxes and those that show homology to the 1.7-kb Psi v-ab/ fragments are designated by P 1.7. The third line shows the human c-ab/ 
0.6-l::b BamHJ and 2.2-kb Hi11di11-EcoRJ probes, which hybridize to 5' and 3' c-ab/ EcaRI fragments, respectively. The sizes of all EcoRI 
c-ab/ fragments are indicated on the fourth line. The bottom line represents the restriction enzyme map of the human c-ab/ gene. Restriction 
enzymes include BamHI (B), Hi11diii (H) and EcoRI (E). A ~~;:~:rt:,it~d characterization of the human c-ab/ locus will be published 
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Fog. 2 Localization of human c-ab/ sequences on the Philadelphia chromosome, using hybrid cell lines and human c-ab/ probes. A, detection 
of the human 5' end 2.9~kbEcoRI c-ab/ fragment in DNA from a, human placenta; b, IOCB-238 (chromosome 9); c, PgMe-2SNU (chromosome 
22q); d, 14CB-21A (chromosome 9q +); e. 1CN-11aNU (chromosome 22q-); f, WESP-2A (chromosome 22q -); g, mouse Pg19: h. Chine~e 
hamster E36; i, mouse WEHI-38: j, Chinese hamster a3. 8, detection of the 3'-end 5.0-kb EcoR! c-ab/ fragment in DNAs as indicate<.< m 
A{a-j). The derivations of all these cell lines and their complements of human chromesomes are summarized in Table 1. 
Methods: All cell lines used in this experiment were grown in large batches (107 -10" cells) and DNA was prepared as described by Jeffreys 
and Flavell'". EcoRI-restricted DNAs (10 fLg per lane) from human placenta, hybrid cell lines, mouse and Chinese hamster fusion partners 
were electrophoresed on 0.7% agarose gels. HindiU and HindliJ-EcoRI-digested A DNAs were included as molecular weight markers (not 
shown). After blotting to nitrocellulose, the filters were hybridized to the 0.6-kb BamHI c-ab/ {A) or 1.1-kb Hindiii-EcoRI c-abl (B) restriction 
fragments described in Fig. L Hybridization and washing :;~~;~~r:~J~~~~~l7'~.SC at 65 'C) were carried out according to the method of 
9q34 (ref. 21). This latter test was necessary to exclude the 
possibility of hidden (broken or rearranged) chromosome 9 
fragments in the 22 and 22q- eel! lines, 
Detection of the human c-ab/ restriction fragments in hybrid 
cell DNAs is often inconclusive using v-abl probes, because 
the human sequences are present in submolar amounts (20-
50%) and also because many of the human c-ab/ restriction 
fragments electrophorese in dose proximity with strongly 
hybridizing mouse or Chinese hamster fragments. To obtain 
molecular probes with specificity for human c-abl sequences, 
two restriction fragments were isolated from Subdones of c-qbl-
containing cosmids, with homology to the presumptive 5' and 
3' proximal EcoRI fragments of c-abl. These are 2.9 and 5.0 kb, 
respectively, in size (Fig. 1). After hybridization and washing 
to high stringency (0.1 xSSC)", the 5'-terminal 0.6-kb BamH! 
probe and the 3'-terminatl.l-kb Hindiii-EcoRl probe cross-
hybridize to a very low extent with mouse or hamster c-ab/ 
sequences. Figure 2A shows an example of a hybridization 
experiment with the 0.6-kb BamHI probe. This Southern blot 
illustrates hybridization of EcoRI-restricted DNAs of hybrid 
cell Jines containing chromosomes 22, 9, 9q+ or 22q-. As 
controls, hybridization of the probe with human placenta DNA 
and DNA from the mouse and Chinese hamster fusion partners 
is shown. It is clear that the 2.9-kb EcoRI fragment, detected 
in human placenta DNA, is also present in the lanes containing 
DNA from the hybrid cell lines 10 CB-23B (chromosome 9), 
1CB-17a NU and WESP-2A (both containing chromosome 
22q-). The band is not detected in Janes containing DNA from 
Table 1 Human chromosome content of human-mouse and human-chinese hamster somatic cell hybrids 
Hybrid 
PgMe-25NU 
10CB-23B 
14CB-21A 
lCB-17aNU 
WESP-2A 
' 2 4 
+ - - + 
- + + -
- + 
+ + 
Human 
Human chromosomes isoenzyme 
10 11 12 13 14 15 16 17 18 19 20 21 22 X Y 9q• 22q- AKI 
+ - - - + -
- - - + 
- - + + + 
- + 
+ -
Ref. 
26 
6 
20 
6 
The origin and details of the initial characterization oft he somatic cell hybrids are described in the references llsted in the last column. PgMe-25NU 
and WESP-2A are hybrids obtained from fusions with mouse Pgl9 and WEHI-3B cells, respectively. Chinese hamster cell line E36 was used to 
produce hybrid clones 10CB-23B and 14CB-21A, while Chinese hamster cell line a3 was used to obtain 1CB-17aNU. Chromosome analysis was 
done using reverse (R) banding with acridine orange, after heat denaturation. At least 16 metaphases were analysed per cell line. The presence 
of human AKl activity was assayed by cellulose acetate (Cellogel) electrophoresis27 . This test is inconclusive for the WESP-2A cell line (x), 
because the expression of AKl was found to be repressed in hybrids derived from fusion with WEHI-3B cells (A.H.M .. G.v.K., unpublished 
results). Chromosome and isoenzyme analyses22 were performed on the same batches of hybrid cells that were used for the isolation of DNA 
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FiR. 3 Locali>.ation of human c-ab/ sequences on the Philadelphia 
chromosome, using a 22q- somatic cell hybrid and a v-a&/ probe. 
EcoRJ-digested DNAs ilOJ.i.g) from human placenta (a), hybrid 
WESP-2A (b) and mouse WEHl-38 cells (c) were hybridized 
with the L7-kb Psi v-abl fragment (Fig. 1), as described in Fig 
2 legend. After hybridization, the filters were washed to 1 X $$C 
at 65 'C. Molecular weights of human c-ab! fragments were 
deduced from co-electrophoresed Hindlll and Hindlli-EcoRl-
digested A DNA markers 
f'gMe-25Nu (chromosome 22}, 14CB-21A (chromosome 9q•), 
Pgl9 and WEHI-38 (mouse controls) or E36 and a3 (Chinese 
hamster controls). Analogous results are obtained when the 
same EcoRI-digested DNAs are hybridized to the 3'-terminal 
1.1-kb Hindii!-EcoRJ probe (Fig .. 2B}. The 5.0-kb EcoRI 
fragment is detected only in DNA from human placenta and 
frGm hybrid cell lines containing chromosome 22q- or 9. 
The above results show that both the 5' and 3' ends of the 
c-ab/ gene are translocated to chromosome 22q-. Because all 
other c-ab/ EcoRI fragments, which hybridize to v-abl sequen-
ces, are flanked by the 2.9-kb and 5.0-kb EcoRJ fragments, it 
seems highly probable that these fragments are also included 
in the translocation to the Philadelphia chromosome. To test 
this possibility directly, hybridization was performed using a 
1.7-kb Psi v-abl probe (Fig. 1). Because of the problems with 
v-abl probes indicated above, only WESP-2A, the hybrid con-
taining the most 22q- sequences (50% of the molar amount), 
was tested. As shown in Fig. 3, the viral probe detects human . 
EcoRI c-ab/ fragments of 11, 7.2, 4.0, 3.4, 2.9 and 2.5 kb 
(weakly). Of these fragments, the 11-kb band has been shown 
to map outside the main human c-ab/ locus10 and will not be 
considered here. The human 2.9-, 3.4-, and 4.0-kb c-ab/ frag-
ments are readily detected in the WESP-2A DNA. In contrast, 
the 7.2-kb EcoRJ fragment can only be seen in a short exposure 
of this filter (not shown), due to spill-over of radiation from 
strongly hybridizing mouse c-ab/ fragments in this area. The 
2.5-kb EcoRJ human c-ab£ fragment co-migrates with a mouse 
fragment of similar size and thus cannot be identified in this 
analysis. 
The hybrid cell lines containing the 9q+ and 22q' chromo-
somes examined in the present study, were obtained from fusion 
experiments with CML cells from three different individuals. 
Therefore, we conclude that in the Philadelphia translocation 
a fragment of chromosome '} is translocated to chromosome 
22q- and that this fragment includes the human c-ab! sequen-
ces. This finding establishes that the translocation is reciprocal, 
a general assumption which is now demonstrated unequivocally. 
Moreover, the data map the human c-ab/ sequences distal to 
AK1 (not translocated to 22q~, 6, 20) on chromosome 9. The 
most interesting aspect is that it raises the possibility of involve-
ment of the human c-ab! gene in the generation of CML. 
In principle, the chromosomal translocation associated with 
CML could lead to elevated levels of c-ab/ expression which, 
by analogy to the c-Ha-ras gene in bladder carcinoma, would 
induce malignant transformation". Elevated levels of c-ab! 
expression could be the result of coupling of the gene to an 
enhancer sequence present on chromosome 22 or, alternatively, 
the gene could be linked to a strong promoter of another gene. 
To test these possibilities, we have initiated studies to done 
the c-ab/ gene from the 22q- chromosome using WESP-2A 
DNA and a cosmid vector system. Finally, it is of interest that 
in some CML patients variant Ph' translocations are observed, 
in which the participation of chromosome 9 cannot be detected 
by classical cytogenetic analysis'·' In another group of CML 
patients the Ph' translocation appears to be completely 
absent". We are now investigating whether the c-ab/ gene is 
translocated to chromosome 22 in these cases also. 
These studies were initiated as part of a collaborative effort 
with W. F. Bodmer; his helpfl'l discussions throughout the work 
are greatly appreciated. We also thank F. Grosveld for impor-
tant contributions to this study, R. A. Flavell for useful sugges· 
tions, Ton van Agthoven, Gail T. Blennerhassett and Pam 
Hansen for technical assistance and Ad Konings and Rita 
Boucke for help with the preparation of the manuscript. The 
work was supported by the Netherlands Cancer Society 
(Koningin Wilhelmina Fonds) and under NCI PHS contract 
NOI-C0-75380. C.R.B. is a recipient of a fellowship from the 
Deutsche Forschungsgemeinschaft. 
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c-sis IS TRANSLOCATED FROM CHROMOSOME 22 TO 
CHROMOSOME 9 IN CHRONIC MYELOCYTIC LEUKEMIA* 
BY JOHN GROFFEN, NORA HEISTERKAMP, JOHN R. STEPHENSON, 
AD GEURTS VAN KESSEL, ANNELIES DE KLEIN, GERARD GROSVELD, 
AND DIRK BOOTSMA 
From the Laboratory of Viral Carcinogenesis, National Cancer Institute, Frederick, 
Maryland 21701; and the Departmmt of Cell BioiOg)' and Gmetics, Erasmus Universil)', 
Rotterdam, The Netherlands 
Several relatively specific chromosomal translocations are known to be associ-
ated with particular human cancers (1-3). One of these, the Philadelphia trans-
location, t(9;22) (q34;qll) is observed in over 90% of chronic myelocytic leuke-
mias (CML)1 (3). Translocation of the qll to qter segment of chromosome 22 
to chromosome 9 results in a deleted form of chromosome 22, referred to as the 
Philadelphia (Ph') chromosome (4). Recently, we have localized a human onco-
gene, c-ab!, on chromosome 9 (q34 to qter) (5) and demonstrated its translocation 
to chromosome 22q- (the Ph' chromosome) in CML (6). Because of the small 
size of the segment of chromosome 9 that translocates to chromosome 22 (6) 
and the localization of immunoglobulin A light chain sequences on chromosome 
22 (7), c-ab! appears to map in close proximity to A sequences in the Ph' 
chromosome. 
Another acute transforming retrovirus, the Simian sarcoma virus (SSV), is a 
genetic recombinant between a nontransforming retrovirus and cellular se-
quences of woolly monkey origin (8, 9). The SSV transforming gene, v-sis, and 
its human cellular homologue, c-sis, have been molecularly cloned (8-IO), and c-
sis has been localized on the q arm of chromosome 22 (II, I2). In the present 
study, we report the localization of c-sis on the q 11 to qter segment of chromo-
some 22 and its translocation from chromosome 22 to chromosome 9 in CML. 
Materials and Methods 
Cells. Ce!l lines, propagated in Dulbecco's modified Eagle's medium supplemented 
with 10% calf serum, included NIH/3T3 mouse cells and a human cell line, A673 (5). 
Somatic cell hybrids containing full complements of either mouse or Chinese hamster 
chromosomes and a limited number of human chromosomes were derived by fusion of 
either mouse or Chinese hamster cells with leukocytes from different CML patients or 
from normal donors (Table I); details concerning their origin and initial characterization 
have been previously reported (13, 14). 
Preparation of a Human c-sis Probe (c-sis Bu). A cosmid clone with a cellular insert of 
-30 kb containing v-sis-homologous sequences was isolated from a library of human lung 
*Supported by contract NOI-C0-75380 from the National Cancer Institute and by the Nether-
lands Cancer Society (Koningin Wilhelmina Funds). 
1 Abbrroialions used h1this paper: CML, chronic myelocytic leukemia; Ph', Philadelphia chromosome; 
SSV, Simian sarcoma virus. 
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carcinoma DNA (15) using, as a probe, a 1.2 kb Psti v-sis restriction fragment in pBR322 
(8), generously provided by K. Robbins and S. A. Aaronson. Isolation of a 1. 7 kb BamHl 
v-sis-homologous restriction fragment from the cosmid clone was performed according to 
previously described methods (15). 
Molecular Hybridization. Restriction_ enzymes were purchased from New England Bio-
labs, Beverly, MA and Bethesda Research Laboratories, Rockville, MD and were used 
according to the suppliers' specifications. DNA were digested with restriction enzymes, 
subjected to electrophoresis through 0. 75% agarose gels, and transferred to nitrocellulose 
essentially as described by Southern (16). Nick translation of probes and filter hybridiza-
tion were as described (15). Specific activity of the probes was 2-5 X I 08 cpm/ fig. After 
hybridization, filters were washed under high stringency conditions (1 0% standard saline 
citrate, 65°C) and exposed to XAR-2 film (Eastman Kodak Co., Rochester, NY) for up to 
5 d at -70"C with Dupont Lightning Plus intensifying screens (Dupont Instruments, 
Wilmington, DE). 
Results 
To prepare a probe suitable for identification of somatic cell hybrids containing 
human c-sis sequences, a previously described (15) cosmid library of human lung 
carcinoma DNA was screened for clones containing sequences homologous to 
the 1.2 kb Pstl v-sis probe. As shown in Fig. 1, a single cosmid clone was obtained 
containing a 30 kb cellular insert with v-sis-homologous cellular sequences. By 
restriction endonuclease analysis this clone was shown to correspond to a previ-
ously described v-sis-homologous human sequence, designated c-sis (12). For 
generation of a c-sis-specific probe, a single 1. 7 kb BamHl fragment, possessing 
strong homology to v-sis (c-sis Bu), was isolated from the cosmid cellular DNA 
insert. 
Human and mouse control cellular DNA were digested with Sst-I and analyzed 
for homology to the above described c-sis Bu probe. As shown in Fig. 1, a single 
mouse cellular restriction fragment of around 10.0 kb (lane B) is detected, while 
the only human c-si.s B1.7 cross-reactive Sst-1 restriction fragment is 3.6 kb in 
length (lane C). The size of the latter restriction fragment corresponds to that 
predicted on the basis of the human c-sis restriction map shown in Fig. 1. Cellular 
DNA from a mouse X human somatic cell hybrid, PgMe-25NU, previously shown 
to have chromosome 22 as its only human component (14), contains the 3.6 kb 
human c-sis B1.7 cross-reactive Sst-I restriction fragment (lane A), thus confirming 
the mapping of c-sis on chromosome 22. Localization of c-sis to the region of 
chromosome 22 (qll to qter) which is translocated to chromosome 9 in CML, is 
established by the absence of c-sis-homologous sequences from hybrid WESP-2A 
(lane D), which contains chromosome 22q- (the Ph' chromosome) but lacks 
detectable amounts of chromosomes 9, 22, or 9q+ (5). 
To independently show the localization of c-sis on chromosome 22 (q11 to 
qter) and demonstrate its translocation to chromosome 9 in CML, a series of 
Chinese hamster X human somatic cell hybrids were analyzed for human cHsi.s 
sequences. As shown in Fig. I, lanes E and F, the only c-sis Bu cross-hybridizing 
Sst-1 restriction fragment in Chinese hamster cellular DNA is around 2.7 kb in 
size and thus clearly resolved from the 3.6 kb human Sst-1 fragment. Hybrid 
lCB-17aNU, which contains chromosome 22q-, lacks detectable human c-sis 
sequences (lane F), while a second hybrid, 14CB-21 A, containing chromosome 
9q+ but not chromosome 9 or 22 (13), is positive for human c~sis sequences (lane 
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FlGL'RE l. Localization of human c~sis on chromosome 22 (qll to qter) and its translocation 
to chromosome 9 in CML. Sstl-digested cellular DNA (10 J.<g/lane) were electrophoresed on 
0. 7% agarose gels, blotted to nitrocellulose, and hybridized to the c~sis Bu probe shown in the 
lower portion of the figure. Cell lines analyzed are described in Table I and include PgMe25Nu 
(A), NIH/3T3 (B), A673 (C), WESP 2A (D), 14CB21A (E), lCBI7ANu (F). The positions of 
single mouse, human, and Chinese hamster c-sis 81.7 homologous Sstl restriction fragments 
are shown. Hind III-digested DNA, included as a molecular weight marker, is shown on the 
left side of the figure. In the lower portion of the figure, the restriction map of the 30 kb 
cellular insert from the v-sis cross-reactive cosmid done of Mbol-digested human lung carci-
noma Dl\A is shown. Mbol (Mbo) sites indicate the ends of the insert; the positions of Xbal 
(Xba) and Sstl (Sst) restriction sites are shown for purposes of orientation of this clone with 
the more detailed previously published restriction maps of c~sis (l 0). The position of a single 
3.6 kb human Sstl restriction fragment overlapping with the 1.7 kb BamHl restriction fragment 
(8 1_7), used as a c-sis-specific probe for analysis of somatic cell hybrids, is also shown. 
E). Finally, hybrid I OCB-23B, which contains chromosome 9 in the absence of 
detectable 22, 9q+, or 21q-, lacks human c-sis (Table I). As internal controls, 
each of the above hybrids were also analyzed for c-abl, a marker for the portion 
of chromosome 9 translocated to chromosome 22 in CML (6), and for AKJ, 
which maps near the breakpoint but within the nontranslocated portion of 
chromosome 9· (Table 1). 
Discussion 
Several of the human cellular homologues of viral oncogenes studied to date 
including c-abl (5, 6), c-sis ( 11, 12), c{es (5, l 7), and c-mos (18, 19) have been 
localized on human chromosomes frequently involved in translocations associated 
with specific human cancers. One of these, c-myc, is translocated from chromo~ 
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TABLE I 
Translocation of c~sis from Chromosome 22 to Chromosome 9 in Chronic Myelocytic Leukemia 
Human chromosomes Oncogenes 
Cell line AKI 
9 22 9q+ 22q c-ab/ c-sis 
Mouse NIH/3T3 NT 
Human A673 NT + + + + + + 
Mouse X human hybrid 
PgMe-25NU + + 
WESP-2A + + 
Chinese hamster X human hybrid 
IOCB-23B + + + 
14CB-21A + + + 
ICB-17a NU + + 
PgMe-25~U cells contain chromosome 22 as their only human component, while each of the other 
five hybrid clones contain a few human chromosomes in addition to those relevant to the t(9;22) 
(q34;qll) translocation (13, 14). Identification of hybrid clones containing c-ab! sequences (6) and 
analysis of human adenylate kinase (AKI) enzymatic activity (6) have been previously reported. Cells 
were analyzed for human c-sis-specific sequences as described in Fig. 1. 
9 9q+ 
w; 
p t, ACONS 
&AK3 
22 22q- (Ph') 
0 0 
q t~~~· C-SIS 
) 
-
: AK1 
,, 
' ;_t: 
{ c-sis 
I 
FIGL'RE 2. Diagrammatic representation of the involvement of c-ab! and c-sis in the Ph' 
translocation. Chromosome banding pauerns are as previously shown by Yunis (3); map 
positions of A CONS, AK3, and AK I are as previously reponed (24, 25). Localization of c-ab/ 
within the terminal portion of chromosome 9 (q34), which is translocated to chromosome 22 
in CML, is as described by de Klein et al. (6) while localization of c-sis in the region of 
chromosome 22 (q II to qter) translocated to chromosome 9 is based on the results of the 
present study. 
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some 8 to chromosomes 14, 2, or 22, each of which contain immunoglobulin 
sequences, in Burkitt's lymphoma (1, 19-21). Similarly, c-abl maps on the region 
of chromosome 9 which translocates to chromosome 22 in CML (5, 6). Other 
trans!ocations, such as the t( 15; 17) reciprocal translocation associated with acute 
promyelocytic leukemia (3), involve regions to which human cellular oncogenes 
(in this case cfes) have been mapped (22), but appear to be independent of 
immunoglobulin sequences. The present demonstration that c-sis is translocated 
from chromosome 22 to chromosome 9 in CML raises the possibility that c-sis 
rather than c-ab! may be involved in CML. Resolution of these alternatives will 
require a determination of the proximity of these genes to the breakpoints in 
chromosomes 22 and 9, respectively, and analysis of the expression of their 
transcriptional and translational products in CML cells. 
In addition to possible implications regarding the cause of CML and the 
significance of the associated t(9;22) (q34;qll) translocation, the localization of 
c-sis within the translocated region of chromosome 22 (Fig. 2) provides a unique 
molecular marker for studies of the more complex translocations associated with 
minority populations of CML patients. These can involve translocation of the 
q II to qter region of chromosome 22 to chromosomes other than chromosome 
9, or can in some instances involve more complex rearrangements including 
three or occasionally even four or five chromosomes (23). Analysis of these 
translocations using c-ab! and c-sis probes should allow a determination of the 
critical translocation event resulting in the generation of CML. 
Summary 
By analysis of a series of somatic cell hybrids derived by fusion of either mouse 
or Chinese hamster cells with leukocytes from different chronic myelocytic 
leukemia (C;'viL) patients or from normal donors, we have localized the human 
oncogene, c-sis, on the q 11 to qter segment of chromosome 22 and demonstrated 
its translocation from chromosome 22 to chromosome 9 (q34) in CML. 
We thank P. Hansen and G. T. Blennerhassett for excellent technical assistance. 
Rmi~'ed for publimtion 10 Janual)' 1983 and in revised form 23 March 1983. 
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Localization of the c-abl oncogene 
adjacent to a translocation break point 
in chronic myelocytic leukaemia 
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The human c~abl oncogene maps within the region (q34·qter) of chromosome 9 which is translocated to chromosome 
22, the Philadelphia (Ph') chromosome, in chronic myelocytic leukaemia (CML). The position of the Ph' chromosomal 
break point is shown to be variable and, in one CML patient, has been localized immediately 5' of, or within, the c-abl 
oncogene. A DNA restriction fragment corresponding to this site has been molecularly cloned and shown to represent a 
chimaeric fragment of DNA from chromosomes 9 and 22. 
HUMAN cellular sequences designated oncogenes have been 
identified using retroviral transformation-specific sequences as 
molecular probes. Evidence for the potential involvement of 
such oncogenes in human cancer is accumulating rapidly. For 
instance, human tumour-derived DNA sequences, isolated on 
the basis of their ability to transform mouse cells phenotypically 
in tissue culture, have been shown to correspond to particular 
classes of cellular oncogenes1- 5. More recently, amplification of 
specific cellular oncogenes in tumour cells has been demon-
strated6-8 and other human oncogenes have been shown to be 
involved in highly specific chromosomal translocations charac-
teristk of particular classes of human neoplasia"""13 . 
The Abelson strain of murine leukaemia virus (MuL V) rep-
resents a recombinant between Moloney MuLV and c-ab/, a 
cellular oncogene of mouse origin14. In contrast to other 
oncogenic retroviruses, Abelson MuL V transforms lymphoid 
cells in virro 1' and induces a rapid 8-ce\llymphoma in vivo16 , 
We have previously reported the molecular cloning of the v-abl 
homologue (c-ab/) from a human cosmid library17. Human v-abl 
homologous sequences were shown to be dispersed over a total 
region of around 32 kilobases (kb) and to contain a minimum 
of six introns. Extensive homology in nucleic acid and amino 
acid sequence was demonstrated between the tyrosine phos-
phorylation region of c-ab/ and corresponding regions of the 
v-.src, v-yes and v-fes/ fps family of viral oncogenes, as well as 
a more distant relatedness to the catalytic chain of the mam-
malian cyclic AMP-dependent protein kinase18• These findings 
suggest that each of these oncogenes was probably derived from 
a common progenitor and may represent members of a diverse, 
but highly related, family of cellular genes encoding protein 
kinases. 
The human c-ab! oncogene was initially mapped to the long 
(q) arm of chromosome 9 (ref. 19). This observation was of 
interest in view of the frequent involvement of chromosome 9 
in the translocation with chromosome 22, t(9; 22), characteristic 
of chronic myelocytic leukaemia (CML)~0• Analysis of a series 
of rodent-human somatic cell hybrids containing either the 9q+ 
or the 22q- (Philadelphia, Ph') chromosome demonstrated the 
translocation of human c-ab/ from chromosome 9 to the Ph' 
chromosome9• We show here that in one Ph'-positive CML 
patient, the chromosomal break point maps within 14 kb 5' of 
the human c-ab/ oncogene. Such a break point could not be 
identified at this position in the DNAs of two other patients, 
arguing that the chromosomal break in Ph' -positive CML can 
occur at variable sites on chromosome 9. These findings strongly 
implicate the human c-ab/ oncogene in Ph'-positive CML. 
Search for the t(9; 22) junction site 
To investigate the possibility that the chromosome 9 break point 
in the t(9; 22) may be localized either within or in close proxim-
ity to the human c-ab/ oncogene, high molecular weight DNA 
was isolated from biopsy samples of the spleens of three CML 
patients, each of which contained high percentages of leukaemic 
cells. In addition, DNA was isolated from an erythroleukaemic 
cell line, K562, established from a CML patient in blast crisis21 . 
Each DNA was digested wi.th Bam HI and subjected to Southern 
blot analysis. As shown in Fig. I a, the restriction enzyme pat-
terns of K562 DNA and DNA of patient 0319129 were indistin-
guishable from those of control DNA, when hybridized to a 
previously described' 7 v-ilbl probe, P1 7. Similarly, no differen-
ces in restriction enzyme patterns could be detected in the other 
two CML DNAs, or in any of the DNAs using other restriction 
enzymes or probes isolated from different regions of the human 
c-ab/ locus (not shown). 
Chromosomal walking 
As no rearrangements could be detected in the v-abl 
homologous cellular DNA region encompassed by our cosmid 
clones, a probe was prepared corresponding to an 0.4-kb Hin-
diii-EcoRI fragment (0.4 HE) mapping within the 5' domain 
of the human c-ab/ locus (Fig. 2) and was used to screen a 
previously described human cosmid library22 • Although recom-
binants representative of approximately 10 times the complete 
human genome were analysed, no positive clones were obtained. 
Analysis of total human DNA revealed that a Bam HI fragment 
of -14.5 kb hybridized to the 0.4 HE probe. To characterize 
this restriction fragment further, a library of size-fractionated 
Bam HI-digested total human DNA was constructed in Charon 
30. Screi:ning of the library with the 0.4 HE probe revealed 
seven positive recombinant phage clones. All positive plaques 
were extremely small and turbid. The insert of one of these 
positives was subcloned into pBR328 (p5' -c-ab!) and subjected 
to detailed restriction enzyme analysis as shown in Fig. 2b. No 
sequences in the 14.5-kb fragment hybridized to any of a series 
of previously described17 probes corresponding to the complete 
v-abl genome. 
As indicated in Fig. 2b, an 0.2-kb probe was prepared from 
the 5' terminus of p5' -c-ab/ by digestion with Bam HI and 
EcoRI. This probe hybridized to a Hindiii fragment, of 
-9.5 kb, in all DNAs examined, suggesting that sequences 
immediately 5' to the newly cloned region are non-rearranged 
(Fig. lc, lanes 3-7). As expected, a fragment of 14.5 kb was 
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0.2 BE l'ee Fig. 2) are imlicatcd at the t>ottom of the ligurc. Frozen 
'plccn ti>'uc w"' ohtarnetl through the :-.J!H Rc;ource' and Logi;-
ti~' Branch, DCCP. Pati~ntll31 'il2'i "'a' a 20-yr·old male, patient 
1121~1{)) wa' a 57-yr·ol<.l male and patient 031 l06H wa' a 1:>7-yr· 
olJ female. Cc>lllmc K%2, pedigree 722, (GM )372) wa' uhtaineJ 
from the Human Genetic Mutant Cell Repo,itory. Camden. ~ew 
Je"ey_ DNA"'"' prepare<.llrom t;,_,ue and cell line' accor<.lmg to 
Jeffrey' an<.l Flavell'"- DNA wa' <.lige,ted with rc,triction ~nzymes, 
dectrophore,e<.l on 0.75"/o agaro>e gel> an<.l hloned according to 
the method of Southern·"_ l'olation of prnbe,, hybri<.lizmion and 
o.a,htng,, to 11.3 x SSC" at t\5 'C were "' dc,crihed d'cwhcre 17 '' 
!1-lnlecular v.,cight> of the hyhri<.lizing fragments (khl arc a> 
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detected in BumHI-digestcd normal human DNA. while in 
DNA ofCML patient 031 \l129, an additional Bum HI restriction 
fragment of -3.1 kb (Fig. !c. lane II was id~ntified. Similarly. 
the 0.4-kb HE probe isolated from the 5' region of c-ub/ hybrid-
ized with a 14.5-kb BumHl fragment in the other two 
CMLDNAs {Fig. I b). In DNA from CML patient 0319129. 
however. an extra Bum HI fragment of -30 kb was visible (lane 
2!. The most likely explanation for these findings is that one 
allelic copy of DNA sequences 5' to c-ab/ in CML patient 
0319129 DNA is normal while the second is rearranged: these 
appear to be present in about a I; I molar ratio. 
To define more accurately the region where DNA of patient 
0319129 differs from the normal region, probes including an 
0.52-kb £coR! fragment (0.52 E) and an 0.76-kb EcoR!-
1-find!l! fragment {0.76 HE) (>e~ Fig. 2b) were prepared from 
pS'-c-ubL corresponding to the approximate region of rear-
ranged sequences in the DNA of patient 0319129. As shown 
in Fig. 3, extra DNA fragments were found with these probes 
on restriction enzyme digestion of DNA0319129 with Bglll. 
X bal. Sst! and Hindi!!. The 9.5-kb 5' Hindlll fragment, which 
hybridized to the 0.52-kb £coR! probe, seemed to be present 
in a normal quantative ltvel, as did the :!.0-kb frdgment hybridiz-
ing to the 0.76-kb HE probe. A rearrangement thus appeared 
to have taken place within the 1.25-kb Hind Ill fragment since, 
in addition to the normal 1.:!5-kb Hindll! fragment, a fragment 
of 2.2-kb can be identified 
Molecular cloning 
As human c-ub/ is translocated to the Philadelphia chromosome 
(22q-) in CML, we rea~0ned that the transposed sequences in 
DNA of CML patient 031Yl29 should include most of the 
14.5-kb BumH! fragment; the 5' sequences of this fragment 
would presumably remain on chromosome 9, linked to scquen-
c~'> fromchromn>ome 22, thus accounting for the 3.1-kb Bum HI 
fragment (Fig. lc, lane 11. The Y.5-kb Bglll fragment {Fig. 3b) 
would thu> repre:.ent the chromm;ome 22/9 chimaeric fragment 
localized at the Ph' translocation break point; the 6.0-kb Bglll 
fragment (Fig. 3b) would contain sequences from chromosomes 
9 and 22, on the 9q+ chromosom~. Alternatively, the differences' 
between the DNA of patient 0319129 and control DNA could 
bt the result of DNA rearrangements, deletions or insertions 
having no connection with the t(9; 22) Ph' translocation. 
To distinguish between these possibilities, DNA from CML 
pati~nt 0319129 was digested with Bg/IJ, size fractionated in 
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c-ahllo~u' ;, indicated in a_ EwRI site' are marked 
hy 'mall ,·cnical line<; v-abl homologous sequences 
~'"indicated by 'olid bars. The vertical arrow indi-
<:at~s the hrcak point m the D~A ot CML (JJ 1912'1. 
A '"'triction map of p5' -c-ab/ is shown in b; probes 
U>Cd in thi' 'tudy, mdkated a> hatched boxe>. are 
:h<>wn bcn~ath the map. The pBgll! 9q+ fmgment 
Ln ,. "a 'ubclone of a 6.0-kb Bglll fragment isolated 
lrom C:v!L patient 0319129: in band c the Bglrr 
'ite within 200 hp of the 5' Bam HI site an<.l a Hpal 
'ire rn hetll'cen these two restriction ;tte> are not 
,nown. The soli<.l bar indicate< sequence; from 
c·h"'mmome 9 whil~ the <>peo bar rcpresenb~~4uen· 
c·c, f"'m chromo>ome 22. Cloning and subdoning 
nf th~ p5'-c-ab/ and Bg/Jl-9q+ sequences "'"' 
~ccording to pr~'iously described methoJs-''. 
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lrugments ."olated from low meltmg pomt agarose 
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Fig. 3 ReMriction enzyme analysis of the DNA of CML patient 
0319129. Restriction enzymes used and the molecular weights of 
the fragments in the Bgll1 and Hindlll digestion> are as indicated. 
-"P-Iabelled Hind!ll digestion frdgments of A DNA 'm the centre 
of the figure serve as a molecular weight marker for the Xbal and 
S<tl digestions. Southern blots were hybridized with a mixture of 
the 0.52 E and 0.76 HE probe~ (;ee Fig. 2b), as described in Fig 
1 legend DNA of the cell line A673 is >hown in lanes a: DNA 
of CML0319!29 is in lanes b. 
the 6-7-kb range, and a library constructed in Bam HI-digested 
Charon 30 phage arms. Three positive clones were identified 
on screening with the 0.2-kb BE probe. Because each of the 
po5itive clones contained an additional inserted Bglll fragment. 
some Bgiii sites had remained intact. allowing the subcloning 
of most of the 6.0-kb Bgiii fragment by Bglii~Hpa! digestion 
into plasmid ORFn. Colonies containing this recombinant plas-
mid were visible only on a two- to threefold longer incubation 
at 37 'C than neighbouring non-positive colonies. This particular 
DNA re£.ion may thus contain wquences that inhibit bacterial 
growth. Possibly explaining our failure to detect these sequences 
in cosmid libraries. As shown in the restriction enzyme map of 
this fragment (Fig. 2c). the EcoRI site 3' of the 0.52-kb EcoR! 
fragment is still present. In contrast. an Sst! site immediately 
3' of it and all other restriction enzyme sites to the 3' arc either 
missing or different from those found in the same region in 
pY-c-abl. These findings localize a putative break point in 
pY-c-abl between the EcoR! and Sst! sites. S~quence; 5' of 
this point in the 6.0-kb Bg/JI fragment hybridize to p5' -c-ab/: 
sequences 3' of it do not (results not shown). 
To determine the origin of the 6.0-kb Bg/11 fragment, a 1.2-kb 
Hindlll-Bg/Jl probe (1.2 HBg) was prepared (Fig_ 2c). As 
shown in Fig. 4. using ;tringent washing conditions. this probe 
hybridized to a 5.0-kb Bglil fragment in DNA of the human 
cell line A204 (lane 2). but not to sequences in mouse DNA 
(lane 1) or in rodent-human somatic cell hybrids containing 
human chromosome 9 (lane 4)" 1n an independent hybrid 
(PgMe-25Nu), ho~ever. containing chromo>ome 22 as it> only 
human component , a 5.0-kb Bglll fragment was detected (lane 
3). Moreover, using the same probe both 5.0-kb and 6.0-kb 
BgliJ fragments were identified in the DNA of patient 0319129 
(lane 6). The 1.2 HBg probe did not hybridize to sequences in 
the human-mouse somatic cell hybrid WESP-2A (Fig. 4, lane 
fig. 4 Chrommomalloc·ul!zation of 
the 3' domain of pBglll·9q+. High 
molecular weight DNA' were 
digested with Bg/1!. electrophore,ed 
on an 0. 75% agMo'c gel, blottd and 
hybridized to the I .2 HBg pro he (,cc 
Fig. 2cl and included mome ll~ne 
I), A204 (lane 21. Pg.Mc-25:-Ju 
lchromo">me 22. bne JJ. IIICB-
23B lchromo\nmc 9.lane 4), WESP-
2A ithromooome 22q-, lane 51 and 
CML p~tient 031912'1 (lane fil 
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Fig. 5 Amplification of c-ab/ in the crythroleukacmic cell line 
K.'i62. Control human DNA 110 f!.g. lane> I in each panel) v.-a> 
run next to Ill fl.g. Iiane~ 21 and 2.5tJ-~ (lanes JJ K502 DNA 
"P·Iat>clled Hmdlll-digcsted A DNA ;,-included"' a molecular 
weight standard for a a~d b (0.6% agarme gels I and for c and d 
10.75% agarme gels). a, DNA, were dige,!ed with EwRI and 
hybridized to a previou,]y described v-abl probe. v-abl P, 7 I ref 
17)_ b, EcoRl-dtge,1cd DNA\ were hybridized to a Bglll-Hindlll 
probe. isola!ed from a human C, done HuA .'i (rd. 251. c. BarnHI-
dige\red DNA hybridized to a previOusly de;cribed'" 1.7-kb 
BarnHl probe prep-ored from a human <>sis cu;mid clone. d, 
Bglll-Jige;tcd D:--JA, hybridized 10 the 1.2 HBg probe (FJg. 2cJ. 
5). which contain; the Philadelphia chromooome in the absence 
of 9,9q+ or 22. Thus. the 6.0-kb Bgll! fragment cloned from 
patient 0319129 D:-JA must contain, in addition to >eqHence> 
from chromosome lJ, sequences originating from the translo-
cated region of chromosome 2:?.. 
Amplification of c~abl 
Although the K562 cell line l~cks a cytogenetically identifiable 
Ph' chromosome (ref. 24 and A. Hagemeijer, personal com-
munication). it was reponed to contain a small ring chromosome 
rl22), which 't> probably derived from a Ph' chromosome'~. Our 
results sugge;t that, at a minimum. K51i2 contains a chromo-
somc(s) resembling the Ph' chromosome marker. As shown in 
Fig. 5d. using the 1.2 HBg probe. a non-amplified 5.0-kb Bg/ll 
fragment was detected in K562 DNA. In contrast. human c-ab/ 
sequences are amplified at least fourfold in K562 DNA, as are 
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fig. 6 Schematic representation of the 1(9; 22} in CML patient 
0319129. The sizes of the Bglll fragments detected with probes 
from chromosome 9 and 22 are indicated. Regions in black origi-
nate from chromosome 9; hatched regions are from chromosome 
22. An X indicates the 1(9; 22) chromosomal break point The 
human c-sis oncogene and the C, region on chromosome 22 are 
shown for purposes of orientation; human c-sis is localized on 
chromosome 22 (ref. 34) and is translocated to chromosome 9 in 
CML'6. C, is localized in band q 11 of ctuomosome 22 (ref. 10), 
and is not involved in the Ph' translocation (unpublished results). 
sequences up to 17 kb upstream of the most 5' v-abl homologous 
EcoRI region (Fig. lc). A ll.O-kb EcoRI fragment (Fig. Sa) 
that hybridizes to the v-ab/ P~. 7 probe but has no linkage with 
the main human c-ab/ locus17 is non-amplified and thus serves 
as an internal control. The immunoglobulin light-chain constant 
region (C,)25 is also amplified at least fourfold (Fig. Sb). This 
latter observation is consistent with the localization of human 
c-ab/ and C, sequences on the same amplification 1.1nit, presum-
ably a part of the Ph' chromosome. In concordance with this 
conclusion, C, remains on the Ph' chromosome in the t9: 22 
(unpublished observations). In contrast, another human 
oncogene, c-sis, which is located on chromosome 22 and 
transferred to chromosome 9 in the Ph' translocation26 , is non-
amplified (Fig. 5c). Fina!ly, the fact that the 5.0-kb Bglll frag-
ment normally localized on chromosome 22, is non-amplified 
in K562, supports the assumption that it is translocated to 
chromosome 9 in this cell line. 
Conclusions 
The present findings establish that in one of three CML patient 
DNAs examined, the Ph' chromosomal break point is localized 
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within 14 kb of the most 5' v-ab/ homologous region. Becau~e 
the position of the most 5' exon in human c-ab/ is not known, 
the possibility that the t(9; 22) break point may even map within 
a coding region of the human c~ab/locus cannot be excluded. 
We have not localized the break points in the DNAs of the two 
other CML patients or in DNA of the cell line WESP-2A, 
containing the 22q- chromosome. Our findings, however, estab-
lish that the site of the Ph' translocation break point is variable 
and suggest that break points in the latter DNAs may be located 
5' of the -80 kb of cloned DNA encompassing the human c-ab/ 
locus. Similarly, the t(8; 14) translocation in Burkitt lymphoma, 
involving the human c-myc oncogene, does not appear to involve 
.l. single siteHI-lz.n. The orientation of human c-ab/ on chromo-
some 9, with its 5' region towards the centromere of the chromo-
some (Fig. 6), is established by the fact that the break point has 
been found 5' to the human c-ab/ locus. 
K562 cells lack a cytogenetica!ly identifiable Ph' chromosome 
despite their derivation from a CML patient in blast cell crisis2 '. 
However, genes on either side of the break point in the Ph' 
chromosome, c-ab/ and C,_, are not only present in this cell line, 
but are amplified. In contrast, no amplification was found in the 
case of c-sis, normally on chromosome 22 but translocated to 
chromosome 9 in Ph' -positive CML, or a DNA region translo-
cated to chromosome 9 corresponding to a restriction fragment 
containing the t(9; 22) break point isolated from a CML patient. 
The amplification seems to be specific; neither human c-fes, on 
chromosome 15 (ref. 19), nor c-fms, on chromosome 5 {ref. 
28), is amplified (data not shown). The finding that c-ab/ is 
amplified in K562 can be explained in two ways: it can reflect 
the fact that these cells were grown in tissue culture, possibly 
resulting in specific chromosomal aberrations and/ or amplifica-
tions; alternatively, the c-ab! may have been amplified during 
the blast crisis of the patient, the overproduction of the c-ab/ 
gene product being the cause of the disease. The relative amplifi-
cation of a region of DNA, which includes both c-ab/ and C, 
sequences, suggests that the two are nearly contiguous in this 
cell line. 
We have previously demonstrated the translocation of a small 
piece of chromosome 9 to chromosome 22 in CML patients 
carrying the Ph' chromosome9• The size of this fragment was 
calculated to be less than 5,000 kb, suggesting a potential role 
of the c-ab/ oncogene in CML. The isolation, in the present 
study, of a region of DNA from a CML patient that contains a 
chromosomal break point which is localized within 14 kb of the 
c-ab/ locus, the specific amplification of c-ab! sequence in the 
K562 cell line, and the finding that c-abl is translocated to 
chromosome 22 in complex Ph' translocations29 further impli-
cate the c-ab! oncogene in chronic myelocytic leukaemia. 
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Summary 
We have identified and molecularly cloned 46 kb of 
human DNA from chromosome 22 using a probe 
specific for the Philadelphia (Ph') translocation 
breakpoint domain of one chronic myelocytic leu-
kemia (CML) patient. The DNAs of 19 CML patients 
were examined for rearrangements on chromosome 
22 with probes isolated from this cloned region. In 
17 patients, chromosomal breakpoints were found 
within a limited region of up to 5.8 kb, for which we 
propose the term "breakpoint cluster region" (bcr). 
The two patients having no rearrangements within 
bcr lacked the Ph' chromosome. The highly specific 
presence of a chromosomal breakpoint within bcr in 
Ph' -positive CML patients strongly suggests the in-
volvement of bcr in this type of leukemia. 
Introduction 
Chronic myelocyt1c leukemia (CML) is characterized by the 
presence of the Ph1ladelph1a (Ph') chromosome 1n the 
leukemic cells of 96% of all CML patients. The Ph' chro· 
mosome is the result of a translocation between chromo-
some 22 and chromosome 9 (Rowley, 1973, 1982; Sand-
berg, 1980); its presence has Important prognostic and 
diagnostic value. Previously we described the localization 
of the human c-ab/ oncogene (Heisterkamp et al .. 1983a). 
to chromosome 9 (Heisterkamp et al., 1982) and demon-
strated its translocation to the Philadelphia (22q-) chro-
mosome in CML (de Klein et al., 1982}. This demonstrated 
unequivocally that the t(9:22) is recprocal. As the break-
point on chromosome 9 is at the most telomenc band on 
this chromosome, q34, human c-ab/ must be translocated 
on a relatively small fragment of less than 5000 kb to 
chromosome 22, suggesting a potential role lor the c-ab/ 
oncogene in CML. This hypothesis was strengthened by 
the isolation of a chimeric DNA fragment from one CML 
pat1ent containing sequences from chromosome 9 and 22 
and located 14 kb immediately 5' of human v-abl homol-
ogous sequences (Heisterkamp et al .. 1983b). In the 
present study, we have used the chromosome 22-specific 
sequences of the chimeric DNA fragment to isolate a 
second chimeric chromosome 9/22 (9q+) fragment from a 
:j: Present address: Oncogene Sc1ence. !nc 222 Statoon Plaza N., Mineola, 
NY 11501 
different CML patient. The chromosome 9-specific se-
quences in this fragment must be localized at a minimal 
distance of 40 kb from the human v-abl homologous 
sequences. Using the same probe, we have isolated an 
extended region on chromosome 22 from non-CML human 
DNA. In contrast to the situation on chromosome 9, the 
breakpoints on chromosome 22 in the DNAs of these two 
CML patients had occurred in the same region, although 
not at an identical site. Subsequently, we investigated the 
genomic organization of this area in a number of other 
Ph' -positive CML patients: all exhibited abnormal restric-
tion enzyme patterns, indicating that in Ph+ -positive CML 
a breakpoint occurs in a single well defined region of 
chromosome 22. 
Results 
Isolation of a 9q ... Chimeric Fragment 
Previously we have ISOlated a chimeric DNA fragment 
containing sequences originating from chromosomes 9 
and 22 !Figure 18} from a CML patient, 0319129. On 
chromosome 9, the breakpoint was located immediately 
to the 5' of human v-abl homologous sequences {Figure 
1A) and may even be w'lth'n the human c-ab/ oncogene. 
However, the DNAs of two other CML patients did not 
conta1n rearrangements 1n this region: furthermore, we 
have molecularly cloned an additional 11 kb of DNA to the 
5' and have found no rearrangements in th1s area lor these 
two DNAs (results not shown}. Therefore, we decided to 
Investigate whether we could localize the Ph' translocation 
breakpoint to a specific s1te on chromosome 22. Using a 
1.2 kb H1nd 111-Bgtll fragment (1.2 HBg, see Figure 18} 
containing chromosome 22 sequences from the break-
point reg1on of CML patient 0319129 as a probe, we 
examined the DNA of the leukemic cells of a second 
patient (02120185}. As shown in Figure 2A, this probe 
detects a normal 5.0 kb Bgl II fragment in control DNA 
(lane 1), in DNA of patient 0319129 (lane 2) and 1n DNA 
of patient 02120185 (lane 3}. As expected, it also detects 
the breakpoint fragment of DNA 0319129 (Figure 1 B and 
F1gure 2, lane 2). In DNA of patient 02120185, an extra 
Bgt II fragment of 6.6 kb is VIsible (Figure 2, lane 3). 
Similarly, this probe hybridizes to a normal 3.3 kb Bam HI 
fragment in all three DNAs (Figure 2B}, but detects an 
additional abnormal 11.3 kb Bam HI fragment in DNA 
02120185 {lane 3}. As we could detect additional restriction 
enzyme fragments with other restnction enzymes in DNA 
02120185 (data not shown}, we decided to examine 
whether these abnormal fragments were the result of the 
presence of a chromosomal breakpoint. Using the 1.2 kb 
HBg fragment as a probe, we molecularly cloned the 11.3 
kb Bam HI fragment in charon 30. In this fragment only 1.2 
kb of DNA, homologous to the probe, was defined as 
or'1g.1nating from chromosome 22; to determine all chro-
mosome 22-specific sequences in the 11.3 kb Bam HI 
fragment, it was necessary to isolate the homologous 
region on chromosome 22 from non-CML DNA For this 
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F1gure 1. Position of the 9q~ Chromosomal Breakpoint in Spleen DNA of 
Pat1ent 0319129 in Relat1on to Human v-abl Homologous Sequences 
(A) The human v-abl homologous regions are designated I through VII and 
are Indicated by sol1d bars; Eco Rl $lies are marked by small vertical lines. 
The vertical arrow points to the breakpoint in the DNA of CML patient 
0319129. (8) The molecularly cloned reg•on of DNA of patient 0319129 
that contains a breakpoint. The solid bar indicates sequences from chro· 
mosome 9, while the open bar represents sequences from chromosome 
22. The 1.2 kb HBg probe 1S indicated as a hatched box. Restriction 
enzymes incJude: Bam HI (8), Bglll (Bg), Htnd Ill (H), Sst I ($), Xba I (Xb), 
Xho I (Xh) and Eco AI (E) 
purpose, a previously described (Groffen et al., 1982) 
human lung carcinoma cosmid library was screened w1th 
the 1.2 kb HBg probe. Three cosmid clones were isolated. 
which contained overlapping portions of the same region. 
Molecular Cloning of Ph' Breakpoint Region of 
Normal Chromosome 22 
As shown in Figure 3A, a regton of approxtmately 46 kb 
was molecularly cloned: the 1.2 kb HBg probe hybridizes 
to a Bgl II fragment of 5.0 kb, located centrally in the 
cloned region. No homology is apparent between the 
restriction map of this region and that of human c-sis 
{Dalla-Favera et al., 1981), an oncogene sttuated on chro-
mosome 22 but translocated to chromosome 9 in the Ph' 
translocation (Grotfen et al., 1983a). Th1s conftrms earlier 
reports that indicated that c-sis is not located tn the 
immediate proximity of the Ph' breakpoint (Bartram et al., 
1983a). In variant Burkitt lymphoma. a t{8:22) has been 
described in whtch the immunoglobulin light chain was 
found to be involved {de Ia Chapelle et al., 1983). The 
light-chain-constant regton (CA) and the Ph' chromosomal 
breakpoint have been localized to chromosome 22 band 
qll (Rowley, 1973: McBnde et al., 1982: Yums, 1983): this 
suggests that c-ab/ could be translocated into CA in 
patients with CML However, a probe isolated from the A 
constant regton showed no cross-homology with the above 
described chromosome 22 sequences_ Additionally. no 
hybridizatton to a murine A-variable region probe (Miller et 
al., 1981) was observed (results not shown). 
To facilitate comparison of the 11.3 kb Bam HI fragment 
wtth homologous sequences on chromosome 22, the 5.0 
kb Bgl II fragment was subcloned into pSV2-neo (Figure 
38). In concordance wtth our previous results (Hetsterkamp 
et al., 1983b), in the 6.0 kb Bglll breakpotnt fragment from 
CML patient 0319129. restriction enzyme sites 3' to the 
most 3' Eco Rl stte originate from chromosome 22 (Figure 
3Cl. In the 11.3 kb Bam HI fraqment (Figure 3D) approxi-
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F•gure 2 Restnct10n Enzyme Analysis of CML ONAs 
Ten m1crogram of h•gh molecular weight DNA was digested wtlh 8giii(A) 
or Bam HI (8). electrophoresed on 0 75% agarose gels_ and blotted ON As 
analyzed were from human celll1ne GM3314 (lane 1 ). CML pat1ent 0319129 
(lane 2). and CML pa11en1 02120185 (lane 3). Frozen spleen t1ssues 
1nclud1ng those used as a source for the 1solatron of DNAs shown •n -F•gure 
5, were obtained through tM B10IOQ1Cal Carc1nogenes1s Branch, DCCP 
Hybndlzat,on was w1th the 1.2 kb Heg probe (see F1gure 1 ): l1llers were 
washed to 0_3 x SSC at es•c. Molecular we1gh1s ot tragments hybrid1Z1ng 
to the probe are 1nd1cated tn k1iobases 
mately 2.5 kb of DNA, including the 3' Bam HI stte and 
extending to the 3' Xho I site, originates from chromosome 
22. 
The 11.3 kb Bam HI Fragment Also Contains a 
Breakpoint 
To establish conclusively that the 11.3 kb Bam HI fragment 
represents a chimeric fragment of chromosomes 22 and 
9. we isolated a 1.3 kb Eco Rl fragment from the chro· 
mosome 22 nonhomologous region. Using thts fragment 
as a probe, homologous sequences were detected tn Bgl 
11-dtgested mouse DNA (Ftgure 4. lane 1) and Chinese 
hamster DNA (not shown). These bands. however, were 
clearly resolved from the Bgl II fragment vistble tn human 
DNA (lane 2). No human sequences homologous to the 
probe were detected in rodent-human somatic cell hybrtds 
PgMe-25Nu, havtng human chromosome 22 as tts only 
human component (lane 4) or in WESP-2A. (lane 3) con-
taining a Ph' chromosome but not chromosome 9 or 9q+ 
(de Klein et al .. 1982). In the rodent-human somattc cell 
hybrids lOCB-238 (lane 5), containtng human chromo-
some 9 and tn 14CB-21A. containing a 9q+ chromosome 
(not shown), a Bglll fragment of human origin homologous 
to the probe clearly was present. The only human DNA 
sequences these two hybrtds have in common are those 
ongtnating from chromosome 9. Therefore. the 11.3 kb 
Bam HI fragment possesses a breakpoint and represents 
a chimeric fragment containing chromosome 9- and 22-
specilic sequences isolated from a second CML patient 
Clustering of Ph' Breakpoints on Chromosome 22 
in CML Patients 
Since in each of the above two CML DNAs the breakpoint 
in the t(9:22) on chromosome 22 was localized within a 
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F•gure 3 ComparaHve Restnction En;>;yme Analysis of the Breakpoint 
Region on Chromosome 22 w~h Two Sq• Breakpoint Reg1ons 
A restrict<on enzyme map of the cloned reg1on 1n which chromosomal 
breaks occur on chromosome 22 is shown in (A): a subclone con:aining 
the 5.0 kb Bglll fragment In (B) is compared w.th the 6.0 kb Bgtll and 11.3 
kb Bam HI restriction en;>;yme fragments of the 9q• chromosomes in (C) 
and (D): heavy Iones ind1cate sequences from chromosome 22. whereas 
llghllines Indicate sequences originating from chromosome 9. B = Bam 
HI: Bg = Bglll, Bs = BstE II; E = Eco AI: H = Hind Ill: K = Kpn 1: S = Sst 
t:X=Xbai:Xh=Xhol 
common region, we decided to investigate this area in 
other CML ONAs As the 1.2 HBg probe had detected 
abnormal (9q+) Bgl II restriction fragments in DNAs 
0319129 and 02120185, we subJected 17 additional in-
dependent CML DNAs to similar analysts: six of these were 
from spleen tissue, nine were from patient blood. and two 
were from bone marrow_ As shown in Figure 5, lanes 1-
13. CML DNAs from spleen, blood, and bone marrow all 
contatned idditionai Bgl II fragments hybridtzing to the 1.2 
HBg probe; the DNAs of the patients shown in lanes 14-
17 did not exhibit abnormal Bgi II fragments. Two of these 
(H81-258. lane 14 and COSO. lane 15) showed deviant 
restriction enzyme patterns with other restriction enzymes 
(this will be discussed below) 
To confirm that the 1.2 HBg probe detected chromo· 
somal rearrangements and not merely DNA polymor-
phisms for the restriction enzyme Bgl II, all DNAs were 
subjected to digestion with at least one. but in most cases 
two or more different restriction enzymes. After hybridiza-
tion with tt>e 1.2 HBg probe, abnormal restriction enzyme 
fragments were detected in ail Ph' -positive CML DNAs 
(also see below). Therefore, a polymorphism for Bgl II 
seems an unlikely explanation for the abnormal fragments 
shown in Figure 5; moreover, in the DNAs of most patients, 
abnormal fragments of different molecular weights are 
detected with the 1.2 HBg probe. 
No extra Bgi II fragments were found in DNA isolated 
from cultured fibroblasts of patient H80-251 (lane 18) 
although an extra Bgl II fragment is clearly visible in DNA 
isolated from the leukemic cells of this patient (lane 7). 
Moreover, DNA isolated from the fibroblast cell line, AG 
1732. established from a Ph'-positive CML patient, also 
lacked abnormalities (lane 1g) in this regton. Finally, in DNA 
isolated from leukemic cells ol a Ph' -negative CML patient 
(lane 17) and of a two-year-old child with juvenile Ph'-
negative CML, no visible rearrangements were found (lane 
16), confirming our results of previous experiments (Bar· 
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Fogure 4_ Oflgin of the 5' Sequences of the 11.3 kb Bam HI Fragment 
High molecular weoght DNAs, including mouse (lane 1 ). human cell l1ne 
A204 (tane 2). WESP-2A (chromosome 22q-, lane 3). PgMe·25Nu (chro 
mosome 22, lane 4), and tOCB-236 (chromosome 9, lane 5) were d1gested 
with Bglll. electrophoresed on an 0.75% agarose gel, blotted, and hybnd· 
1zed to a 1.3 kb Eco Rl probe ISOlated from the 1 1_3 kb Bam HI fragment 
tram et ai., 1983b) in which no transiocations concerning 
c-ab! to chromosome 22 or c·sis to chromosome g were 
found in Ph' -negative CML. 
Sublocalization of Ph' Breakpoints on Chromosome 
22 
As is apparent from the detatled restriction enzyme analysis 
of the breakpoirt lragments of the DNAs of patients 
0319129 and 02120185, the exact breakpoints are not 
localtzed at identical sites on chromosome 22. To subio· 
caltze the breakpoints in the DNAs ol the other CML 
patients more precisely, we arbitrarily divided the 5.0 kb 
Bgl II fragment into segments bordered by restriction en-
zyme sites for Bgi II, Bam HI, and Hind Ill (see F-igure 6, 
bottom)_ Region 0 thus extends from the 5' Bgi II stte to 
the first 5' Hind ill site, region 1, a 0.6 kb Hind ill-Bam HI 
fragment, is bordered by the same Hind ill site at the 5' 
and a Bam HI site 3' to it Region 2 is delineated by this 
Bam HI stte at the 5' and a Hind 1111 site 3' to it: region 3 is 
the 1.2 kb Hind 111-Bgl II fragment (1.2 HBg) used as a 
probe in the experiments described above. Region 4 is 
outside the 5.0 kb Bgi II fragment and is bordered at the 
5' by the Bglll site and at the 3' by a Bam HI site. 
As is evident from the restriction enzyme map of the 6.0 
kb breakpoint fragment of CML DNA 0319129 (Figure 3C), 
the Bam HI site from chromosome 22 tn region 1 is found 
on the 9q+ chromosome, whereas the Hind Ill site 5' to it 
is missing: therefore, a break must have occurred between 
these two restriction enzyme sites in region 1_ In accord· 
ance with this, only a (normal) 3.3 kb Bam HI fragment is 
detected with the 1.2 HBg probe, which originates from a 
region 3' to the Bam HI site (Figure 28, lane 2). In DNA 
02120185, however, this Bam HI site is missing on the 9q+ 
chromosome (Figure 30) and, therefore, the 1.2 HBg probe 
detects, in addition to the normal 3.3 kb Bam Hi fragment, 
the 11.3 chimeric Bam HI fragment As the 3' Hind Ill site 
at region 2 is present in this 9q+ fragment, the breakpoint 
in this DNA is in region 2. 
In DNA 0311068, as in DNA 0319129, only a normal3.3 
kb Bam HI fragment is detected with the 1.2 HBg probe, 
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F1gure 5. AnalySIS of DNAs from CML Pallents 
ONAs analyzed 1ncluda 1solates from CML pat<ent 0311068 {lane 1), 7701C (lane 2). C999 (lane 3), C481 {lane 4), 679·100 (lane 5), 879-216 (lane 6}. HSQ-
251 {lane 7). CML 0 (lane 8). H81-154 (lane 9). H81-122 (lane 10). H81 ·1 18 (lane 11 ), H79-179 (lane 12). H77-94 (lane 13), H81·258 (lane 14). COSO (lane 15). 
COl 1 (lane 16). and H79-147 (lane 1 7) Also shown are DNAs iSOlated from fibroblasts of pat•ent HS0-251 (lane 18) and from the fibroblast celll1ne AG 1732 
(lane 19) 
DNAs 1n lanes 1-4 and 15-16 were •solated from the frozen spleens of CML pa11ents: those from CML pat1ents 0311068 and 7701C contained a very h1gh 
percenlage of leiJ<erniC cells~ the percentage of leukemiC cells 1n the other spleen tissues IS not known There are no data concermng the presence of a Ph' 
chromosome if\ cells of these spleens. DNAs 1n lanes 7-14 and 17 were 1solaled lrom blood and those'" lanes 5-Sirom bone marrow. Cells from wh•ch 
DNA was •solated were examned lor lhe presence ol the Ph' chromosomal marker. bone marrow and blood cells of all pahenls except patient H7g·147 were 
Ph' -pos•l1ve. The human f•broblast cell line AG 1732. obtained from the Human Genet1c Mutant Cell RepOSIIDry (Camden, New Jersey) was establ•shed from 
a CML pat1ent carry1ng the Ph' chromosome 1n her leukemiC cells. DNA (tO 11g) was d1gested With Bglll, electrophoresed on an agarose gel, blotted. and 
hybr;d,zed to the 1.2 kb HBg probe 
indicating that no break has occurred within this fragment 
(Figure 6, lane 1 ). When the 0.6 kb Hind Ill-Bam HI 
fragment encompassing region 1 is used as a molecular 
probe, a normal 5.0 kb and two abnormal Bgtll fragments 
of 4.0 and 3.2 kb are VISible. The 3.2 kb Bgt II fragment 
represents a 9q+ chimeric fragment containing the 3' Bgl 
II site from the 5.0 kb Bglll fragment on chromosome 22, 
as it is also detected with the 1 .2 HBg probe (Figure 5, 
lane 1). The 4.0 kb Bgl II fragment is a 22q- chimeric 
fragment with the 5' Bgl II s'1te or'1g·1nating from chromo-
some 22; it is not detected by the 1.2 HBg probe. The 
breakpoint in DNA 0311068 must be located in region 1. 
The 1.2 HBg probe detects, in addition to a normal 3.3 
kb Bam HI fragment. an abnormal 6.2 kb Bam HI fragment 
1n CML DNA 7701C (Figure 6, lane 3). The Bam HI site 
bordering region 2 at the 5' must, therefore, be absent 
from the 9q+ chromosome. The Hind Ill site at the 3' of 
region 2 has been retained, as only one normal 4.5 kb 
Hind Ill fragment is visible alter hybridization to 1.2 HBg 
(Figure 6, lane 4). This CML DNA must contain a breakpoint 
in region 2. 
Patient C481 and H77 ·92 apparently have a breakpoint 
in region 3, encompassing the 1.2 HBg probe. For exam-
ple, in DNA of patient C481 the 1.2 HBg probe hybridizes 
to three restr'1ct1on enzyme fragments ·In every restr'tction 
enzyme digest: abnormal Bglll fragments of 6.0 and 2.8 
kb and a normal one of 5.0 kb (Figure 5, lane 4), abnormal 
Hind Ill fragments of 7.0 and 3.5 kb in addition to a normal 
4.5 kb fragment (Figure 6, lane 7), abnormal Bam HI 
fragments o17.5 and 5.2 kb and a normal3.3 kb fragment 
174 
(Figure 6, lane 8). Therefore, in this CML DNA, the 1.2 HBg 
probe detects both the 22q- and 9q+ breakpoint frag-
ments. 
The situation in the DNA of patient COSO is less clear. 
As only one normal 5.0 kb Bgl II fragment is visible after 
hybridization to 1.2 HBg (Figure 5, lane 15), a chromosomal 
breakpoint most likely has occurred outside the Bgl II 
fragment. As the 1.2 HBg probe detects an abnormal 5.0 
kb Hind Ill fragment in addition to the normal 4.5 kb Hind 
Ill fragment (Figure 6, lane 6), a chromosomal breakpoint 
may be situated immediately 3' of the 5.0 kb Bgl II 
fragment. This is supported by the hybridization of the 
same probe tc an abnormal13 kb Bam HI fragment (and 
the normal 3.3 kb fragment, Figure 6, lane 5). The break-
potnt has therefore been tentatively placed in region 4; in 
DNA of this patient, the 1.2 HBg probe would detect only 
22q- restnction enzyme fragnents 
Using different restriction enzymes and probes from the 
5.0 kb Bgl 11 fragment, we have analyzed the location of 
the breakpoint in all CML DNAs shown in Figure 5, lane 
1-15. These results are summarized in Table 1. 
Discussion 
In the present studies we have identified and clon-ed a 
breakpoint cluster region {bcr) on chromosome 22, in-
volved in the chromosomal translocation, t(9;22), of Ph'· 
positive CML. In total we have studied 19 CML patients; 
ten of these were shown to be Ph' -positive by cytogenet-
ical analysis. All ot the patients of this latter group pOS· 
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F1gure 6 Analysis of Ph' TransJocat1on Breaxpninls on Chromosome 22 
Top. DNA of patients was digested with Bam HI (lanes 1. 3, 5, 7). Bgt It 
{lane 2), or Hind Ill (lanes 4. 6, 8). Hybridization was with lhe 1.2 kb HBg 
probe; lane 2 tS hybnd;zed with a 0.6 kb HB probe indtcated in the botlom 
of the figure. Molecular weights of marker fragments in kilobases are 
tndi)':ated in the left of the figure. Bottom: bCf, the region w1lh1n the cloned 
chromosome 22 sequences contaJn1ng Ph' translocation breakpoints 1den· 
t1fied 1n this study, 1s shown schematically. The numbers refer to the 
subre{Jions mentioned in the text: the probes used are indicated above the 
figure 
sessed a chromosomal break Within bcr Of the remaining 
nine patients, one was cytogenetically charactenzed as 
Ph' -negative and a second patient has Ph' -negative juve-
nile CML: as expected, they did not exhibit a breakpoint 
in this region. Seven of seven nonkaryotyped patients 
were Ph' ·positive because a chromosomal break could be 
identified within bcr. The involvement of bcr in the Ph' 
translocation is highly specific for CML, as analogous 
rearrangements were not found in DNAs isolated from 
other neoplastic tissues or cell lines, Including DNAs from 
four acute myeloid leukemia patients, one olcute myelo-
monocytic leukemia patient, glioblastoma, melanoma, mul-
tiple myeloma, and teratocarcinoma cell lines (data not 
shown). Since abnormalities were not seen in a fibroblast 
cell line established from a Ph' -positive CML patient, 1n 
cultured fibroblasts of a Ph' -positive CML patient. or in 
leukemic cells of two Ph' -negative CML patients, we be-
lieve these rearrangements to be highly specific for the 
leukemic cells in Ph' -positive CML patients. In two patients 
these rearrangements were ngorously analyzed and shown 
to represent chromosomal breakpoints. Probes, isolated 
Table 1. Breakpoint location WJ\hin bcr of Ph' -positive CML Patients 
CML Breakpoint CML 8reakpo1nt 
Patient Location Patient Location 
0311068 HBt-122 2. 3 
7701C H81-t18 2. 3 
C9<l9 H79-179 
C481 H77-94 
879-100 HSt-258 u 
878-216 o. 1, coso 
HS0-251 0.' 0319129 
CML-0 02120185 
HBt-164 
'· 3 
The dillerenl breakpoint subregions (0 4) are as lndocated 1n F1gure 6, 
bottom For some pal1ents, the exact breakpoint subreg1on has not yet 
been determoned: more than one subregion IS Indicated for these pat1ents 
1n the table 
from the bcr, in particular the 1.2 kb HBg probe, are highly 
specific tools for the identification of the Ph' translocation 
in leukemic DNA and as such, may be of diagnostic value, 
in particular when no metaphase chromosome spread can 
be obtained. 
We have molecularly cloned a region of chromosome 
22 from non·CML DNA that contains the Ph' breakpoints 
in CML DNA The orientation of the chromosome 22· 
specific sequences in the two 9q+ breakpoint fragments 
determines the orientation of the breakpoint cluster region 
on the chromosome: the most 5' end will remain on 
chromosome 22 (Figure 7) and, depending on the exact 
position of a breakpoint, a smaller or larger region of bcr 
will be translocated to chromosome 9. Although the break-
point on the Ph' chromosome is in band q11 (Rowley, 
1973; Yunis, 1983) and the A light-chain constant region 
has been localized to the same band (McBride et al., 1982; 
our unpublished results) no cross-homology was observed 
between the chromosome 22 cosmid clones and CA. As 
of yet, these clones contain unidentified sequences. Ex· 
periments to determine if this region of chromosome 22 
contains protein coding regions andjor enhancer se-
quences are in progress. 
Previously we have reported the isolation of a Ph' 
breakpoint fragment containing chromosome 9 sequences 
originating approximately 14 kb 5' of human v-ab/ homol· 
ogous sequences (Heisterkamp et al., 1983b). However, 
we were unable to detect chromosomal breakpoints in 
other CML DNAs up to 11 kb 5' of this breakpoint. The 
9q+ breakpoint fragment from a second CML patient, 
isolated in the present study, contains 9 kb of DNA 
originating from chromosome 9. Preliminary results sug-
gest that these sequences must be separated by, at 
minimum, 27 kb of DNA 5' of the previously reported 
breakpoint. Therefore, the breakpoint on chromosome 9 
appears to be variable in different Ph'-positive CML pa-
tients and may be found within a relatively large but limited 
region on chromosome 9; the region of chromosome 9 
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Ftgure 7 Dtagrammaltc Representalton o! the Ph' Translocatto~ 
The honzontal arrows tnd•cate the chromosomal breakpotnt rn chromosome 
22 Mapptng of c-s1s to the reQIOn of chromosome 22(o123 to qt3 li 
\ra~slocated to chromosome 9 IS as prevtously descnbed (Grolfen et at 
19il3a: Bartram et al.. 1983a) LocaltLalton of c-ab! to the termt~ai portton 
of chromosome 9 (q34), whrcn 15 translocated to chromosom~ 22 tn the 
Ph' transtocotton_ 15 as descnbed '" the lex: The max,rr.um stze ol bcr 
from the 5' Bgllllo the 3' Bam HI stte IS 58 kb 
contatning human c-ab! (q34-qter) that is translocated to 
chromosome 22 is too small to be visualized by cytoge-
netic analysis and dcies not exceed 5000 kb (Heisterkamp 
et al., 1983b; de Klein et al., 1982}. 
At present, we do not know whether the two breakpoints 
we have Identified actualiy occur within human c-ab/ coding 
sequences: the most 5' exon of human c-ab! has not yet 
been determined. However. the possibility must be consid-
ered that the human c-ab/ oncogene extends over a much 
larger region than that characterized by homology to the 
viral oncogene v-abl: whereas the v·abl oncogene is 3.5 
kb in length (Goff et at., 1980). Homologous RNA species 
ranging in s1ze from 5-7 kb (Ozanne et al., 1982: Westin 
et al., 1982}, have been reported 1n humans. In contrast to 
the Situation on chromosome 9, the breakpoints on chro-
mosome 22 seem to be clustered in a very limited region 
It is evident. however, even at the restriction enzyme level, 
that the breakpoints have not occurred in one specific site 
but rather are distributed over a reg1on of up to 5.8 kb. 
Analogous to the t(9;22} in Ph'-positive CML, a t(8;14) 
is found in many patients with Burkitt lymphoma: in the 
latter case, the human oncogene c-myc, located on chro-
mosome 8, (Dalla-Favera et al., 1982; Taub et aL, 1982} is 
often translocated 1nto the immunoglobulin heavy-chain 
locus on chromosome 14 (Taub et al., 1982; Dalla-Favera 
et aL, 1983: Adams et al., 1983; Erikson et al., 1983; 
Hamlyn and Rabbits, 1983). The breakpoints on chromo-
some 8 may be distnbuted over a relatively large reg1on 5' 
of human c-myc (Oalla-Favera et al., 1983: Adams et al., 
1983: Erikson et al., 1983), a situation analogous to that 
of human c-ab/ on chromosome 9. On chromosome 14. 
breakpoints 1n the variable (Erikson et al., 1982) and in the 
constant region of the heavy-chain locus have been re-
ported in Burkitt lymphoma, 1ndicat1ng that neither the 
breakpoints on chromosome 8 nor those 14 can be found 
w1th1n a breakpoint cluster region as discussed in the 
present study. The bcr on chromosome 22 seems as of 
yet to be unique in human. However, the existence of bcrs 
on other human chromosomes is not unlikely taking into 
consideration the Increasing number of reports of other 
highly specific translocations in neoplastic diseases (for a 
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review, see Yunis, 1983). 
Thr specifiCity of tne presence of a chromosomal break· 
point on chromosome 22 within bcr in Ph' -positive CML 
indicates that this region may be involved in CML. Addi-
tionally, a human oncogene, c-ab/, is consistently translo-
cated to chromosome 22, even in patients with complex 
Ph' translocations (Bartram et al., 1983b} and is amplified 
1n a CML cell l1ne, K562, (Heisterkamp et al., 1983b). 
Although the breakpomts on chromosome 9 are d1stnbuted 
over a relatively large region of DNA 5' to human v-abl 
homologous sequences, the specific translocation of this 
oncogene in the t(9;22) must be of functional significance 
Therefore. we believe that both human c-ab/ and bcr may 
be associated with Ph' -positive CML 
EKperimental Procedures 
Somatic Cell Hybrids 
PgMt:-25 Nu IS a human-mouse somat1c cell hybnd obta,ned from fus,on 
w1lh mouse Pg19 cells. 11 con1a1ns as 1ts only human component chromo 
some 22 Ch1nese hamsler cell''ne E36 was used 10 oota1n hybnds 10C8 
238 a~c HC8-21A The hybnd 10CB-23B conta.ns human chromoso-1les 
5. 9. 11 and 19. whereas 14CB-21A has rela1ned chromosomes 4. 7. 8 
14 20. and 9q• (Geurts van Kessel et a• _ t98tb Geuns van Kessel el al.. 
1981C de Kle1n el al. 1983) WESP 2A was obta1ned by tusK•n ol mouse 
WEHI-38 ce'IS w•lh leui<ocytes of a Ph' -pos111ve CML pallent and conta1ns 
r,uman chromosomes 7. 8. and 14 1n add1l1on to lhe Ph' chromosome (de 
Kle1rt el al 1983) 
Southern Blot Analysis 
H1gt- molecular we1ght ONAs were ISOlated as descnbed {Jeffreys and 
Flavell. 1977). digESted w1lh restncl10n enzymes. a~d electrophoreseo on 
agarose gets Blolttng was accordrng to Southern (1975) on nrtrocellulose 
(Scnlelcher and Schuell. pH 7 9) N1ck transla•.1on ol probes and (,Iter 
hybndiZJI,ons were as descnbeo (Flavell et al.. 1978. Bernards and Flavell 
1980) Spec,f,c activity ol the probes were 2-5 x 10" cpm/1'9 Fillers were 
Bxposed to XAR-2 111m (Kodak) al ~?O'C w1th Ouponl Llghtn,ng Prus 
nlens,lylf\g screens 
!solation of Probes 
DNA D!obes ·Nere prepared by d1gest'on w1lh appropnale restnct,on en 
lymes I oil ow eo by electrophoresiS lhrough low-rr8'11ng po1n1 agarose gels 
Oewed bands were cut trom the gel and brought Into solut10n by heat1ng 
al 65'C lor 30 mtn Agarose was removed by two exlract,ons w1lh phenol 
equllbraled wrth 0 3 M NaOAc (pH 5.0). ano one extracl1on w1th phenol/ 
chlorolormflsOamylalcohol (25·24"1) DNA was preCIPitated w1lh elhanol 
a~o 0 2 M NaOAc {pH 4 8) 1n I he presance ol 20 ~gfml Dextran T -500 as 
earner Resrnct,on enzymes and 1ow-melt1ng po1nl agarose were pur-chased 
lrorn Bethesda Research Laboratones and were used according to the 
suppl1er"s spec,flcal,ons 
Molecular Cloning 
Subclon,ng olthe 50 kb Bgllllragrne~t and con,ng of tne 11 3 ko Barr HI 
!ragmen: was according to publ•shed procedures (Grotlen et al. 1983bi 
A pre-<IOUS'Y oescnbed (Grollen el al 1982) human lung carc,noma cosm1d 
l•brary was screened w1tn the 1 2 H8g probe according to the rretnod ol 
Grosvelo el a! {198!) Three POS1t1ve cosm1d clones were ISO!ated and 
mappeo 1ndependenlly by digestion ol 1nd1v1dual restnct,on enzyme lrag 
menls Isolated from low-mell,ng-pornt agarose gels 
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